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1	  ABSTRACT	  
Primary	   myelofibrosis	   (PMF)	   is	   a	   myeloproliferative	   neoplasm	   characterized	   by	  
megakaryocyte	   (MK)	   hyperplasia,	   bone	   marrow	   fibrosis,	   and	   abnormal	   stem	   cell	  
trafficking.	   PMF	   may	   be	   associated	   with	   somatic	   mutations,	   about	   90%	   of	   patients	  
harbor	  one	  of	  three	  “driver”	  mutations,	  with	  mutational	  frequencies	  of	  approximately	  
60%,	  22%	  and	  6%	  for	  JAK2,	  CALR	  and	  MPL,	  respectively.	  Other	  “non-­‐driver”	  mutations	  
have	  also	  been	  described	  in	  PMF	  involving	  different	  cellular	  targets	  such	  as	  epigenetic	  
regulatory	   pathways	   genes	   (ASXL1,	   DNMT3A,	   EZH2,	   IDH1	   and	   IDH2,	   TET2),	   splicing	  
factor	   genes	   (SRSF2,	   SF3B1)	   and	   progression	   to	   leukemia	   (CBL,	   LNK,	   RUNX1,	   TP53).	  
However,	   several	   aspects	   of	   its	   pathogenesis	   remain	   elusive.	   Increasing	   evidences	  
indicate	  that	  the	  deregulation	  of	  microRNAs	  (miRNAs)	  might	  plays	  an	  important	  role	  in	  
hematologic	  malignancies,	  including	  MPN.	  In	  this	  work,	  in	  collaboration	  with	  a	  group	  at	  
the	  Hemopoietic	  Stem	  Cells	  Laboratory	  of	  the	  University	  of	  Modena	  and	  Reggio	  Emilia	  
and	  a	  bioinformatics	  group	  of	  University	  of	  Padua,	   it	  was	  performed	  a	  genome	  wide	  
analysis	  of	  coding	  RNA	  (GEP)	  and	  microRNA	  (miEP)	  expression	   in	  CD34+	  cells	  purified	  
from	  patients	  with	  PMF	  and	  from	  health	  subjects	  initially	  using	  Affymetrix	  technology.	  
By	   means	   of	   miRNA-­‐gene	   expression	   integrative	   analysis,	   it	   was	   found	   different	  
regulatory	   networks	   involved	   in	   the	   dysregulation	   of	   transcriptional	   control	   and	  
chromatin	   remodeling.	   In	   particular,	   it	   was	   identified	   a	   network	   gathering	   several	  
miRNAs	   with	   oncogenic	   potential	   (e.g.	   miR-­‐155-­‐5p)	   and	   targeted	   genes	   whose	  
abnormal	   function	  has	  been	  previously	  associated	  with	  myeloid	  neoplasms,	   including	  
JARID2,	   NR4A3,	   CDC42,	   and	   HMGB3.	   Because	   the	   validation	   of	   miRNA-­‐target	  
interactions	  unveiled	  JARID2/miR-­‐155-­‐5p	  as	  the	  strongest	  relationship	  in	  the	  network,	  
it	   was	   studied	   the	   function	   of	   this	   axis	   in	   normal	   and	   PMF	   CD34+	   cells.	   This	   study	  
showed	  that	  JARID2	  downregulation	  mediated	  by	  miR-­‐155-­‐5p	  overexpression	  leads	  to	  
increased	   in	   vitro	   formation	   of	   CD41+	   MK	   precursors.	   These	   findings	   suggest	   that	  
overexpression	   of	   miR-­‐155-­‐5p	   and	   the	   resulting	   downregulation	   of	   JARID2	   may	  
contribute	  to	  MK	  hyperplasia	  in	  PMF.	  	  
At	   the	   same	   time,	   to	   attain	   deeper	   and	   more	   extensive	   knowledge	   of	   short	   RNAs	  
(sRNAs)	  expression	  pattern	  in	  CD34+	  cells	  and	  of	  their	  possible	  role	  in	  mediating	  post-­‐
transcriptional	  regulation	  in	  PMF,	  CD34+	  cells	  from	  healthy	  subjects	  and	  PMF	  patients	  
were	  sequenced	  with	   Illumina	  HiSeq2000	  technology.	   It	  was	  detected	  the	  expression	  
of	  784	  known	  miRNAs,	  with	  a	  prevalence	  of	  miRNA	  up-­‐regulation	  in	  PMF	  samples,	  and	  
discovered	  34	  new	  miRNAs	  and	  99	  new	  miRNA-­‐offset	  RNAs	  (moRNAs)	   in	  CD34+	  cells.	  
Thirty-­‐seven	  small	  RNAs	  were	  differentially	  expressed	  in	  PMF	  patients	  compared	  with	  
healthy	   subjects,	   according	   to	  microRNA	  sequencing	  data.	   Five	  miRNAs	   (miR-­‐10b-­‐5p,	  
miR-­‐19b-­‐3p,	   miR-­‐29a-­‐3p,	   miR-­‐379-­‐5p,	   and	   miR-­‐543)	   were	   deregulated	   also	   in	   PMF	  
granulocytes.	   Moreover,	   3’-­‐moR-­‐128-­‐2	   resulted	   consistently	   downregulated	   in	   PMF	  
according	  to	  RNA-­‐seq	  and	  qRT-­‐PCR	  data	  both	   in	  CD34+	  cells	  and	  granulocytes.	  Target	  
predictions	   of	   these	   validated	   small	   RNAs	   de-­‐regulated	   in	   PMF	   and	   functional	  
enrichment	   analyses	   highlighted	   many	   interesting	   pathways	   involved	   in	   tumor	  
development	   and	   progression,	   such	   as	   signaling	   by	   FGFR	   and	  DAP12	   and	   Oncogene	  
	   4	  
Induced	  Senescence.	  As	  a	  whole,	  data	  obtained	  in	  this	  study	  deepened	  the	  knowledge	  
of	  miRNAs	  and	  moRNAs	  altered	  expression	  in	  PMF	  CD34+	  cells	  and	  allowed	  to	  identify	  
and	   validate	   a	   specific	   small	   RNA	   profile	   that	   distinguishes	   PMF	   granulocytes	   from	  
those	  of	  normal	  subjects.	  It	  was	  thus	  provided	  new	  information	  regarding	  the	  possible	  
role	  of	  miRNAs	  and,	  specifically,	  of	  new	  moRNAs	  in	  this	  disease.	  	  
The	  expression	  of	  175	  miRnas	  in	  plasma	  samples	  was	  also	  analyzed	  in	  the	  patients	  with	  
PMF	   and	   the	   healthy	   donors	   and	   it	   was	   identified	   the	   presence	   of	   6	   differentially	  
expressed	   miRNAs	   deregulated	   in	   significant	   statistically	   way	   (P	   value	   <0.05):	   miR-­‐
let7b*,	   miR-­‐10b-­‐5p,	   miR-­‐424	   and	   miR-­‐99a	   were	   resulted	   up-­‐regulated	   instead	   miR-­‐
144*	  and	  miR-­‐375	  were	  down-­‐regulated	   in	  PMF	  patients.	  These	  data	  show	  a	  distinct	  
plasma	   miRNA	   expression	   patterns	   in	   patients	   with	   PMF	   compared	   with	   health	  
subjects	  which	  could	  have	  a	  potential	  utility	  as	  prognostic	  biomarkers.	  Finally,	  in	  order	  
to	   clarify	   the	   contribution	   of	   microRNAs	   also	   in	   to	   the	   pathogenesis	   of	   JAK2V617F-­‐
positive	  MPNs,	   it	  was	  analysed	  the	  miRNAs	  expression	  pattern	  in	  erythroid	  (TER119+)	  
and	  mieloid	   (GR1+)	   cells	   purified	   from	   BM	   of	   JAK2V617F	   knock-­‐in	   (KI)	  mouse	  model	  
using	   TaqMan®	   Real	   time	   PCR.	   In	   this	   part	   of	   the	   study,	   it	   was	   identified	   a	   list	   of	  
differentially	  expressed	  miRNAs	  also	  in	  JAK2V617F	  KI	  mouse	  whose	  deregulation	  might	  
contribute	  to	  the	  development	  and	  phenotype	  of	  MPNs.	  	  
The	  results	  of	  this	  work	  provided	  novel	  data	  regarding	  the	  expression	  profile	  of	  small	  
RNA	  expressed	  in	  CD34+,	  granulocytes	  and	  plasma	  of	  PMF	  patients;	  in	  addition,	  for	  the	  
first	   time	   a	   new	   moRNAs	   was	   described	   as	   possible	   contributors	   to	   disease	  
pathogenesis.	   Finally,	   it	   was	   identified	   a	   list	   of	   differentially	   expressed	   miRNAs	   in	  
JAK2V617F	   KI	   mouse	   whose	   deregulation	   might	   contribute	   to	   the	  
development/phenotype	   of	   MPNs.	   This	   information	   may	   represent	   the	   basis	   for	  
further	  studies	  aimed	  at	  a	  deeper	  knowledge	  of	  the	  prognostic	  and	  therapeutical	  role	  













	   5	  
2	  INTRODUCTION	  
2.1	  MYELOPROLIFERATIVE	  NEOPLASMS	  
	  
The	  Myeloproliferative	  disorders	  comprise	  several	  clonal	  hematologic	  diseases	  that	  are	  
thought	  to	  arise	  from	  a	  transformation	  in	  a	  hematopoietic	  stem	  cell.	  	  
The	   main	   clinical	   features	   of	   these	   diseases	   are	   the	   overproduction	   of	   mature,	  
functional	  blood	  cells	  and	  a	  long	  clinical	  course	  (Campbell	  et	  al.,	  2006).	  
William	  Dameshek	  was	   the	   first	   to	   introduce	   the	   term	   “Myeloproliferative	   disorders	  
(MPD)”	  to	  encompass	  Chronic	  Myelogenous	  leukemia	  (CML),	  Polycythemia	  Vera	  (PV),	  
Essential	   Thrombocythemia	   (ET),	   and	   Primary	   Myelofibrosis	   (PMF)	   and	   he	   called	  
attention	   to	   the	   clinical	   and	   bone	   marrow	   morphologic	   similarities	   between	   these	  
diseases	  (Tefferi	  et	  al.,	  2008).	  
Dameshek's	  almost	  60-­‐year-­‐old	   insight	  regarding	  the	  pathogenesis	  of	  MPD	  proved	  to	  
be	   accurate	   in	   that	   all	   four	   MPD	   originate	   from	   a	   common	   ancestral	   clone	   (or	  
oligoclones)	   that	   arises	   from	   a	   polyclonal,	   but	   disease	   susceptible,	   stem	   cell	   pool.	  
Considering	   this	   current	   understanding	   of	   the	   clonal	   structure	   in	   MPD	   and	   their	  
propensity	  to	  transform	  in	  to	  acute	  myeloid	  leukemia	  (AML),	  it	  was	  appropriate	  for	  the	  
2008	  WHO	  classification	  system	  subcommittee	  to	  recommend	  change	   in	  terminology	  
from	  MPD	  to	  “Myeloproliferative	  Neoplasms”	  (MPN).	  	  
The	   2008	   WHO	   MPN	   category	   includes	   not	   only	   CML,	   PV,	   ET,	   and	   PMF,	   defined	  
“Classic”	  MPN	  ,	  but	  also	   	  “non	  classic”	  MPN	  group,	  wich	   include	  chronic	  neutrophilic	  
leukemia	   (CNL),	   chronic	   eosinophilic	   leukemia-­‐not	   otherwise	   specified	   (CEL-­‐NOS),	  
systemic	   mastocytosis	   (SM),	   and	   MPN	   unclassifiable.	   The	   MPNs	   were	   in	   turn	  
considered	  as	  one	  of	   four	  major	   categories	  of	   chronic	  myeloid	  neoplasms,	   the	  other	  
three	   being	   myelodysplastic	   syndromes	   (MDSs),	   MDS/MPN	   and	   “Myeloid	   and	  
lymphoid	  neoplasms	  associed	  with	  eosinophilia	  and	  abnormalities	  of	  PDGFRA,	  PDGFRB	  
or	  FGFR1”	  (See	  Table	  1)	  (Tefferi	  et	  al.,	  2015).	  
In	  the	  group	  fo	  “Classic”	  MPNs,	  CML	  is	  a	  myeloproliferative	  disorder	  that	  characterized	  
by	   the	   translocation	   between	   chromosomes	   9	   and	   22	   [t(9;22)	   (q34;q11.2)],	   which	  
resulting	   in	   the	   formation	   of	   the	   Philadelphia	   (Ph)-­‐chromosome	   containing	   the	   BCR-­‐
ABL	  1	  fusion	  gene,	  	  the	  molecular	  landmark	  of	  100%	  of	  cases	  of	  this	  disease.	  Therefore,	  
“Classic”	   MPNs	   have	   been	   further	   functionally	   classified	   based	   on	   the	   presence	   or	  
absence	  of	  this	  t(9;22)	  chromosomal	  translocation	  in	  the	  Philadelphia	  (Ph)	  and	  it’s	  now	  
well	  established	  that	  the	  three	  main	  classical	  Ph-­‐negative	  MPNs	  are	  PV,	  ET	  and	  PMF.	  	  
In	  the	  MPNs	  and	  the	  other	  chronic	  myeloid	  neoplasms	  are	  characterized	  by	  recurrent	  
somatic	  mutations	   in	   different	   genes	   the	   frequency	   of	  which	   is	   shown	   in	  Table	   2.	   A	  










Tab.	  1:	  The	  2008	  World	  Health	  Organization	  Classification	  for	  Myeloid	  Neoplasms.	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Tab.	  2:	  Chronic	  Myeloid	  Neoplasm	  and	  relative	  associated	  mutation	  (Tefferi	  et	  al.,	  2015).	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2.2	  THE	  “CLASSIC”	  Ph-­‐NEGATIVE	  MYELOPROLIFERATIVE	  NEOPLASM.	  
	  
This	  study	  is	  focused	  on	  the	  three	  main	  Classical	  Ph-­‐negative	  MPN	  and,	  in	  particular	  on	  
the	   PMF	   disease.	   The	   classification	   is	   based	   on	   which	   myeloid	   cell	   lineage	   is	  
predominantly	  expanded	  in	  the	  blood;	  in	  PV	  and	  ET	  there	  are	  respectively	  elevated	  red	  
cell	   mass	   and	   elevated	   platelet	   number.	   PMF	   is	   more	   complex	   disease	   and	   patients	  
display	   bone	   marrow	   fibrosis,	   variable	   myeloid	   cell	   number,	   extramedullary	  
hematopoiesis	  and	  hepatosplenomegaly.	  
Patients	  with	  PV	  and	  ET	  have	  a	  high	  risk	  of	  thrombotic	  and/or	  haemorrhagic	  events	  and	  
may	   progress	   to	   an	   accelerated	   myelofibrosis	   phase,	   while	   all	   three	   subtypes	   are	  
associated	  with	   a	   long	   term	   risk	   of	   transformation	   to	   acute	  myeloid	   leukemia	   (AML)	  
with	  a	  uniformly	  poor	  prognosis.	  The	  risk	  of	  leukemic	  transformation	  is	  highest	  in	  PMF,	  
where	  it	  is	  estimated	  to	  be	  approximately	  10-­‐20%	  at	  10	  years.	  In	  PV	  the	  risk	  is	  2.3	  %	  at	  
10	   years	   and	   7.9	   %	   at	   20	   years	   (Tefferi	   et	   al.,	   2014).	   Transformation	   to	   AML	   is	  
considered	  relatively	  uncommon	  in	  ET	  (Vardiman	  et	  al.,	  2009).	  	  
	  
2.2.1	  POLYCYTHEMIA	  VERA	  AND	  ESSENTIAL	  THROMBOCYTHEMIA.	  
	  
PV	  is	  a	  pathologic	  condition	  presenting	  an	  increase	  of	  red	  blood	  cells	  as	  a	  result	  of	  the	  
autonomous	  and	  clonal	  proliferation	  of	  bone	  marrow	  stem	  cells	  (Fig.1).	  
Described	  for	  the	  first	  time	  by	  Vaquez	  (Vaquez	  et	  al.,	  1892)	  	  in	  1892	  and	  singled	  out	  as	  a	  
clinical	  entity	  by	  Osler	  (Osler	  et	  al.,	  2008),	  it	  was	  considered	  a	  slow	  but	  fatal	  disease	  up	  
to	   a	   few	   years	   ago.	   However,	   in	   the	   last	   decade,	   changes	   in	   the	   physiopathologic	  
criteria	  and	  the	  identification	  of	  the	  JAK2	  protein	  mutation	  (JAK2V617F)	  led	  the	  way	  to	  
diagnostic	  advances,	  better	  risk	  classification	  and	  the	  development	  of	  new	  therapies.	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  A	  	   	  B	   	  
	  
Fig.	  1:	  (A)	  Typical	  polycythaemia	  vera	  histology	  with	  panmyelosis	  and	  pleomorphic,	  clustered	  
megakayrocytes.	  Haematoxylin	  and	  Eosin	  (H&E)	  stain;	  original	  magnification	  940.	  (B)	  Borderline	  increase	  
in	  reticulin	  fibres	  (World	  Health	  Organization	  fibrosis	  score	  0–1)	  accompanying	  panmyelosis.	  Gomori	  
silver	  stain	  for	  reticulin;	  original	  magnification	  940..	  
	  
The	  annual	  incidence	  of	  PV	  is	  ~2	  per	  100,000	  inhabitants,	  respectively,	  if	  based	  on	  large	  
population	  surveys	  and	  adjusted	  to	  a	  standard	  population. 
While	  there	  is	  no	  known	  familial	  disposition	  to	  PV,	  rare	  families	  have	  been	  described	  in	  
which	  multiple	  members	  develop	  myeloproliferative	  neoplasms,	  including	  PV	  (Bellanné-­‐
Chantelot	   C.	   et	   al.,	   2006).	   Studies	   of	   these	   families	   suggest	   the	   presence	   of	   an	  
autosomal	   dominant	   mutation	   that	   may	   predispose	   to	   acquisition	   of	   a	   secondary	  
somatic	  mutation	  such	  as	  a	  JAK2	  mutation. 
Signs	   and	   symptoms	   of	   PV	  
are	   caused	   by	   a	   higher	  
erythrocytic	   load,	   leading	   to	  
increases	   in	   blood	   viscosity	  
and	  as	  a	  consequence	  to	  the	  
decrease	   of	   its	   flow.	   It	   is	  
seen	   in	   middle	   age	  
individuals	   who	  
characteristically	   present	   a	  
cyanotic	   blush,	   more	   easily	  
seen	   in	   the	   face,	  mainly	   lips,	  
nose	   tip	   and	  ears.	   The	   same	  
color	  alteration	  is	  also	  found	  
in	   the	   distal	   portion	   of	   the	  
limbs	   (Bellanné-­‐Chantelot	   C.	  
et	  al.,	  2006).	  Increased	  blood	  
pressure	   is	   frequently	   found	  
in	  PV	  and	  this	  disease	  may	  be	  
the	   cause	   of	   imbalance	   in	   the	   arterial	   hypertension.	   Common	   complaints	   are	  
headaches,	   tinnitus,	   paresthesia	   and	   erythromelalgia	   which	   are	   related	   to	   the	   vaso	  
occlusive	   phenomena	   (Bellanné-­‐Chantelot	   C.	   et	   al.,	   2006).	   Pruritus	  may	  occur	   after	   a	  
hot	  or	  tepid	  baths	  and	  there	  can	  be	  some	  exacerbation	  of	  gout.	  All	  of	  these	  symptoms	  
	  	  	  	  	  	  	  Tab.	  3:	  WHO	  Diagnostic	  Criteria	  for	  Polycythemia	  Vera	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tend	   to	   improve	   or	   disappear	   with	   treatment.	   The	   majority	   of	   patients	   present	  
splenomegaly	   of	   varying	   degrees	   at	   diagnosis	   or	   during	   the	   evolution	   of	   the	   disease.	  
They	   complain	   about	   feeling	   early	   satiety,	   increased	   abdominal	   volume,	   left	  
hypochondriac	  pain	  or	  bowel	  constipation	  	  (Bittencourt	  et	  al.,	  2012).	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
The	   diagnosis	   is	   based	   on	   the	   British	   guidelines	   and	   on	   the	  WHO	   2008	   criteria	   and	  
requires	  the	   integration	  of	  clinical,	   laboratorial,	  and	  histology	  factors	   (Table	  3).	  These	  
are	  important	  points	  for	  proving	  the	  hematic	  changes	  by	  measurements	  of	  erythrocytic	  
mass	  and	  Hb,	  as	  well	  as	  demonstrating	  the	  presence	  of	  JAK2V617F	  or	  other	  mutations	  
having	  a	  similar	  function.	  
The	   bone	   marrow	   is	   hypercellular	   in	   all	   sectors,	   mainly	   in	   the	   erythrocytic	   and	  
megakaryocytic	  lineages.	  Erythroid	  and	  myeloid	  precursors	  are	  morphologically	  normal	  
whereas	   megakaryocytes	   may	   present	   in	   loose	   and	   hyperlobulated	   groups	   located	  
close	  to	  the	  bone	  trabecula.	  The	  requirement	  is	  the	  presence	  of	  both	  major	  criteria	  and	  
at	   least	   one	   of	   the	  minor	   ones,	   or	   the	   first	  major	   criterion	   associated	   to	   two	  minor	  
criteria.	  
ET	   is	   characterized	   by	   megakaryocytic	   proliferation	   with	   consequent	   increased	  
peripheral	  platelets	  (Fig	  2).	  Its	  course	  is	  chronic	  and	  may	  progress	  to	  myelofibrosis	  or	  
acute	  leukemia	  (Tefferi	  et	  al.,	  2008).	  
The	  incidence	  varies	  between	  0.6	  to	  2.5	  cases	  per	  100,000	  persons/year.	  (Johansson,	  
2006).	  It	  is	  a	  disorder	  of	  middle	  age	  and	  is	  rare	  in	  childhood	  (one	  case	  per	  one	  million	  
children).	  It	   is	  predominant	  in	  females	  (2:1).	  It	   is	  often	  diagnosed	  following	  incidental	  
finding	   of	   a	   high	   platelet	   count,	   although	   some	  patients	   present	  with	   thrombotic	   or	  
haemorrhagic	  complication.	  There	  is	  possibly	  family	  involvement.	  	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  A	  	   	  	  	  	  	  	  	  	  	  B	   	  
Fig.2:	   Essential	   thrombocythaemia,	   A:	   Peripheral	   blood	   smear.	   The	   major	   abnormality	   seen	   is	   marked	  	  
thrombocytosis.	  The	  platelets	  show	  anisocytosis,	  but	  are	  often	  not	  remarkably	  atypical;	  	  
B:	   Bone	  marrow	   biopsy.	   The	   enlarged	  megakaryocytes	   (PAS	   staining).	   They	   reveal	   abundant	   amounts	   of	  mature	  
cytoplasm	  and	  deeply	  lobulated	  and	  hyperlobulated	  (stag-­‐horn-­‐like)	  nuclei.	  
	  
ET	   is	  an	   indolent	  disorder	  and	  affected	  patients	  have	  a	   long	  survival.	  The	  main	  risk	   is	  
thrombosis,	  while	  myelofibrosis	  and	  leukemia	  are	  rare	  and	  late	  complications.	  
This	   disease	  was	   attributed	   to	   the	   proliferative	   advantage	   of	  megakaryocytic	   factors	  
related	   to	   thrombopoietin	   (TPO)	   and	   its	   cellular	   receptor	   (c-­‐Mpl).	   The	   mutations	  
involved	   in	   MPN	   start	   early	   in	   the	   stem	   cell.	   Megakaryocytic	   precursors	   are	  
hypersensitive	  to	  TPO	  and	  the	  action	  of	  cytokines:	  TGF	  beta,	  Interleukins	  3	  (IL-­‐3),	  IL-­‐6	  
and	   IL-­‐11,	   which	   interact	   with	   the	   bone	   marrow	   microenvironment,	   promoting	   the	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growth	  of	  megakaryocytes.	  	  In	  35	  to	  70%	  of	  cases,	  acquired	  somatic	  mutation	  occur	  in	  
the	   Janus	   kinase	   2	   (JAK2V617F),	   responsible	   for	   phosphorylation	   and	   signaling	  
activators	   of	   transcription	   (STAT).	   Three	   novel	   somatic	   mutations	   in	   the	  
juxtamembrane	  region	  at	  codon	  515	  MPL	   (W515L,	  W515K,	  S505N)	  explain	  defects	   in	  
signaling	  pathways	  of	  molecules	  STAT3,	  STAT5,	  mitogen	  activator	  protein	  (MAPK)	  and	  
phosphatidylinositol-­‐3kinase	  AKT	  (PI3K/AKT),	  giving	  a	  gain	  in	  function	  and	  proliferative	  
advantage	  to	  megakaryocytes	  (Girodon	  et	  al.,	  2009).	  
In	  the	  WHO	  guidelines	  published	  in	  2008	  the	  diagnostis	  criteria	  are	  four	  (Table	  4).	  
The	  platelet	  threshold	  is	  lowered	  to	  450x109/L,	  as	  the	  earlier	  use	  of	  a	  threshold	  level	  of	  
600	   x	   109/L	   compromises	   the	   detection	   of	   early-­‐phase	   disease,	   since	   the	   95th	  
percentile	   for	   normal	   platelet	   count,	   adjusted	   for	   gender	   and	   race,	   is	   below	   400	   x	  
109/L.	   The	   demonstration	   of	   JAK2V617F	   mutation	   that	   is	   present	   in	   50-­‐55%	   of	   ET	  
patients,	  or	  the	  demonstration	  of	  other	  clonal	  marker,	  is	  included.	  But	  since	  the	  	  
importance	   of	   the	  
JAK2V617F	  marker	  
is	   limited	   by	   its	  
lower	  frequency	  in	  
ET,	   a	   bone	  
marrow	   biopsy	   is	  
still	  required	  (as	  in	  
the	   former	   2001	  
WHO	   criteria)	  
(Thiele	   et	   al.,	  
2006)	  to	  help	  with	  
the	   differential	  
diagnosis	  between	  	  
	  
JAK2V617F-­‐
negative	   ET	   and	  
reactive	  
thrombocytosis	  
and	   to	  
differentiate	   ET	   from	   other	   chronic	   myeloid	   neoplasms,	   including	   cellular	  
phase/prefibrotic	  PMF	  and	  myelodysplastic	  syndromes	  (MDS).	  Of	  special	  consideration	  
is	  the	  differentiation	  between	  ET	  and	  PMF	  grade	  0	  (CPMF0),	  which	  shows	  a	  different	  
morphology	  of	  the	  megakaryocytes	  (smaller,	  hypolobulated	  and	  clustered).	  	  
An	  important	  addition	  to	  our	  knowledge	  has	  been	  the	  discovery	  of	  new	  mutations	  in	  
calreticulin	  (CALR)	  gene	  in	  2013	  (Nangalia	  et	  al.,	  2013;	  Klampfl	  et	  al.,	  2013).	  	  	  These	  
alterations	  account	  for	  approximately	  30%	  of	  cases	  of	  essential	  thrombocythemia	  and	  
with	  the	  	  JAK2V617F	  mutation,	  the	  thrombopoietin	  receptor	  MPL	  W515K/L	  mutation	  
are	  mutually	  exclusive	  in	  essential	  thrombocythemia	  and	  support	  a	  novel	  molecular	  
categorization	  of	  essential	  thrombocythemia.	   
After	   the	   first	   clinical	   approach	   in	   according	   to	   WHO	   criteria,	   when	   evaluating	  
	  	  	  	  	  	  	  	  	  Tab.	  4:	  WHO	  Diagnostic	  Criteria	  for	  Essential	  	  Thrombocythemia.	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thrombocytosis,	   the	  detection	  of	   JAK2V617F,	  MPL	  and	  also	  CALR	  mutations	   confirms	  
the	  presence	  of	  an	  underlying	  MPN	  but	  their	  absence	  does	  not	  exclude	  the	  possibility	  
since	  up	  to	  20%	  of	  patients	  with	  ET	  might	  be	  triple	  negative.	   In	  these	  cases	  the	  bone	  
marrow	  morphology	  is	  crucial	  for	  the	  diagnosis	  (Tefferi	  and	  Barbui,	  2015).	  
	  
2.2.2	  MYELOFIBROSIS	  	  	  
The	  term	  myelofibrosis	   (MF)	   refers	   to	  primary	  MF	   (PMF)	   	   (Tefferi	  et	  al.,	  2007)	  and	  to	  
the	   phenotypically	   overlapping	   conditions	   that	   develop	   as	   (usually)	   late	   evolution	   of	  
either	  polycythemia	  vera	   (PPV-­‐MF)	  or	  essential	   thrombocythemia	   (PET-­‐MF)	   (Barosi	  et	  
al.,	   2008).	  Most	   information	   available	   in	   the	   literature	   concerns	   PMF,	   and	   rigorously	  
defined	  criteria	  for	  risk	  stratification	  have	  been	  developed	  specifically	  for	  PMF.	  
These	  disease	  occurs	  in	  0.5-­‐	  1.5	  cases	  per	  100,000	  people	  per	  year,	  most	  commonly	  in	  
the	  sixth	  or	  seventh	  decades	  of	   life	  and	  affecting	  both	  genders.	  Rarely,	  MF	  can	  occur	  
from	  the	  neonatal	  period	  to	  the	  ninth	  decade	  of	  life.	  	  In	  infants	  the	  disorder	  can	  mimics	  
the	   classic	   disease	   or	   show	   certain	   features	   but	   not	   others,	   such	   as	   absence	   of	  
hepatosplenomegaly	  	  (Sekhar	  et	  al.,	  1996).	  	  
Among	   the	  MPN	  Ph	   negative,	  MF	   is	   the	  worst	   among	   the	   chronic	  myeloproliferative	  
neoplasms	  in	  terms	  of	  survival	  	  (4-­‐5.5	  years)	  and	  quality	  of	  life	  (Cervantes	  et	  al,	  2012).	  
In	  addition,	  when	  the	  survival	  of	  patients	  with	  this	  disease	  was	  compared	  with	  that	  of	  
individuals	  of	   the	  same	  age,	  and	  the	  same	  gender	   in	   the	  general	  population,	   it	   saw	  a	  
31%	  reduction	  in	  life	  expectancy	  (Barbui	  et	  al.,	  2012).	  Even	  the	  survival	  of	  patients	  with	  
myelofibrosis	  secondary	  does	  not	  seem	  to	  differ	  from	  those	  with	  PMF.	  	  
The	  main	  causes	  of	  death	  are:	  evolution	  in	  acute	  leukemia	  (in	  20%	  of	  cases	  at	  10	  years	  
after	   diagnosis),	   infection	   and	   bleeding	   secondary	   to	   bone	   marrow	   failure,	   portal	  
hypertension	   or	   liver	   failure	   secondary	   to	   thrombosis	   of	   the	   hepatic	   veins,	   venous	  
thrombosis	  or	  metaplasia	  myeloid	  liver,	  thrombosis	  in	  other	  territories	  and	  heart	  failure	  
(Barbui	  et	  al.,	  2012).	  	  
25%	  of	  patients	  with	  MF	   is	  completely	  asymptomatic	  and	  generally	   turns	  out	   to	  have	  
the	   disease	   after	   more	   extensive	   investigations	   made	   following	   a	   simple	   analysis	   of	  
blood	   or	   a	   peripheral	   blood	   smear	   in	   which	   abnormalities	   are	   detected,	   or	   again,	  
following	  a	  ultrasound	  done	  for	  different	  reasons	  in	  which	  it	  discovers	  the	  presence	  of	  
an	  enlarged	  spleen	  (splenomegaly	  is	  a	  typical	  characteristic	  of	  patients	  with	  MF).	  	  
On	  the	  other	  hand,	  in	  patients	  with	  symptoms,	  the	  most	  common	  factor	  is	  the	  fatigue	  
caused	  by	  anemia,	  a	  typical	  feature	  of	  the	  disease	  and	  greatly	  affects	  the	  quality	  of	  life	  
of	   these	   patients.	   Other	   nonspecific	   symptoms	   include	   fever,	   night	   sweats,	   itching,	  
bone	   pain	   and	  weight	   loss	   that	   are	   present	   at	   diagnosis	   in	   20-­‐50%	   of	   patients,	   to	   a	  
greater	   extent	   in	   the	   elderly.	   In	   addition	   it	   can	   also	   occur	   early	   satiety	   and	   gastric	  
emptying	   slow	   as	   consequences	   of	   the	   pressure	   on	   the	   stomach	   from	   the	   spleen	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  -­‐	  Pathogenesis	  	  
PMF	   is	  characterized	  in	  the	  WHO	  2008	  classification	  (major	  criterion)	  as:	  "presence	  of	  
megakaryocyte	   proliferation	   and	   atypia,	   usually	   accompanied	   by	   reticulin	   and/or	  
collagen	  fibrosis,	  or	  in	  the	  absence	  of	  significant	  reticulin	  fibrosis,	  the	  megakaryocytic	  
changes	  must	  be	  accompanied	  by	  an	  increased	  bone	  marrow	  cellularity	  characterized	  
by	   granulocytic	   proliferation	   and	   often	   decreased	   erythropoiesis	   (es.:	   prefibrotic	  
cellular-­‐phase	  disease).	  	  
There	   may	   be	   a	   moderate	   increase	   in	   reticulin	   fibers,	   but	   no	   collagen	   is	   seen.	  
Megakaryocyte	   alterations	   are	   rather	   discriminating:	   anomalous	   topography,	   with	  
prominent	   morphological	   abnormalities:	   pleomorphism,	   aberration	   of	   the	   nuclear	  
cytoplasmic	   ratio	   due	   to	   large,	   bulbous	   and	   hyperchromatic	   cloud-­‐shaped	   nuclei,	  
disorganization	   of	   nuclear	   lobulation,	   naked	  megakaryocytes	   and	  maturation	   arrest.	  
Early	   fibrosis	   leads	   to	  sinus	  dilatation	  as	  a	   result	  of	   stromal	   retraction	   (Ahmed	  et	  al.,	  
2006)	  (Fig.3)	  .	  
	  
	  	  	   	  
	  	  	  	  
Fig.3:	   Example	   of	  morphological	   feature	   of	   primary	  myelofibrosis	   and	   grading	   of	   bone	  marrow	   fibrosis.	   (A)	   Pre-­‐
fibrotic	  primary	  myelofibrosis	  (MF-­‐0)	  ;	  (B)	  Early-­‐stage	  primary	  myelofibrosis	  (MF-­‐1):	  loose	  network	  of	  reticulin	  fibres	  
with	  many	  intersection,	  especially	  in	  perivascular	  areas.	  (C)	  Fibrotic	  stage	  primary	  myelofibrosis	  (MF-­‐2)	  :	  diffuse	  and	  
dense	   increase	   in	   reticulin	   fibres,	  with	  extensive	   intersection	  and	  occasionally	  with	   focal	  bundles	  of	   collagen.	   (D)	  
Fibrotic	   stage	   primary	   myelofibrosis	   (MF-­‐3):	   diffuse	   and	   dense	   increase	   in	   reticulin	   fibres,	   with	   extensive	  
intersections	  and	  coarse	  bundles	  of	  collagen.	  
	  
	  
Studies	  by	  Vannucchi	  A.	   et	   al	   have	   shown	   the	   central	   role	  of	  megakaryocytes	   in	   the	  
pathogenesis	   of	   the	   disease	   and	   the	   importance	   of	   fibrogenic	   cytokines	   such	   as	   the	  
Transforming	  Grow	  factor-­‐beta	  (TGF-­‐β)	   in	  the	  production	  of	  collagen	  and	  reticulin	  go	  
to	  constitute	  the	  fibers	  in	  the	  bone	  (Vannucchi,	  Bianchi	  et	  al.,	  	  2005).	  	  
TGF-­‐β	   is	   the	  most	   important	   growth	   factor	   in	   the	   biogenesis	   of	  marrow	   fibrosis.	   Its	  
main	  functions	  are:	  	  
•	  stimulation	  of	   fibroblasts	  to	  the	  medullary	  production	  of	  pro	  collagen	  type	   I	  and	   III	  
and	  to	  the	  synthesis	  of	  fibronectin;	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•	   inhibition	   of	   enzymes	   responsible	   for	   the	   degradation	   of	   the	   extracellular	   matrix	  
collagenase-­‐like;	  	  
•	   induction	   to	   the	   synthesis	  of	   inhibitors	  of	  proteases	   such	  as	  plasminogen	  activator	  
inhibitor.	   The	   resulting	   picture	   is	   the	   accumulation	   of	   extracellular	   matrix	   which	  
contributes	  to	  a	  further	  progression	  of	  fibrosis.	  The	  MF,	  therefore,	  could	  be	  linked,	  on	  
the	  one	  hand,	  the	  increase	  in	  the	  number	  of	  megakaryocytes	  and	  their	  maturation	  is	  
not	  complete	  and	   that,	   consequently,	   the	   release	  of	  high	  amounts	  of	  growth	   factors	  
present	   in	   the	   granules	   α	   (such	   as	   the	   TGF-­‐β)	   (Chagraoui,	   Komura	   et	   al.,	   2002;	  
Vannucchi,	  Bianchi	  et	  al.,	  2005).	  
To	  confirm	  the	  fact	  that	  the	  histological	  changes	  of	  the	  bone	  marrow	  are	  mediated	  by	  
cytokines	   has	   been	   seen	   that	   both	   the	   cellular	   levels	   that	   extracellular	   levels	   of	  
fibrogenic	   cytokines	   and	   angiogenic	   properties	   are	   altered	   in	   patients	   with	  
myelofibrosis	  (Ramashwar	  et	  al.,	  1994).	  In	  the	  MF,	  and	  then,	  the	  bone	  marrow	  fibrosis	  
occurs	  in	  response	  to	  a	  clonal	  proliferation	  of	  hematopoietic	  stem	  cells	  that	  lead	  to	  a	  
profound	  morphologically	  abnormal	  hyperplasia	  of	  megakaryocytes	  and	  populations	  of	  
monocytes	   which	   release	   growth	   factors	   fibrogenic.	   What	   follows	   from	   the	   clinical	  
point	  of	  view,	   finally,	   it	  was	  a	   result	  of	   the	  alteration	  of	   the	  hematopoietic	   stem	  cell	  
and	  its	  progeny	  rather	  than	  related	  to	  the	  event	  of	  simple	  marrow	  fibrosis	  (Hofmann	  et	  
al.,	   2007).	   The	   second	   factor,	   neoangiogenesis,	   in	  particular	   in	  bone	  marrow,	  due	   to	  
the	   proliferation	   of	   endothelial	   cells	   has	   been	   postulated	   to	   be	   mediated	   by	   an	  
increase	   in	   the	   production	   and	   release	   of	   factors	   such	   as	   b-­‐FGF	   and	   VEGF	   by	  
megakaryocytes.	   The	   involvement	   of	   the	   latter	   suggests	   a	   possible	   link	   between	  
angiogenesis	  and	   fibrosclerosis	  medullary	   (Barbui,	  2012).	  Finally,	   in	  addition	   to	   these	  
two	   characteristics,	   considerable	   importance	   is	   the	   amount	  of	   CD34+	   stem	   cells	   that	  
are	   a	   undifferentiated	   progenitor	   cells	   of	   the	  myeloid	   lineage,	   present	   in	   individuals	  
with	  MF	  about	  360	  times	  greater	  not	  only	  compared	  to	  normal	  controls,	  but	  also	  with	  
respect	  to	  patients	  with	  TE	  or	  PV,	  from	  18	  to	  30	  times	  more.	  The	  number	  of	  circulating	  
CD34+	  cells	  tends	  to	  increase	  with	  the	  progression	  of	  the	  disease	  and	  there	  is	  a	  close	  
correlation	  between	  a	  very	   large	  number	  (>	  300x106	  /	  L)	  and	  the	  upcoming	   leukemic	  
evolution	   (Barosi	   et	   al.,	   2012).	   Compared	   to	   controls,	   in	   patients	   with	  MF	   they	   are	  
present	   in	   the	  circulation	  also	  many	  more	  pluripotent	  cells,	   in	  particular,	   the	  colony-­‐
forming	  units	  CFU-­‐MK	  (colony-­‐forming	  unit-­‐megakaryocyte),	  and	  also	  CFU-­‐GM	  (colony	  
forming	   unit	   granulocyte-­‐monocyte),	   BFU-­‐E	   (burst-­‐forming	   unit	   erythrocyte),	   CFU-­‐
GEMM	  (colony	  forming	  unit	  granulocyte,	  erythroid,	  monocyte,	  	  megakaryocyte).	  
About	   animal	   models,	   transgenic	   and	   knock-­‐in	   mice	   expressing	   mutant	   JAK2	   have	  
provided	   compelling	   evidence	   that	  mutated	   JAK2	   (typically	   JAK2V617F)	   is	   a	   driver	   in	  
this	   major	   subset	   of	   myeloproliferative	   neoplasms,	   however	   these	   mice	   are	   poor	  
models	   for	  PMF.	  PMF	  characteristics	  such	  as	  megakaryocyte	  proliferation	  and	   fibrosis	  
have	  been	  recapitulated	   in	  mice	  expressing	   thrombopoietin	  (Villeval	  et	  al.,	  1997),	   the	  
NF-­‐E2	  transcription	  factor	   (Kaufmann	  et	  al.,	  2012),	  vascular	  endothelial	  growth	  factor	  
(Maes	  et	  al.,	  2010)	  or	  reduced	  levels	  of	  GATA1	  (Vannucchi	  et	  al.,	  2008),	  suggesting	  that	  
abnormal	   erythroid/megakaryocyte	   development	   and/or	   abnormal	   release	   of	  
cytokines	  may	  be	  a	  key	  factor	  in	  the	  disease.	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-­‐	  Diagnosis	  of	  PMF	  
Current	   diagnosis	   of	   PMF	   is	   based	   on	   the	   2008	   World	   Health	   Organization	   (WHO)	  
criteria,	   (Tefferi	  et	  al.,	  2008)	   (	  which	  enlist	  histopathologic,	  morphologic,	   clinical,	  and	  
molecular-­‐cytogenetic	   variables).	   Histopathology	   is	   key	   to	   the	   diagnosis,	  
demonstrating	  the	  atypia	  of	  megakaryocyte	  proliferation	  even	  in	  the	  absence	  of	  overt	  
reticulin	   fibrosis;	   it	   also	   helps	   in	   the	   differential	   diagnosis	   with	   nonclassical	   MPN	  
disorders,	  myelodysplastic	   syndromes	   including	   the	  del(5q)	   syndrome,	  PV	  or	   ET	  with	  
initial	  BM	  fibrosis,	  and	  other	  myeloid	  neoplasms.	  An	  other	  major	  diagnostic	  criterion	  is	  
represented	  by	  the	  detection	  of	  JAK2V617F	  or	  a	  MPL	  mutation,	  occurring	   in	  60%	  and	  
5%-­‐10%	   of	   the	   patients,	  
respectively,	   and	   other	   MPN-­‐
associated	   molecular	  
abnormalities	   (eg,	  CBL,	   ASXL1,	  
TET2,	   and	  EZH2)	   or	   clonal	  
markers	   (particularly	   trisomy	   9	  
or	   13q−)	   that	   distinguish	   PMF	  
from	   	   reactive	   marrow	   fibrosis	  
(Tefferi	   et	   al,	   2010)	   absence	  of	  
BCR/ABL	   rearrangement	   allows	  
the	   exclusion	   of	   chronic	  
myelogenous	   leukemia.	   Minor	  
criteria	   are	   represented	   by	  
leukoerythroblastosis,	   raised	  
serum	   lactate	   dehydrogenase	  
levels,	   anemia,	   and	  
splenomegaly	  (See	  Table	  5).	  
Despite	  the	  diagnostic	  criteria	  used	  in	  the	  different	  classifications	  are	  reproducible	  and	  
clinically	   useful,	   the	   current	   WHO	   classification	   does	   not	   take	   into	   account	   some	  
aspects	  molecular	   recently	   identified	   in	  MPN,	  without	   ensuring	   complete	   diagnostic	  
specificity.	  With	  the	  discovery	  of	  mutations	  in	  the	  gene	  CALR	  (which	  will	  be	  discussed	  
in	  more	  detail	  later),	  the	  90%	  of	  patients	  with	  ET	  and	  PMF	  are	  characterized	  by	  at	  least	  
one	  alteration	  clonal	  specific	  enough	  to	  confirm	  the	  diagnosis	  of	  MPN.	  	  In	  light	  of	  this,	  
in	   a	   recent	   paper	   by	   Tefferi	   et	   al.,	   It	   has	   proposed	   a	   revision	   of	   the	   2008	   WHO	  
diagnostic	  criteria	  determining	  what	  is	  reasonable	  to	  expect	  to	  make	  the	  diagnosis	  of	  
PMF	   in	   the	   presence	   of	   three	  main	   criteria	   such	   as:	   (1)	   a	   typical	  morphology	   in	   the	  
bone	  marrow,	  (2)	  the	  absence	  of	  evidence	  for	  another	  myeloid	  malignancy	  who	  CML,	  
PV	  or	  ET,	  and	  (3)	  the	  presence	  of	  mutations	   in	  JAK2,	  CALR	  or	  MPL.	   In	  the	  absence	  of	  
mutations	  in	  JAK2,	  CALR	  or	  MPL	  (ie	  cases	  called	  "triple	  negative"),	  the	  diagnosis	  of	  PMF	  
would	   require	   not	   only	   the	   presence	   of	   the	   first	   two	   criteria	   but	   also	   more	   the	  
exclusion	   of	   reactive	   marrow	   fibrosis	   and	   the	   presence	   of	   clinical	   and	   laboratory	  
factors	  that	  are	  typical	  of	  the	  PMF.	  These	  additional	  criteria	  are	  now	  incorporated	  as	  
minor	  criteria	  in	  the	  revision	  scheme	  that	  include	  the	  presence	  of	  anemia	  and	  palpable	  
splenomegaly,	   the	   presence	   of	   leucoeritroblastosis	   or	   the	   increase	   in	   lactate	  
	  	  	  	  	  	  Tab.	  5:	  WHO	  Diagnostic	  Criteria	  for	  Primary	  Myelofibrosis.	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dehydrogenase	   (LDH)	   (Tefferi	   et	   al,	   2014).	   Once	   the	   diagnosis	   of	   PMF,	   in	   order	   to	  
decide	   the	   best	   therapeutic	   strategy	   to	   be	   used	   for	   each	   patient	   and	   define	   the	  
prognosis,	  should	  be	  established	  in	  which	  risk	  category	  prognostic	  belongs.	  
In	   fact,	   just	   in	   order	   to	   stratify	   patients	   into	   different	   risk	   categories,	   lWG-­‐MRT	   has	  
initially	  developed	  an	  International	  Prognostic,	  the	  IPSS	  (International	  Prognostic	  Score	  
System)	   (Cervantes	  et	   al,	   2009),	   based	  on	  data	   from	  Clinical	   and	   laboratory	   features	  
obtained	   from	   a	   series	   of	   1001	   patients	   with	   PMF.	   To	   predict	   the	   survival	   of	   these	  
patients,	   this	   system	   takes	   into	   account	   five	   variables,	   determined	   at	   the	   time	   of	  
diagnosis:	   (1)	   age	  over	  65,	   (2)	  hemoglobin	   levels	  below	  100	  g/L,	   (3)	  white	  blood	  cell	  
count	  higher	  to	  25	  *	  109	  /	  L,	  (4)	  a	  percentage	  of	  blasts	  in	  the	  peripheral	  blood	  greater	  
than	  or	  equal	   to	  1%,	  and	   (5)	  presence	  of	   constitutional	   symptoms	   (eg.	  night	   sweats,	  
weight	  reduction	  of	  10%	  over	  6	  months,	  fever	  devoid	  of	  infection).	  
Based	  on	   these	  parameters,	   patients	  were	  divided	   into	   four	  different	   classes	  of	   risk,	  
the	  category	  of	   low	  risk,	   intermediate	  risk	  1,	  2	  at	   intermediate	  risk	  and	  high	  risk.	  The	  
same	   parameters	   used	   dall'IPSS	   prognosis	   have	   been	   incorporated	   in	   a	   time-­‐
dependent	   prognostic	   score,	   applicable	   at	   all	   times	   of	   the	   natural	   history	   of	   the	  
disease,	   called	   DIPSS	   (Dynamic	   International	   Prognostic	   Scoring	   System).	   Each	  
parameter	  is	  assigned	  a	  single	  point,	  with	  the	  exception	  of	  anemia,	  which	  affects	  more	  
prognosis	   (2	   points).	   This	   score	   can	   identify	   patients	   who	   have	   a	   more	   aggressive	  
course	  of	  the	  disease,	  so	  they	  can	  properly	  orient	  the	  therapeutic	  choices	  (Passamonti	  
et	  al,	  2010).	  Other	  factors	  not	   included	  nell'IPSS	  who	  had	  an	  impact	  on	  survival	  were	  
represented	  by	   the	  need	   for	   transfusions,	  a	  platelet	  count	  of	   less	   than	  100	  *	  109	   /	   L	  
and	   an	   "unfavorable	   karyotype	  defined".	   These	   three	   variables	  were	   included	   in	   the	  
recently	   defined	   a	   new	   prognostic	   score	   Dynamic	   International	   Prognostic	   Scoring	  
System-­‐plus	   (DIPSS-­‐plus),	  which	  allows	  a	  better	   score	  prognostic	   classification	   (Table	  
6).	  
	  










For	   each	   factor	   is	   assigned	   a	   point	   ,	   and	   so,	   depending	   on	   the	   number	   of	   factors	  
present,	  it	  is	  possible	  to	  subdivide	  the	  patients	  (	  also	  in	  this	  case	  as	  it	  did	  for	  the	  IPSS	  )	  
in	   four	   different	   risk	   groups	   :	   low-­‐risk	   (	   0	   negative	   prognostic	   factors	   )	  with	  median	  
survival	   of	   185	  months	   ,	   intermediate	   risk-­‐1	   (	   factor	   1	   )	   with	  median	   survival	   of	   78	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months	  ,	  intermediate	  risk	  -­‐2	  (	  2	  factors	  )	  with	  median	  survival	  of	  35	  months	  ,	  high	  risk	  
(	  at	   least	  3	  factors	   )	  with	  median	  survival	  of	  16	  months	  (	  Tefferi	  et	  al.	   ,	  2014)	   (Fig.4).	  
Since	   the	   publication	   of	   DIPSS-­‐plus	   score,	   several	   studies	   that	   suggest	   additional	  
prognostic	  information	  have	  been	  published.	  
For	  example	  Tefferi	  and	  colleagues	  demonstrated	  that	  a	  >	  80%	  2-­‐year	  mortality	  in	  PMF	  
patients	  was	   predicted	   by	  monosomal	   karyotype,	   inv(3)/i(17q)	   abnormalities,	   or	   any	  
two	  of	  circulating	  blasts	  >9%,	   leukocytes	  ≥	  40*109/L	  or	  other	  unfavourable	  karyotype	  
(Tefferi	  et	  al.,	  2011).	  
	  
 
Fig.4: DIPSS-­‐plus	   (Dynamic	   international	   prognostic	   scoring	   system	   1	   karyotype	   1	   platelet	   count	   1	   transfusion	  
status)	  risk	  stratification	  in	  793	  patients	  with	  primary	  myelofibrosis	  seen	  at	  Mayo	  Clinic	  Rochester	  (with	  permission	  
from	  Gangat	  et	  al.,	  2011).	  
	  
More	  recently,	  a	  number	  of	  DIPSS-­‐plus-­‐independent	  risk	  factors	  in	  PMF	  were	  identified	  
and	   they	   include	   “driver	  mutations”	   other	   than	   type	   1	   or	   type	   1-­‐like	  CALR	   variants,	  
(Tefferi	  et	  al.,	  2014)	  monosomal	  karyotype,	  (Vaidja	  et	  al.,	  2011)	  nullizygosity	  for	  JAK2	  
46/1	  haplotype,	  (Tefferi	  et	  al.,	  2010)	  low	  JAK2V617F	  allele	  burden,	  (Tefferi	  et	  al.,	  2008,	  
Guglielmelli	   et	   al.,	   2009)	   presence	   or	   number	   (Guglielmelli	   et	   al.,	   2014)	   of	   IDH1/2,	  
EZH2,	  SRSF2	  or	  ASXL1	  mutations	  (Vannucchi	  et	  al.,	  2013)	  	  and	  increased	  serum	  IL-­‐8,	  	  IL-­‐
2R	   (Tefferi	  et	  al.,	  2011)	  or	   serum	   free	   light	   chain	   levels	   (Pardanani	  et	  al.,	  2012).	   In	  a	  
recent	  international	  study	  of	  570	  patients	  with	  PMF	  (Pardanai	  et	  al.,	  2012)	  the	  authors	  
reported	  the	  longest	  survival	  in	  CALR+ASXL1-­‐	  patients	  (median	  10.4	  years)	  and	  shortest	  
in	   CALR–ASXL1+	   patients	   (median	   2.3	   years).	   CALR+ASXL1+	   and	   CALR–ASXL1-­‐	   patients	  
had	   similar	   survival	   and	   were	   grouped	   together	   in	   an	   intermediate	   risk	   category	  
(median	  survival	  5.8	  years).	  
Some	  of	  the	  above	  outlined	  clinical	  and	  genetic	  risk	  factors	  have	  also	  been	  associated	  
with	  increased	  risk	  of	  leukemic	  transformation.	  
-­‐	  Treatment	  
Treatment	   of	   patients	   with	   myelofibrosis	   is	   based	   on	   symptoms	   and	   risk	   category.	  
Asymptomatic,	   low	   risk	   myelofibrosis	   (DIPSS-­‐plus	   0–1	   risk	   factors)	   patients	   may	   be	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observed.	   Symptomatic,	   intermediate-­‐2	   or	   high-­‐risk	   (DIPSS-­‐plus	   2–4	   risk	   factors)	  
patients	   are	   considered	   treatment	   with	   a	   JAK2	   inhibitor,	   a	   clinical	   trial,	   or	   are	  
considered	  an	  allogeneic	  stem	  cell	  transplant.	  Patients	  that	  are	  not	  candidates	  for	  JAK2	  
inhibitors	   or	   stem	   cell	   transplant	   was	   treated	   with	   agents	   such	   as	   androgens,	  
immunomodulatory	  agents	  (i.e.,	  thalidomide),	  interferon,	  or	  hydroxyurea	  (Mesa	  et	  al.,	  
2003).	   Unfortunately,	   these	   treatment	   options	   are	   only	   helpful	   in	   a	   minority	   of	  
patients,	   are	   not	   usually	   durable,	   and	   do	   not	   appreciably	   alter	   the	   biology	   of	   the	  
disease	  (Barbui	  et	  al.,	  2011).	  
Improved	   understanding	   of	   the	   disease	   biology	   of	  MPNs	   has	   led	   to	   the	   approval	   of	  
Ruxolitinib,	  the	  first	  oral	  JAK1/2	  inhibitor,	  by	  the	  Food	  and	  Drug	  Administration	  in	  2011	  
for	   the	   treatment	   of	   patients	   with	   intermediate	   and	   high-­‐risk	   myelofibrosis.	   The	  
approval	   of	   Ruxolitinib	   was	   based	   on	   two	   large,	   international,	   phase	   III	   studies:	  
COMFORT	  I	  and	  II	  (Verstovsek	  et	  al.,	  2012;	  Harrison	  et	  al.,	  2012).	  
The	  JAK-­‐inhibitors	  act	  mainly	  by	  inhibiting	  dysregulated	  JAK-­‐STAT	  signalling,	  present	  in	  
all	  MF	  patients.	   They	   are	   not	   selective	   of	   the	  mutated	   JAK2	   so	   they	   are	   indicated	   in	  
both	  JAK	  mutated	  and	  unmutated	  MF	  patients.	  	  
In	   the	   COMFORT	   I	   study,	   patients	   with	   myelofibrosis	   were	   randomized	   to	   receive	  
Ruxolitinib	  or	  placebo	  (Verstovsek	  et	  al.,	  2012).	  Patients	  in	  the	  COMFORT	  II	  study	  were	  
randomized	  in	  a	  2	  :	  1	  fashion	  to	  receive	  ruxolitinib	  or	  best	  available	  therapy.	  Patients	  
were	   eligible	   regardless	   of	   their	   JAK2	   mutational	   status	   and,	   importantly,	   noted	   to	  
benefit	   regardless	   of	   their	   JAK2	   mutational	   status.	   The	   primary	   endpoint	   of	   both	  
studies	  was	  spleen	  volume	  reduction	  of	  35%	  at	  24	  and	  48	  weeks	  for	  COMFORT	  I	  and	  II,	  
respectively,	  by	  MRI.	  Secondary	  endpoints	  in	  the	  COMFORT	  I	  study	  included	  durability	  
of	  response,	  improvement	  in	  symptom	  burden	  as	  measured	  by	  myelofibrosis	  symptom	  
assessment	   form,	  and	  overall	  survival	   (OS).	   In	  the	  COMFORT	   I	  study,	  42%	  of	  patients	  
experienced	  spleen	  volume	  reduction	  by	  24	  weeks,	  and	  in	  the	  COMFORT	  II	  study,	  28%	  
of	  patients	  compared	  with	  0%	  in	  the	  best	  available	  therapy	  group	  experienced	  a	  35%	  
spleen	   volume	   reduction	   at	   48	   weeks.	   In	   addition,	   45%	   of	   patients	   experienced	  
significant	  symptom	  improvement	  in	  the	  ruxolitinib	  group.	  
The	   benefits	   of	   ruxolitinib	   were	   durable	   and,	   in	   addition,	   both	   studies	   reported	   a	  
significant	   improvement	   in	   OS	   (results	   of	   the	   COMFORT	   II	   study	   were	   updated	   in	   a	  
recent	   study	  with	  3-­‐year	   follow-­‐up	  confirming	  an	   	  OS	  benefit).	  On	   the	  basis	  of	   these	  
results,	  patients	  with	  intermediate	  or	  high-­‐risk	  myelofibrosis,	  who	  have	  splenomegaly,	  
and/or	  constitutional	  symptoms	  can	  consider	  the	  use	  of	  ruxolitinib.	  It	  is	  the	  first	  drug	  
approved	  for	  MF	  treatment	  (Verstovsek	  et	  al.,	  2010).	  
It	   should	  be	  noted	   that	  despite	   improvement	   in	   the	  understanding	  of	   the	  molecular	  
biology	   of	  myelofibrosis	   and	   the	   approval	   of	   ruxolitinib,	   the	   only	   curative	   treatment	  
approach	  for	  this	  disease	  is	  allogeneic	  stem	  cell	  transplantation.	  
By	  far	  ASCT	  (allogeneic	  stem	  cell	  transplantation)	   is	  the	  only	  treatment	  modality	  that	  
can	  either	  cure	  or	  prolong	  life	  and	  is	  therefore	  recommended	  in	  either	  DIPSS-­‐plus	  high	  
(i.e.	  presence	  of	  at	   least	   four	  of	  the	  8	  DIPSS-­‐plus	  risk	   factors)	   (Gargat	  et	  al.,	  2011)	  or	  
molecularly	  high	  (absence	  of	  type	  1/type	  1-­‐like	  CALR	  mutation	  and	  presence	  of	  ASXL1	  
or	  related	  high	  risk	  mutation)	  (Tefferi	  et	  al.,	  2014)	  	  risk	  disease	  (Ballen	  et	  al.,2010).	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Pre-­‐transplant	   JAK-­‐inhibitor	   treatment	   can	   reduce	   spleen	   size	   and	   improve	  
constitutional	  symptoms,	  but	  is	  currently	  being	  tested	  in	  clinical	  studies	  and	  should	  be	  
regarded	  as	  experimental.	  
	  
2.3	  MOLECULAR	  BASIS	  OF	  MYELOPROLIFERATIVE	  NEOPLASM	  
2.3.1.DRIVER	  MUTATIONS	  IN	  MYELOPROLIFERATIVE	  PH-­‐	  DISORDERS.	  
	  
Our	  biological	  understanding	  of	  the	  MPNs	  was	  markedly	  advanced	  with	  the	  discovery	  
of	   the	   JAK2V617F	  mutation	   in	  2005	   (Levine	  et	  al.,	  2005)	   .	   This	  work	  and	  subsequent	  
genetic	   investigations	  haverevealed	  a	  number	  of	  mutations	   inside	  and	  outside	  of	   the	  
JAK–STAT	   pathway.	   The	   majority	   of	   patients	   with	   myelofibrosis	   have	   a	   mutation	   in	  
JAK2	  ,	  MPL,	  or	  CALR	  (	  Nangalia	  et	  al.,	  2013;	  Klampf	  et	  al.,	  2013)	  ,	  and	  these	  mutations	  
may	   be	   thought	   of	   as	   driver	   mutations	   in	   myelofibrosis.	   Furthermore,	   all	   of	   these	  
mutations	  appear	  to	  exert	  their	  effects,	  at	  least	  in	  part,	  by	  activating	  JAK–STAT	  	  target	  
genes.	  
Indeed,	   in	  one	  analysis	  of	  gene	  expression	   in	  MPN	  patients	  with	   JAK2,	  MPL,	  or	  CALR	  	  
mutations	  versus	  controls,	  gene	  expression	   is	  unable	  to	  distinguish	  between	  patients	  
with	  MPN	  with	  different	  driver	  mutations,	  but	  was	  able	  to	  discriminate	  between	  MPN	  
patients	  and	  controls.	  Furthermore,	   this	  analysis	   revealed	  activation	  of	   the	  JAK–STAT	  
pathway	   as	   a	   central	   feature	   in	   MPN	   patients,	   indicating	   the	   central	   role	   for	   this	  
pathway	  in	  such	  patients	  regardless	  of	  which	  driver	  mutation	  was	  present.	  
-­‐	  JAK2	  mutations	  
JAK2	   is	   the	   member	   of	   the	   Janus	   tyrosine	   kinase	   family	   that	   is	  
responsible	   for	   signal	   transduction	   by	   the	   erythropoietin,	  
thrombopoietin,	   granulocyte	   macrophage	   colony	   stimulating	  
factor,	   and	   granulocyte	   colony-­‐stimulating	   factor	   receptors	   in	  
hematopoietic	   cells,	   as	   well	   as	   for	   signal	   transduction	   by	   many	  
cytokine	  receptors,	  such	  as	  interleukin	  IL-­‐3,	  IL-­‐5,	  and	  IL-­‐6	  receptors	  
(Verma	   et	   al.,	   2003).	   JAK2	   is	   normally	   activated	   when	   these	  
receptors	   bind	   their	   cognate	   ligands.	   In	   2005,	   the	   first	   recurrent	  
molecular	   abnormality	   has	   been	   identified	   in	   this	   gene:	   the	  
JAK2V617F	  mutation.	  It	  is	  a	  result	  of	  a	  G	  to	  T	  nucleotide	  shift	  at	  nt	  
1849	   in	   exon	   14,	   (a	   point	   mutation	   resulting	   in	   a	   switch	   from	  
phenylalanine	   to	   valine	   at	   amino	   acid	   position	   617	   (V617F))	  
that	   is	   located	   in	   the	   tyrosine	   kinase-­‐like	   domain-­‐2	   (JH2),	  
pseudo-­‐kinase	  domain	  of	  JAK2,	  and	  likely	  results	  in	  the	  loss	  of	  
auto-­‐inhibitory	   control	   and/or	   cytokine-­‐induced	   hyper-­‐
activation	  of	  JAK2	  (Kundrapu	  et	  al.,	  2008)	  (Fig.	  5).	  
Expression	  of	  V617F-­‐mutated	  allele	  in	  cytokine-­‐dependent	  cell	  
lines	   conferred	   cytokine	   independence	   and	   cytokine	   hypersensitivity	   through	   the	  
constitutive	  activation	  of	  signal	   transducers	  and	  activators	  of	   transcription-­‐5	  (STAT5),	  
	  Fig.5:	   Structure	   of	   the	  
cytosolic	   tyrosine	   kinase	  
JAK2.The	   V617F	   mutation	  
is	   located	   in	   the	   pseudo	  
kinase	  domain.	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v-­‐akt	   murine	   thymoma	   viral	   oncogene	   homolog	   1	   (AKT)	   and	   extracellular	   signal-­‐
regulated	  kinase	  (ERK)-­‐	  dependent	  pathways	  (Levine	  et	  al.,2005;	  	  Vainchenker	  W	  et	  al.,	  
2013)	   (Fig.	   6);	   in	   addition,	   mice	   transplanted	   with	   marrow	   cells	   transduced	   with	   a	  
retrovirus	   expressing	   JAK2V617F	   invariably	   developed	   erythrocytosis	   (James	   et	   al.,	  
2005;	  Wernig	  et	  al.,	  2006;	  Lacout	  et	  al.,	  2006;	  	  Bumm	  et	  al.,	  2006;	  Zaleskas	  et	  al.,	  2006)	  
eventually	  associated	  with	  leucocytosis,	  splenomegaly	  and	  later	  changes	  suggestive	  of	  
transformation	  to	  post-­‐polycythemic	  myelofibrosis	  (Wernig	  et	  al.,	  2006;	  Lacout	  et	  al.,	  
2006;	  	  Bumm	  et	  al.,	  2006;	  Zaleskas	  et	  al.,	  2006).	  
	  
	  
Fig.	  6:	  Mechanism	  of	  activation	  of	  JAK2	  Kinase	  activity	  by	  mutations	  in	  the	  JAK2	  signalling	  pathway.	  
	  
More	  recently,	  transgenic	  mice	  presenting	  an	  expression	  of	  mutated	  allele	  lower	  than	  
wild-­‐type	  one	  have	  been	  generated,	  and	  found	  to	  develop	  an	  ET-­‐like	  phenotype	  (Tiedt	  
et	   al.,	   2008;	   Shide	   et	   al.,	   2007);	   overall	   these	   data	   suggest	   that	   the	   JAK2V617F	  
mutation	  is	  an	  integral	  component	  of	  the	  myeloproliferative	  process	  that	  underlies	  the	  
different	  classic	  MPNs.	  	  
The	   frequency	  of	   JAK2V617F	  mutation	   is	   estimated	  at	   over	   95%	   in	  PV,	   60%	   in	   ET	  or	  
PMF	  (Verstovsek	  et	  al.	  2006;	  Vizmanos	  et	  al.	  2006)	  as	  well	  as	  	  50%	  in	  patients	  with	  the	  
infrequent	   entity	   ‘refractory	   anaemia	   with	   ringed	   sideroblasts	   and	   thrombocytosis’	  
(RARS-­‐T).	  The	  mutation	  can	  be	  found	  on	  one	  or	  both	  alleles	  (homozygosity)	  as	  a	  result	  
of	  a	  mitotic	  recombination	  process	  that	  occurs	  in	  most	  patients	  with	  PV	  or	  PMF	  and	  a	  
minority	   only	   of	   ET	   (James	   et	   al.,	   2005;	   Levine	   et	   al.,	   2007;	   Kralovics	   et	   al.	   2005)	  
Additional	  complex	  mutations,	  deletions	  or	   insertions	  have	  been	  detected	  in	  exon	  12	  
of	   JAK2	   and	   are	   usually	   associated	   with	   clinical	   features	   typical	   of	   a	   JAK2V617F-­‐
negative	  PV	  or	  idiopathic	  erythrocytosis	  (Scott	  et	  al.,	  2011).	  
The	  activated	  kinase	  promotes	  cell	  proliferation	  and	  resistance	  to	  cell	  death,	  as	  well	  as	  
hypersensitivity	   to	   hematopoietic	   growth	   factors	   and	   cytokines	   signaling	   through	  
receptors	   utilizing	   JAK2.	   Thus,	   cells	   expressing	   the	  mutant	   JAK2	   have	   both	   a	   growth	  
and	   a	   survival	   advantage	   over	   their	   normal	   counterparts	   and	   expand	   their	   numbers	  
autonomously.	  	  
This	   effect	   is	   most	   pronounced	   in	   maturing	   hematopoietic	   cells,	   which	   require	  
erythropoietin,	   thrombopoietin,	   and	   granulocyte	   colony-­‐stimulating	   factor	   for	  
proliferation	   and	   survival,	   compared	  with	   undifferentiated	  hematopoietic	   stem	   cells,	  
which	  do	  not	  (Parganas	  et	  al.,	  1998)	  and	  in	  which	  only	  the	  thrombopoietin	  receptor	  is	  
	   20	  
expressed	  (Solar	  et	  al.,	  1998).	  	  
The	  presence	  of	  JAK2V617F,	  as	  mentioned	  in	  the	  previous	  paragraphs,	  is	  now	  included	  
as	  a	  major	  criterion	  in	  the	  revised	  World	  Health	  Organization	  (WHO)	  diagnostic	  criteria	  
for	  PV,	  where	   it	   is	  considered	  as	  a	  clonal	  marker	  for	  ET	  and	  MF	  (Tefferi	  et	  al.,	  2008);	  
furthermore,	   JAK2	   mutational	   load	   has	   been	   suggested	   to	   be	   correlated	   with	   the	  
phenotypes	  of	  disease.	  
The	   JAK2V617F	  mutation	   can	   be	   present	   in	   a	   heterozygous	   state	   or	   can	   progress	   to	  
homozygosity	   most	   frequently	   by	   a	   mitotic	   recombination	   event	   resulting	   in	  
uniparental	   disomy.	   Different	   studies	   suggested	   that	   in	   ET	   and	   PV,	   a	   higher	   allele	  
burden	   is	   associated	   to	   disease	   progression	   to	   MF	   (Steensma	   et	   al.,	   2006)	   ,	   but	   in	  
contrast,	  a	  low	  allele	  burden	  is	  related	  to	  an	  inferior	  overall	  and	  leukemia-­‐free	  survival	  
in	   MF	   (Steensma	   et	   al.,	   2006).	   It	   can	   be	   an	   important	   marker	   in	   monitoring	   the	  
molecular	  response	  to	  the	  novel	  JAK2	  inhibitors.	  
The	  only	  curative	  treatment	  for	  MF	  is	  allogenic	  stem	  cell	  transplantation	  (ASCT),	  which	  
was	   initially	   associated	   with	   significant	   transplantation-­‐related	   mortality.	   Studies	  
reported	  that	  JAK2V617F	  mutation	  disappears	  after	  ASCT	  and	  reappears	  in	  the	  case	  of	  
ensuring	  relapse,	  and	  the	  value	  of	  this	  mutation	  as	  a	  minimal	  residual	  disease	  marker	  
to	   guide	   adoptive	   immune	   therapy	   is	   well	   established	   (Huijsmans	   et	   al.,	   2011).	  
Detection	  of	  this	  mutation	  status	  and	  allele	  burden	  is	  helpful	  in	  differential	  diagnosis,	  
prognosis,	  disease	  phenotype,	  complication,and	  evolution.	  
JAK2	  is	  an	  obligatory	  kinase	  for	  the	  proliferation	  and	  differentiation	  of	  erythroid	  cells	  
and	  megakaryocytes	   and,	   therefore,	   is	   a	   relevant	   therapeutic	   target	   for	   agents	   that	  
specifically	   inhibit	   its	   activity.	   To	   date,	   clinical	   trials	   are	   investigating	   several	   JAK2	  
inhibitors	   in	  patients	  with	  myeloproliferative	  disorder,	  and	  more	   inhibitors	  are	  being	  
developed.	  The	  results	  to	  date	  indicate	  that	  these	  inhibitors	  reduce	  splenomegaly	  and	  
alleviate	   constitutional	   symptoms,	   such	   as	   night	   sweats,	   fatigue,	   and	   pruritus,	   in	   a	  
reversible	  manner,	  suggesting	  that	  a	  substantial	  inflammatory	  component	  contributes	  
to	   the	   signs	   and	   symptoms	   of	   the	   myeloproliferative	   disorders	   (Mesa	   et	   al.,	   2007),	  
possibly	   through	   JAK2V617F–activated	   cytokine	   receptors.	   However,	   these	   inhibitors	  
have	   had	   only	   a	  modest	   impact	   on	   the	   JAK2V617F	   allele	   burden,	   although	   this	  may	  
require	   a	   longer	   duration	   of	   therapy.	   At	   the	   same	   time,	   pluripotent	   hematopoietic	  
stem	  cells	  do	  not	  seem	  to	  require	  JAK2	  for	  their	  survival	  or	  proliferation	  (Parganas	  et	  
al.,	   1998),	   and	   JAK2	   mutations,	   unlike	   the	   BCR-­‐ABL	   fusion	   kinase	   in	   chronic	  
myelogenous	   leukemia,	   are	   probably	   not	   the	   initiating	   molecular	   event	   in	  
polycythemia	  vera,	  essential	  thrombocytosis,	  or	  primary	  myelofibrosis.	  
	  	  -­‐	  MPL	  mutations.	  
Another	  recurrent	  molecular	  abnormality	  of	  MPN	  is	  represented	  by	  somatic	  mutations	  
at	   codon	   515	   of	  MPL,	   (Pikman	   et	   al.,	   2006)	   which,	   as	   is	   the	   case	   with	   JAK2V617F,	  
involve	  early	  myeloid	  and	  lymphoid	  progenitors.	  Mutations	  in	  this	  gene	  are	  identified	  
one	  year	  after	  the	  discovery	  of	  JAK2V617F	  alteration.	  
MPL	  gene	  (named	  after	  myeloproliferative	  leukemia	  virus	  oncogene	  homolog)	  consists	  
of	   12	   exons	   and	   it	   is	   located	   on	   chromosome	   1p34;	   it	   encodes	   a	   635-­‐amino	   acids	  
protein,	  constituted	  by	  two	  cytokine	  receptor	  motifs	  (CRMs	  –	  approximately	  200	  amino	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acids	   each),	   a	   22	   residues	   trans-­‐membrane	   domain	   (amino	   acid	   492-­‐513)	   and	   an	  
intracellular	   domain	   containing	   two	   conserved	   motifs	   termed	   Box	   1	   and	   Box	   2	  
(Mignotte	  et	  al.,	  1994).	  
MPL	   gene	   is	   highly	   expressed	   in	   early	   hematopoietic	   progenitors	   and	   in	   cells	   of	   the	  
megakaryocytic	  lineage	  (Kaushansky	  et	  al.,	  2005).	  	  
	  The	   two	   most	   common	   MPL	   mutations,	   which	   are	   located	   in	   the	   cytoplasmic	  
juxtamembrane	   portion,	   are	   represented	   by	   W515L	   (a	   tryptophan	   to	   leucine	  
substitution)	   and	   W515K	   (a	   tryptophan	   to	   lysine	   substitution).	   They	   have	   been	  
detected	   in	  5%	  to	  11%	  of	  patients	  with	  PMF	  and	   in	  up	   to	  9%	  of	   JAK2V617F-­‐negative	  
cases	  of	  ET	  (Beer	  et	  al.	  2008;	  Vannucchi	  et	  al.,	  2007).	  Other	  unusual	  MPL	  mutations	  (eg	  
MPLW515S,	  W5151A,	  and	  MPLS505N,	  initially	  discovered	  in	  association	  with	  inherited	  
familial	  thrombocytosis)	  have	  also	  been	  reported	  (Williams	  et	  al.,	  2007).	  
MPLW515L	   induced	   both	   cytokine-­‐independent	   growth	   and	   TPO	   hypersensitivity	   in	  
cell	   lines,	   resulting	   in	   constitutively	   activated	   JAK-­‐STAT/ERK/Akt	   signaling	   pathways,	  
(Chaligne	  et	  al.,	  2008)	  and	  caused	  a	  PMF-­‐like	  disease	  in	  mice	  (Pikman	  et	  al.,	  2006).	  	  
At	   variance	   with	   the	   JAK2V617F	   transplantation	   model,	   the	   disease	   induced	   by	  
MPLW515L	   was	   characterized	   by	   a	   rapidly	   fatal	   course,	   marked	   thrombocytosis,	  
leukocytosis,	  hepatosplenomegaly,	  and	  bone	  marrow	   fibrosis,	  all	   reminiscent	  of	  PMF	  
(Pikman	   et	   al,	   2006).	   Interestingly	   in	   some	   patients,	  multiple	  MPL	   mutations	   or	   the	  
coexistence	  with	  JAK2V617F	  allele	  were	  described	  (Guglielmelli	  et	  al.,	  2007;	  Vannucchi	  
et	  al.,	  2008;	  Lasho	  et	  al.,	  2006).	  The	  presence	  of	  the	  MPL	  mutations	  does	  not	  seem	  to	  
have	   an	  effect	   on	   survival	   or	   on	   leukemic	   transformation	  and	   fibrotic.	   Cases	  of	   PMF	  
with	  the	  MPL	  mutation	  were	  associated	  with	  older	  age,	   low	  hemoglobin	   levels	  and	  a	  
greater	   likelihood	   of	   addiction	   to	   frequent	   blood	   transfusions	   (Tefferi	   et	   al.,	   2010;	  	  
Guglielmelli	  et	  al.,	  2007)	  .	  
-­‐	  CALR	  mutations	  
Calreticulin	   (CALR)	   is	   a	   developmentally	   highly	   conserved,	   multicompartmental	   and	  
multifunctional	   protein	   best	   known	   for	   its	   role	   as	   a	   Ca+	   binding	   chaperone	   in	   the	  
endoplasmic	  reticulum	  (ER)	  lumen	  (Gold	  et	  al.,	  2010).	  The	  CALR-­‐1	  gene	  (the	  product	  of	  
calreticulin-­‐2	  has	  only	  been	  detected	   in	  the	  testis)	   is	   located	  on	  human	  chromosome	  
19	  and	  mouse	  chromosome	  8,	  spanning	  4.6	  and	  3.6	  kb,	  respectively,	  and	  contains	  nine	  
exons	  with	   a	   highly	   conserved	   sequence	   (96%	   amino	   acid	   identity)	   between	   human	  
and	  mouse.	  Mature	   CALR	   is	   a	   46-­‐kDa	   protein	   that	   consists	   of	   three	   structurally	   and	  
functionally	   distinct	   domains	   (Fig.7).	   One	   of	   these,	   the	   acidic	   C-­‐terminal	   domain,	   is	  
involved	  in	  cellular	  calcium	  homeostasis—cells	  that	  are	  deficient	  in	  CALR	  have	  reduced	  
calcium	  storage	  capacity	   in	   the	  ER	  and	  overexpression	  of	  CALR	  augments	  ER	  calcium	  
retention.	   The	   C-­‐domain	   terminates	   in	   a	   KDEL	   sequence;	   KDEL	   receptors	   function	   in	  
the	   retrieval	   of	   KDEL-­‐containing	   proteins	   from	   the	   cis-­‐Golgi	   back	   to	   the	   ER.	   The	   C-­‐
terminus	   of mutant	   CALR	   lacks	   KDEL	   which	   raises	   the	   possibility	   of	   cellular	  
mislocalization,	  however,	  preliminary	  evidence	  from	  localization	  studies	  of	  exogenous	  
overexpression	  of	  mutant	  CALR	  in	  target	  cells,	  as	  well	  as	  localization	  studies	  of	  myeloid	  
cells	   from	   CALR	   mutated	   patients	   has	   shown	   that	   mutant	   CALR	   largely	   retains	   its	  
localization	  within	  the	  ER	  (Nangalia	  et	  al.,	  2013;	  Klampf	  et	  al.,	  2013).	  	  Within	  the	  lumen	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of	  ER,	   and	   in	   concert	  with	  other	   chaperone	  proteins,	  CALR	  plays	   an	  essential	   role	   in	  
ensuring	  proper	  protein	  and	  glycoprotein	  folding.	  CALR	  has	  structural	  homology	  with	  
calnexin	  and	  both	  function	  in	  concert	  in	  the	  so-­‐called	  “calnexin/calreticulin	  cycle”,	  a	  N-­‐
glycan-­‐dependent	   quality	   control	   process	   that	   ensures	   correct	   glycoprotein	   folding	  
and/or	  degradation	  and	  prevents	  protein	  aggregation	  (Caramelo	  et	  al.,	  2008).	  Amongst	  
other	   roles,	  CALR	   is	   implicated	   in	   the	   assembly	   and	   cell	   surface	   expression	   of	  major	  
histocompatibility	   complex	   (MHC)	   class	   I	   molecules.	   Disruption	   of	   CALR	   is	  
embryonically	   lethal	  with	   the	   embryos	   showing	  markedly	   decreased	   ventricular	  wall	  
thickness	  and	  intertrabecular	  recesses	  in	  the	  ventricular	  walls.	  This	  appears	  to	  be	  due	  
to	   impaired	  myofibrillogenesis	   as	   a	   result	   of	   abnormal	   ER	   calcium	   availability.	   CALR-­‐
mediated	  regulation	  of	  calcium	  homeostasis	  may	  influence	  multiple	  additional	  cellular	  
functions	   including	   integrin-­‐mediated	   signaling.	   In	   addition	   to	   canonical	   ER	   related	  
functions,	  CALR	   is	  reported	  to	  be	  found	   in	  the	  cytosol,	  nucleus,	  at	  the	  cell	  surface	  as	  
well	  as	  extracellularly,	  where	  it	  accomplishes	  multiple	  functions	  as	  a	  critical	  mediator	  
of	  physiological	  and	  pathological	  processes	  such	  as	  the	  immune	  response,	  proliferation	  
and	   apoptosis,	   cell	   phagocytosis,	   wound	   healing,	   and	   fibrosis	   (Gold	   et	   al.,	   2010).	  
Calreticulin	   (CALR)	   gene	  was	   first	   recognized	   as	   a	   somatic	  mutation	   in	   patients	  with	  
MPNs	   who	   had	   no	   mutations	   in	   either	  JAK2	  or	  MPL	  by	   Klampfl	  et	   al.	  (Klampfl	   et	   al.,	  
2013	  )	  and	  Nangalia	  et	  al.	  (Nangalia	  et	  al.,	  2013)	  in	  2013.	  Ever	  since	  this	  discovery,	  its	  
molecular	  and	  pathogenic	  roles,	  and	  its	  clinical	  significance	  have	  been	  the	  hot	  research	  
topic	  in	  the	  field	  of	  hematopathology.	  All	  the	  mutations	  identified	  so	  far	  occur	  in	  exon	  
9,	  with	  the	  exception	  of	  a	  few	  non-­‐recurrent	  point	  mutations	  (Wu	  et	  al.,	  2014),	  almost	  
all	   these	   mutations	   are	   indels.	   More	   than	   50	   different	  CALR	  indels	   have	   been	  
described.	  Klampfl	  et	  al.	  has	  defined	  those	  with	  a	  52-­‐bp	  deletion	  (p.L367fs*46)	  as	  type	  
1	  mutation	  and	  those	  with	  a	  5-­‐bp	  TTGTC	  insertion	  (p.K385fs*47)	  as	  type	  2	  mutations.	  	  
	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Fig.7:	  CALR	  gene	  structure	  and	  its	  encoded	  protein.	  
	  
They	  have	  found	  that	  these	  two	  types	  of	  mutations	  accounted	  for	  more	  than	  80%	  of	  
all	  CALR-­‐mutant	  patients	  and	  the	  other	  mutation	  types	   including	  type	  3,	  4,	  5,	  and	  11	  
were	   observed	   at	  much	   lower	   frequencies,	  many	   of	   which	   were	   detected	   only	   in	   a	  
single	  patient	   (Klamfl	  et	  al.,	  2013).	   Interestingly,	   the	   frequency	  of	   type	  1	  mutation	   is	  
significantly	   higher	   in	   PMF	   than	   in	   ET,	   suggesting	   a	   specific	   role	   of	   this	  mutation	   in	  
myelofibrotic	   transformation	   (Rumi	   et	   al.,	   2014).	   Most	   of	   the	   mutations	   are	  
heterozygous	  mutation.	  Homozygous	  CALR	  mutations	  are	  very	  rare	  and	  they	  are	  all	  5-­‐
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bp	   insertions	   (Nangalia	   et	   al.,	   2013).	   Due	   to	   the	   high	   prevalence	   of	  CALR	  mutation	  
in	  JAK2V617F-­‐	   and	  MPL-­‐non-­‐mutated	   patients,	   it	   has	   been	   suggested	   that	   the	  
presentence	   or	   absence	   of	  CALR	  mutation	   be	   added	   to	   the	   British	   Committee	   for	  
Standards	   in	   Haematology	   criteria	   for	   the	   diagnosis	   of	   ET	   and	   PMF.	   However,	  
using	  CALR	  mutation	   for	   risk	   stratification	  or	  proposed	   International	  Prognostic	  Score	  
for	   ET	   (IPS-­‐ET)	   is	   not	   recommended.	   Since	   these	  uses	  have	  not	  been	   tested	  and	   the	  
IPS-­‐ET	   score	   was	   tested	   upon	   retrospective	   selected	   groups	   of	   patients	   who	   were	  
already	   receiving	   treatment	   (Harrison	   et	   al.,	   2012).	   Similarly,	   a	   revision	   of	   WHO	  
diagnostic	   criteria	   for	   MPNs	   has	   been	   proposed,	   too	   (Tefferi	   et	   al.,	   2014).	   The	  
CALR	  mutations	   are	   frequent	   in	   JAK2/MPL-­‐unmutated	   ET/PMF	   and	   thus	   provide	   a	  
much	  needed	   clonal	  marker	   in	   such	   cases.	   In	   the	   context	   of	   consistent	  morphology,	  
CALR,	   as	   well	   as	  JAK2	  and	  MPL	  mutations,	   is	   relatively	   specific	   to	   MPN	   and	   should	  
therefore	   be	   separated	   from	   ‘other’	   clonal	   markers	   such	   as	   abnormal	   karyotypes.	  
However,	  CALR	  mutations	   do	   not	   fully	   address	   the	   molecular	   gap	   in	  JAK2/MPL-­‐
unmutated	  disease	  or	  distinguish	  between	  ET	  and	  early/prefibrotic	  PMF.	  As	  such,	  their	  
availability	  does	  by	  no	  means	  undercut	  the	  necessity	  of	  bone	  morrow	  morphology	  as	  a	  
major	  diagnostic	  criterion	  in	  both	  ET	  and	  PMF	  (Tefferi	  et	  al.,	  2014).	  
	  
2.3.2	   OTHER	  GENE	  MUTATIONS	  FREQUENTLY	  OCCURRING	  IN	  MPN.	  	  
Approximately	  5-­‐10%	  of	  MPNs	  are	  triple	  negative	  for	  JAK2,	  MPL,	  and	  CALR.	  Mutations	  
in	  many	  other	  genes	   including	  genes	   involved	   in	   JAK-­‐STAT	  pathway,	  such	  as	  LNK	  and	  
CBL,	   	   genes	   involved	   in	   epigenetic	   regulation	   such	   as	  ASXL1,	   DNMT3A,	   TET2,	   EZH2,	  
IDH1,	   IDH2,	   as	  well	   as	   in	   genes	   involved	   in	  mRNA	   splicing,	   such	   as	   SRSF2	   have	   also	  
been	  described	  in	  recent	  years	  in	  patients	  with	  MPNs	  (Nangalia	  et	  al.,	  2014).	  It	   is	  not	  
clear	   whether	   they	   explain	   all	   the	   MPNs	   when	   all	   these	   mutations	   are	   taken	   into	  
account.	  It	  is	  also	  not	  clear	  whether	  these	  mutations	  are	  mutually	  exclusive	  or	  whether	  
they	   are	   the	   drivers	   of	   the	   disease.	   The	  mutations	   in	   these	   genes	   are	   discussed	   as	  
follows.	  
	  
-­‐Mutations	  in	  other	  genes	  involved	  in	  JAK-­‐STAT	  pathway:	  LNK	  and	  CBL	  
mutations	  	  
Over	   the	   years	   following	   the	   discovery	   of	   the	   mutation	   in	   the	   JAK2	   and	  MPL	   ,	   as	  
already	   mentioned	   they	   have	   been	   identified	   in	   patients	   with	   PMF	   new	   alterations	  
present	  in	  two	  other	  genes	  that	  are	  involved	  in	  the	  signaling	  pathway	  JAK-­‐STAT	  :	  LNK	  
and	  CBL	  .	  
LNK,	   also	   called	   SH2B3,	   is	   a	   member	   of	   the	   SH2B	   family,	   which	   contains	   2	   other	  
members.	   This	   family	   of	   adaptor	   proteins	   is	   characterized	   by	   a	   conserved	   structure	  
with	  3	  main	  domains	  (a	  proline-­‐rich	  amino	  terminus,	  a	  plekstrin	  homology	  domain,	  an	  
SH2	  domain)	  and	  a	  conserved	  tyrosine	  at	  the	  C-­‐terminus.	  LNK	  plays	  an	  important	  role	  
in	  hematopoiesis	  by	  negatively	  regulating	  JAK2	  activation	  through	  its	  SH2	  domain,	  thus	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inhibiting	  EPO-­‐R	  and	  MPL	   signaling	   (Tong	  et	  al,	   2005;	  Tong	  et	  al.,	   2004).	   In	  addition,	  
LNK	  negatively	  regulates	  c-­‐KIT	  and	  FMS	  signaling	  (Simon	  et	  al).	  LNK-­‐deficient	  mice	  have	  
an	   increased	   HSC	   pool	   with	   enhanced	   self-­‐renewal	   properties	   and	   increased	  
quiescence	  (Takaki	  et	  al.,	  2002).	  
This	  phenotype	  probably	   results	   from	   increased	  TPO/MPL	  signaling	   (Seita	  et	  al.2007)	  	  
because	   TPO	   is	   required	   for	   maintaining	   HSC	   quiescence	   and	   the	   HSC	   reservoir	  
(Velazquez	  et	  al.,	  2002).	   In	  addition,	  Lnk	   -­‐/-­‐	  mice	  develop	  MPN	  with	   thrombocytosis,	  
splenomegaly,	  and	  fibrosis	  (Velazquez	  et	  al.,	  2002)	  	  and	  marked	  B-­‐cell	  overproduction.	  
As	  expected	  from	  its	  negative	  role	  in	  JAK2	  signaling,	  LNK	  is	  also	  capable	  of	  attenuating	  
the	   signaling	   induced	   by	   MPLW515L	   or	   JAK2V617F	   (Gery	   et	   al.,	   2007).	   Loss	   of	   LNK	  
accelerates	   the	   development	   of	   MPN	   induced	   by	   JAK2V617F	   in	   murine	   models	  
(Bersenev	  et	  al.,	  2010).	  
In	   JAK2V617F	   positive	   patients,	   LNK	   expression	   is	   increased	   and	   modulates	   the	  
myeloproliferative	  process	  (Baran	  et	  al.,	  2010).	  In	  2010,	  Oh	  et	  al	  identified	  2	  mutations	  
in	   LNK	   exon	   2,	   one	   in	   a	   patient	  with	   PMF	   and	   the	   other	  with	   ET;	   both	  MPNs	  were	  
JAK2V617F	  negative.	  The	   first	  mutation	   leads	   to	  a	  premature	  stop	  codon	  resulting	   in	  
the	  absence	  of	   the	  PH	  and	  SH2	  domains,	  whereas	   the	   second	   (E208Q)	   is	  a	  missense	  
mutation	  in	  the	  PH	  domain.	  In	  the	  first	  mutation,	  the	  capacity	  to	  inhibit	  TPO	  signaling	  
is	   lost,	  whereas	   in	   the	   second	  mutation,	   some	   inhibitory	   function	   is	  maintained.	  The	  
frequency	  of	  mutations	   in	  LNK	   is	   low	  (Oh	  et	  al.,	  2010).	  However,	  other	  mutations	  of	  
LNK	  have	  been	  found	  in	  leukemic	  transformation	  of	  MPN	  at	  a	  greater	  frequency	  (13%)	  
(Pardanani	  et	  al.,	  2010).	  All	  mutations,	  except	  one,	  target	  a	  hot	  spot	  located	  between	  
codons	  208	  and	  234.	  Interestingly,	  some	  of	  these	  mutations	  appear	  to	  be	  late	  events	  
involved	   in	   disease	   progression	   because	   they	   were	   not	   found	   in	   the	   chronic	   phase	  
(Pardanani	   et	   al.,	   2010).	   In	   addition	   some	   LNK	   mutations	   were	   associated	   with	  
JAK2V617F,	   although	   it	   is	   not	   known	   whether	   LNK	   mutants	   and	   JAK2V617F	   were	  
present	  in	  the	  same	  cell.	  It	  has	  been	  also	  reported	  that	  LNK	  exon	  2	  mutations	  can	  be	  
found	   in	   pure	   erythrocytosis	   (Lasho	   et	   al.,	   2010).	   One	   mutation	   (A215V)	   had	   been	  
previously	  described	  in	  PMF	  blast	  crisis,	  and	  another	  (E208X)	   leads	  to	  absence	  of	  the	  
PH	  and	  SH2	  domains	  as	  the	  mutant	  described	  in	  PMF	  (Oh	  et	  al.,	  2010).	  This	  finding	  may	  
suggest	   that	   the	   phenotype	   of	   the	  MPN	   induced	   by	   LNK	  mutations	  may	   depend	   on	  
different	  parameters,	  including	  the	  presence	  of	  other	  mutations.	  
The	   CBL	   protein	   is	   a	   regulator	   of	   signal	   transduction,	   which	   acts	   by	   various	  
mechanisms.	   In	  the	  JAK-­‐STAT	  pathway,	   it	  can	  act	  as	  an	  E3	  ubiquitin	   ligase,	  which	  can	  
target	   JAK2,	   as	   well	   as	   the	   erythropoietin	   receptor	   and	   thrombopoietin	   receptor	  
(MPL)	  (Saur	   et	   al.,	   2010)	   and	  (Schmidt	   et	   al.,	   2005)	   for	   degradation.	   c-­‐CBL	   gene	   is	  
located	  at	  11q.23.3	  and	  is	  mutated	  in	  a	  variety	  of	  myeloid	  malignancies	  (Bacher	  et	  al.,	  
2010;	  Kales	  et	  al.,	  2010).	  The	  greatest	   frequency	  of	  mutations	   is	   found	   in	  CMML	  and	  
juvenile	  myelomonocytic	  leukemia.	  In	  acute	  myeloid	  leukemia	  (AML),	  the	  transforming	  
activity	  of	  c-­‐CBL	  may	  be	  related	  to	  an	  increased	  FLT3	  signaling	  (Rathinam	  et	  al.,	  2010).	  
Usually	   variants	   are	   missense	   mutations,	   which	   are	   homozygous	   because	   of	   an	  
acquired	  uniparental	  disomy	  (Ogawa	  et	  al.,	  2010)	  or,	   rarely,	  because	  of	  a	  deletion	  of	  
the	  wild-­‐type	   copy.	   For	   these	   reasons,	  CBL	  has	  been	   considered	  a	   tumor	   suppressor	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gene.	  In	  fact,	  most	  mutated	  CBL	  forms	  behave	  as	   loss-­‐of-­‐function	  molecules	  having	  a	  
dominant-­‐negative	  effect	  on	   c-­‐CBL,	   leading	   to	  an	  excessive	   sensitivity	   to	  a	   variety	  of	  
growth	  factors	  (Sanada	  et	  al.,	  2009).	  Retroviral	  transplantation	  assays	  with	  mutated	  c-­‐
CBL	  induce	  a	  mastocytosis	  phenotype	  and	  myeloid	  leukemia,	  albeit	  with	  a	  long	  latency.	  
Similarly,	  c-­‐CBL	  knockout	  mice	  develop	  a	  mild	  MPN	  with	  an	  increase	  in	  HSC	  (Naramura	  
et	  al.,	  2010).	  In	  the	  chronic	  phase	  of	  classic	  MPN,	  c-­‐CBL	  mutations	  have	  been	  found	  in	  
a	   low	  percentage	  of	  PMF	  patients	  (6%)	  but	  were	  not	  detected	  in	  a	  small	  series	  of	  PV	  
and	   ET	   patients	   (Grand	   et	   al.,	   2009).	   In	   one	   case,	   the	   c-­‐CBL	  mutation	   occured	   after	  
JAK2V617F.	  However,	  during	  progression	  of	  the	  disease,	  JAK2V617F	  was	  outcompeted	  
by	   the	  CBL	  mutant,	   suggesting	   that	   the	  2	  mutations	  had	  occurred	   in	  2	  different	  cells	  
(Grand	   et	   al.,	   2009).	   Similarly	   a	   c-­‐CBL	   mutation	   has	   been	   detected	   in	   blasts	   from	   a	  
JAK2V617F-­‐positive	   MPN,	   which	   became	   JAK2V617F	   negative	   during	   transformation	  
(Beer	  et	  al.,	  2008).	  	  Presently,	  c-­‐CBL	  seems	  to	  be	  involved	  more	  in	  progression	  toward	  
myelofibrosis	  or	  acute	  leukemia	  than	  in	  the	  chronic	  phase	  of	  the	  disorder,	  but	  further	  
studies	  are	  required	  to	  establish	  its	  precise	  role.	  
	  
2.3.3	  MUTATIONS	  IN	  GENES	  INVOLVED	  IN	  EPIGENETIC	  MECHANISMS.	  
Regulation	   of	   transcription	   can	   be	   achieved	   through	   epigenetic	   mechanisms,	   which	  
involve	   DNA	   and	   histone	   modifications.	   The	   most	   common	   mechanisms	   of	  
transcriptional	  repression	  are	  methylation	  and	  hidroxymethylation	  of	  cytosines	  in	  DNA	  
and	  methylation,	  acetylation	  and	  other	  modifications	  of	  histones.	  
Several	   recurrent	   mutations	   outside	   of	   the	   JAK–STAT	   pathway,	   involving	   epigenetic	  
modifiers	  as	  well	  as	  splicing	  factors,	  have	  been	  identified	  in	  MPN	  patients	  and	  appear	  
to	   have	   prognostic	   significance.	   The	   genes	   encoded	   epigenetic	  modifiers	   in	  which	   it	  
was	   demonstrated	   the	   presence	   of	   somatic	   mutations	   in	   myeloid	   neoplasms	   are:	  
ASXL1,	  TET2,	  IDH1/2,	  	  
as	   well	   as	   members	  
of	   the	   polycomb	  
repressor	   complex	   2	  











Fig.8:	   Genetic	   alterations	   of	   epigenetic	   pathways	   in	   MPN.	   The	   normal	   function	   of	   selected	   factors	   important	   for	   histone	  
modification	   and	   DNA	   methylation	   is	   depicted.	   Left	   panel:	   In	   most	   cases,	   the	   biological	   consequences	   of	   mutations	   in	   these	  
pathways	   is	   not	   yet	   well-­‐established.	   Trimethylation	   (me3)	   of	   lysine	   27	   (K27)	   on	   the	   carboxyterminal	   tail	   of	   histone	   H3,	   a	  
nucleosome	   component,	   is	   associated	   with	   transcriptional	   repression.	   ASXL1	   is	   a	   polycomb	   repressive	   complex	   protein	   that	  
maintains	   the	   repressive	   state.	   Right	   panel:	   Cytosine	  methylation	   in	   CpG	   islands	   is	   associated	   with	   transcriptional	   repression.	  
DNMT3A	  is	  a	  de	  novo	  DNA	  methyltransferase	  that	  converts	  unmethylated	  cytosine	  to	  5mC.	  5mC	  is	  converted	  to	  5hmC	  by	  the	  TET	  
proteins	  in	  the	  presence	  of	  alfaKG	  generated	  by	  the	  IDH	  enzymes	  (Graubert	  et	  al.,	  2011).	  
	  
	   26	  
	  
In	  MPNs	  these	  mutations	  occurs	  most	  frequently	   in	  patients	  with	  PMF	  or	  progression	  
to	  acute	  leukemia.	  	  
-­‐TET2	  mutations	  
The	   Ten-­‐Eleven-­‐Translocation2	   (TET2)	   gene	   codes	   for	   a	   2-­‐oxoglutarate	   and	   Fe(II)-­‐
dependent	   hydroxylase	   that	   is	   able	   to	   hydroxylate	   methylated	   cytosine	  
(methylcytosine;	   mC)	   (Ito	   et	   al.,	   2010).	   The	   function	   of	   the	   resulting	   modified	  
nucleotide,	  hydroxymethylcytosine	  (5hmC),	  may	  alter	  chromatin	  structure	  and	  restrict	  
access	  to	  DNA	  methyltransferases,	  which	  mediate	  repression	  of	  gene	  transcription.	   It	  
follows	   that	   loss	   of	   TET	   enzyme	   activity	   results	   in	   increased	   methylation.In	   fact,	  	  
observed	  mutations	  are	  mainly	  small	  insertions	  and	  deletions	  and	  nonsense	  mutations	  
that	  are	  expected	  to	  result	   in	  the	  loss	  of	  function	  of	  the	  protein.	  Missense	  mutations	  
affecting	  conserved	  amino	  acids	  have	  been	  shown	  also	  to	  impair	  the	  catalytic	  activity	  
of	   the	   protein.	   Accordingly,	   patients	   with	   TET2	   mutations	   have	   lower	   global	   5hmC	  
content	  than	  wild	  type	  (Ko	  et	  al.,	  2010).	  	  
TET2	  is	  mutated	  in	  a	  wide	  range	  of	  myeloid	  malignancies	  (Langermeijer	  et	  al.,	  2009).	  	  
TET2	  mutations	   are	   found	   in	   approximately	   14%	   of	  MPNs	   ranging	   from	   ET	   (11%)	   to	  
PMF	   (19%)	   (Tefferi	   et	   al.,	   2009).	   In	   roughly	   20%	   of	   the	   patients,	   2	   mutations	   are	  
observed,	  suggesting	  that	  the	  inactivation	  of	  a	  single	  copy	  of	  TET2	  is	  sufficient	  for	  the	  
transformation	   process.	   TET2	  mutations	   are	   not	   responsible	   for	   the	   familial	   MPNs	  
identified	  to	  date,	  although	  a	  germline	  mutation	  has	  been	  described.	   In	  vitro	  studies	  
have	  first	  shown	  that	  TET2	  mutations	  occur	  before	  JAK2	  mutations	  during	  the	  natural	  
history	   of	   sporadic	  MPNs	   (Delhommeau	   et	   al.,	   2009).	   However,	   subsequent	   studies	  
suggest	  that	  the	  converse	  may	  happen	  and	  also	  that	  TET2	  mutations	  may	  occur	  when	  
MPNs	  transform	  to	  AML	  (Schaub	  et	  al.,	  2010;	  Swierczek	  et	  al.,	  2011;	  Saint-­‐Martin	  et	  al.,	  
2009;	  Abdel-­‐Wahab	  et	  al.,	  2010).	  	  
-­‐	  IDH1/2	  mutations	  	  
IDH1/2	   (Isocitrate	   Dehydrogenase	   1/2):	   IDH1/2	  are	  homodimeric	  NADP+	  dependent	  
enzymes	   involved	   in	   the	   conversion	   of	   isocitrate	   to	   α-­‐ketoglutarate	   by	   oxidative	  
decarboxylation	  prior	  to	  NADPH	  synthesis	  (Dang	  et	  al.,	  2010).	  Heterozygous	  mutations	  
of	  these	  genes	  were	  first	  described	  in	  gliomas	  and	  secondary	  glioblastomas	  and	  then	  in	  
AML	   (Okita	   et	   al.,	   2012;	   Abbas	   et	   al.,	   2010).	   Mutations	   in	   IDH1/2	   can	   lead	   to	   an	  
increase	  in	  NADPH-­‐dependent	  reaction	  of	  α-­‐ketoglutarate	  resulting	  in	  over	  production	  
of	   α-­‐hydroxyglutarate	   which	   is	   a	   potential	   toxic	   substance	   and	   conversely	   have	   a	  
negative	  effect	  on	  the	   function	  of	   the	  TET2	  protein	   (Figueroa	  ME	  et	  al.,	  2010).	   	  Both	  
IDH1/2	  mutations	  and	  TET2	  mutations	  lead	  to	  similar	  hypermethylation	  signatures	  and	  
patterns	   of	   impaired	   myeloid	   differentiation	   and	   increased	   expression	   of	   stem	   cell	  
markers.	  IDH1/2	  mutations	  usually	  involve	  the	  amino	  acid	  R132	  (IDH1),	  R140	  and	  R172	  
(IDH2).	   The	   frequency	  of	   IDH1/2	  mutation	   is	   about	  3-­‐5%,	  1-­‐2%,	   and	  10-­‐20%	   in	  PMF,	  
post-­‐PV/ET	  MF	   and	   in	   MF	   cases	   evolving	   to	   AML	   (Pardanani	   et	   al.,	   2010).	   Also,	   an	  
analysis	  of	  1473	  patients	  with	  MPN	  revealed	  a	   low	   incidence	  of	   IDH1/2	  mutations	   in	  
chronic	  phase	  ET,	  PV,	  and	  MF	  (0.8%,	  1.9%,	  and	  4.2%,	  respectively)	  contrasting	  with	  a	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21.6%	  frequency	  in	  blast	  phase	  (Pardanani	  et	  al.,	  2010).	  Thirtyeight	  IDH1/2	  mutations	  
have	   been	   discovered	   in	   a	   large	   screening	   study	   of	   MPN	   patients	   and	   can	   coexist	  
equally	  with	  mutations	   in	   JAK2,	  MPL,	   and	  TET2	   (Skoda,	   2007).	   Over	   21%	   of	   patients	  
with	  blast	  phase-­‐related	  MPN	  carry	  an	   IDH1/2	  mutation,	  and	  this	  was	   irrespective	  of	  
JAK2V617F	  status	  (Pardanani	  et	  al.,	  2010;	  Green	  et	  al.,	  2010).	  This	  appears	  to	  indicate	  
that	   IDH1/2	  mutations	   can	   also	   influence	   the	   transformation	   of	  MPN	   to	   blast	   phase	  
disease.	   Interestingly,	   leukemic	  blasts	  and	  progenitor	  cells	  can	  possess	  both	  mutated	  
IDH2	   and	   JAK2V617F,	   and	   in	   other	   patients	   with	   MPN-­‐transformed	   leukemia,	   the	  
mutated	   IDH1/2	   may	   be	   present	   in	   blasts	   with	   wild-­‐type	   JAK2	   and	   absent	   in	   the	  
progenitor	   cells	   with	   JAK2V617F	   (Green	   et	   al.,	   2010).	   These	   data	   have	   shown	   the	  
possibility	  of	  the	  presence	  of	  two	  subclones	  originating	  from	  a	  yet	  unidentified	  primary	  
clone	  or	  two	  independent	  competing	  clones	  arising	  in	  the	  same	  individual.	  
Furthermore,	  mutations	  in	  these	  genes	  are	  usually	  observed	  to	  be	  mutually	  exclusive	  
from	  mutations	  of	  JAK2,	  TET2,	  and	  MPL	  (Tefferi	  et	  al.,	  2011).	  	  
Also,	  in	  a	  more	  recent	  study	  of	  IDH1/2	  mutations	  in	  a	  cohort	  of	  301	  patients	  with	  PMF,	  
it	  was	  shown	  that	  IDH1/2	  mutations	  are	  associated	  with	  decreased	  overall	  survival	  and	  
leukemia-­‐free	  survival	  in	  PMF	  	  (Dang	  et	  al.,	  2010).	  
	  
-­‐	  ASXL1	  	  mutations	  	  
ASXL1	   gene	   encodes	   the	  Additional	  SeX	  combs–Like	   protein-­‐1	   	  which	   is	   one	   of	   the	  
three	   mammalian	   homologs	   of	  Drosophila	  Additional	   Sex	   Comb	   (Asx)	   gene,	   named	  
after	   the	   fact	   that	  Asx	  deletion	  caused	  homeotic	   transformation	  due	   to	  dysregulation	  
of	  Hox	  genes,	  whose	  spatially	  and	  quantitatively	  appropriate	  expression	  is	  essential	  for	  
the	   anterior-­‐posterior	   specification	   of	   axial	   structures	   during	   mammalian	  
development.	  ASXL1	  maps	  to	  human	  chromosome	  20q11.21,	  consists	  of	  12	  exons	  and	  
encodes	  a	  protein	  composed	  of	  1,541	  amino	  acids.	  	  Mutations	  in	  ASXL1	  are	  frameshifts	  
and	  stop	  mutations	  located	  within	  the	  12th	  exon	  of	  the	  gene;	  they	  usually	  affect	  only	  
one	  copy	  of	   the	  gene	  and	  result	   in	   the	   loss	  of	   the	  carboxyterminal	  PHD	  domain.	  The	  
frequency	   is	   low	   in	   low-­‐grade	   disorders	   but	   greater	   in	   late	   MDS,	   AML,	   and	   in	  
proliferative	  CMML.	  In	  MPNs,	  ASXL1	  mutations	  are	  rare	  in	  ET	  and	  PV	  (7%)	  but	  frequent	  
in	   PMF	   (from	   19%-­‐40%)	   (Ricci	   et	   al.,	   2012;	   Carbuccia	   et	   al.,	   2009).	   The	   function	   of	  
ASXL1	   in	   hematopoiesis	   is	   still	   poorly	  understood.	  ASXL1	  knockout	  mice	  have	  a	  mild	  
defect	   in	   hematopoiesis,	   predominantly	   in	   lymphopoiesis	   (Fisher	   et	   al.,	   2010).	   A	  
marked	  decrease	  in	  myeloerythroid	  progenitors	  was	  observed	  but	  without	  detectable	  
effect	  on	  HSC.	  Its	  role	  in	  human	  hematopoiesis	  is	  unknown.	  
Finally	   ,a	   large	   study	   conducted	   on	   patients	   with	   PMF	   has	   established	   that	   the	  
presence	  of	  mutations	  of	  ASXL1	  is	  associated	  to	  a	  phenotype	  aggressive	  is	  to	  a	  reduced	  
survival	  	  (Guglielmelli	  et	  al.,	  2011)	  but	  in	  that	  way	  the	  mutations	  of	  ASXL1	  determine	  a	  
phenotype	  of	  disease	  more	  aggressive	  not	  is	  again	  the	  all	  clarified.	  
-­‐DNMT3A	  mutations	  	  
The	  DNMT3A	  heterozygous	  mutations	  were	  initially	  described	  in	  AML	  and	  MDS	  with	  a	  
frequency	  of	  5-­‐22%	   (Lin	  et	  al.,	  2011). However,	  mutations	  have	  been	   found,	  also,	   in	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gene	  DNMT3A	  in	  over	  the	  15%	  of	  patients	  with	  MF	  and	  in	  over	  the	  7%	  of	  patients	  with	  
PV	  (Abdel	  -­‐	  Wahab	  et	  al.,	  2011)	  and	  ET	  (	  Stegelmann	  et	  al.,	  2011).	  	  
This	  gene	  encodes	  a	  DNA	  methyltransferase	  that	   is	  essential	   in	  de	  novo	  methylation.	  
Acquisition	  of	  mutations	  can	  cause	  loss-­‐of-­‐function	  resulting	  in	  homo-­‐dimerization	  and	  
activation	   of	   the	   protein,	   reduction	   of	   the	   activity	   of	   methyltransferase,	   and	  
consequent	  increased	  cell	  proliferation	  (Stegelmann	  et	  al.,	  2011).	  
The	   somatic	  mutations	   in	   this	   gene	   are	   nonsense	   ,	   frameshift	   ,	   and	  missense	   in	   the	  
open	   -­‐	   reading	   frame	   .	   However	   ,	   the	  mutations	  more	   frequently	   lead	   a	   premature	  	  
break	   of	   the	   product	   protein	   (	   nonsense	   or	   mutations	   frameshift	   )	   or	   they	   affect	   a	  
single	  amino	  acid	  :	  R882	  .	  DNMT3A	  can	  play	  a	  significant	  role	  in	  progression	  of	  MPN	  to	  
AML	  in	  the	  presence	  of	  JAK2	  and	  MPL	  mutations.	  It	  has	  been	  showed	  that	  the	  time	  of	  
mutational	  event	  acquisition	  reflects	  the	  disease	  course.	  In	  order	  to	  further	  dissect	  the	  
role	  of	  this	  gene	  in	  MPN,	  a	  study	  described	  the	  isolation	  of	  different	  cellular	   lineages	  
and	  the	  successive	  assessment	  of	   the	  cell	   type	  harboring	  high	   frequency	  of	  DNMT3A	  
mutations.	   Mutations	   were	   identified	   with	   high	   frequency	   in	   CD14+	   (monocytes)	  
enriched	   fraction	   and	  with	   low	   frequency	   in	   CD3+	   and	   CD19+	   (T	   and	   B	   lymphocytes,	  
respectively)	   suggesting	   that	   the	  aberrant	   clone	  does	  not	  occur	   in	   lymphoid	   lineages	  
(Rao	  et	  al.,	  2012).	  Indeed,	  DNMT3A	  mutations	  are	  associated	  with	  over	  expression	  of	  
other	  relevant	  genes	  in	  advanced	  myeloid	  malignancies	  (Stegelman	  et	  al.,	  2011).	  
-­‐EZH2	  mutations	  	  
This	   gene	   is	   located	   in	   chromosome	   7	   (7q36.1)	   and	   belongs	   to	   the	   complex	   2	   of	  
Polycomb,	  a	  mediator	  of	   transcriptional	   silencing	  and	  a	   regulator	  of	  multiple	   cellular	  
process	  like	  proliferation,	  maturation,	  aging	  and	  hematopoietic	  cell	  plasticity	  (Shen	  et	  
al.,	  2008).	  EZH2	  over-­‐expression	  is	  noted	  in	  a	  variety	  of	  solid	  tumors	  like	  prostate	  and	  
breast	  cancer	  and	  it	  has	  been	  reported	  to	  contribute	  to	  tumor	  aggressiveness	  and	  poor	  
cellular	   differentiation.	   (He	   et	   al.,	   2010).	   EZH2	   mutations	   appear	   to	   be	   a	   gain-­‐of-­‐
function	  genetic	  change	  acting	  as	  a	  repressor	  by	  methylating	  the	  histone	  H3	  on	  lysine	  
27	   (H3K27)	   and	   consequently	   inactivating	   the	   chromatin	   (Cao	   et	   al.,	   2002).	   The	  
frequency	  of	  EZH2	  mutations	  is	  approximately	  12%	  in	  MF;	  however,	  mutations	  are	  not	  
exclusively	  found	  in	  MPN	  since	  they	  are	  more	  frequent	  in	  MDS	  (2-­‐6%)	  and	  MDS/MPN	  
(~15%).	  Clinically,	  EZH2	  mutations	  have	  been	  associated	  with	  poor	  prognosis	  (Ernst	  et	  
al.,	  2010).	  
-­‐SRSF2	  mutations	  
A	   other	   gene	   that	   results	   changed	   in	   17%	   of	   patients	   with	   PMF	   is	   SRSF2.	   It	   results	  
changed	   also	   in	   18.9%	   of	   patients	   with	   leukemia	   secondary	   to	  MPN	   and	   in	   28%	   of	  
cases	  is	  associate	  to	  mutations	  of	  IDH1/2.	  The	  mutations	  of	  SRSF2	  have	  been	  found	  in	  
phase	   chronic	   and	   leukemic	   from	   themselves	   patients	   and	   they	   are	   associated	   to	  
prognosis	  unfavorable	  (Lasho	  et	  al,	  2012;	  Zhang	  et	  al.,	  2012).	  Studies	  latest	  have	  taken	  
into	  consideration	  the	  possible	  prognostic	  maening	  of	  some	  of	  these	  mutations.	  	  
This	  status	  established	  that	  a	  set	  of	   four	  mutations	   including	  the	  genes	  ASXL1,	  EZH2,	  
SRSF2	   and	   IDH1/2	   allow	   to	   identify	   patients	   to	   high	   risk	   molecular	   (Category	   High	  
Molecular	   Risk	   -­‐	   HMR,	   or	   patients	   that	   have	   changed	   at	   least	   one	   of	   4	   genes),	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independently	  from	  category	  of	  risk	  IPSS	  (Vannucchi	  et	  al.,	  2013).	  The	  condition	  HMR	  
is	  associated	  to	  a	  hazard	  ratio	  (HR)	  for	  the	  survival	  of	  2.29	  (95%	  CI,	  1.6-­‐3.2)	  and	  of	  2.96	  
(95%	  CI,	  1.8-­‐4.7)	  for	  the	  risk	  of	  blast	  evolution.	  About	  the	  20%	  of	  patients	  considered	  
to	  bass	   risk	   according	   to	   the	   score	   IPSS	  have	  a	  profile	  molecular	   type	  HMR,	   is	   could	  
then	   require	   a	   approach	   therapeutic	   different	   by	   that	   currently	   employed.	   More	  
recently	  Guglielmelli	   et	   al.	   have	  observed	   that	   in	   patients	   that	   have	   two	  or	  more	  of	  
mutations	   including	   in	   category	   HMR	   the	   value	   HR	   for	   the	   survival,	   in	   analysis	  
multivariate	  stratified	  for	  the	  score	  IPSS,	  is	  of	  2.4	  (1.6-­‐3.6)	  while	  for	  the	  evolution	  blast	  
is	   of	   6.2	   (3.5-­‐10.7)	   (Guglielmelli	   et	   al.,	   2014).	   Despite	   the	   fact	   that	   the	   mutational	  
background	  of	  MPNs	  has	  been	  extensively	  investigated,	  the	  molecular	  etiology	  of	  the	  
disease	  has	  not	  been	  fully	  elucidated.	  Indeed	  several	  lines	  of	  evidence	  indicate	  that	  the	  
identified	  mutations	  are	  not	  sufficient	  for	  disease	  initiation	  and	  progression.	  	  	  
2.4	  OTHER	  POSSIBLE	  EPIGENETIC	  MECHANISMS	  INVOLVED	  IN	  
PATHOGENESIS	  OF	  MPN:	  microRNAs.	  
	  
Early	   studies	   have	   shown	   how	   aberrantly	   expressed	   microRNAs	   are	   a	   hallmark	   of	  
several	   diseases	   like	   cancer.	   MicroRNA	   expression	   profiling	   was	   shown	   to	   be	  
associated	  with	  tumour	  development,	  progression	  and	  response	  to	  therapy,	  suggesting	  
their	  possible	  use	  as	  diagnostic,	  prognostic	  and	  predictive	  biomarkers.	  
2.4.1	  WHAT	  IS	  A	  MIRNA?	  
MiRNAs	   were	   defined	   as	   noncoding	   RNAs	   that	   fulfill	   the	   following	   combination	   o	  
expression	  and	  biogenesis	  criteria:	  	  
1. mature	   miRNA	   should	   be	   expressed	   as	   a	   distinct	   transcript	   of	   18-24	   nt	   that	   is	  
detectable	   by	   RNA	   (northern)	   blot	   analysis	   or	   other	   experimental	   means	   such	   as	  
cloning	  from	  size-­‐fractionated	  small	  RNA	  libraries;	  
2. mature	  miRNA	   should	   originate	   from	   a	   precursor	  with	   a	   characteristic	   secondary	  
structure,	  such	  as	  a	  hairpin	  or	  fold-­‐back,	  that	  does	  not	  contain	  large	  internal	  loops	  or	  
bulges.	  Mature	  miRNA	  should	  occupy	  the	  stem	  part	  of	  the	  hairpin;	  
3. mature	   miRNA	   should	   be	   processed	   by	   Dicer,	   as	   determined	   by	   an	   increase	   in	  
accumulation	  of	  the	  precursor	  in	  Dicer-­‐deficient	  mutants.	  
In	  addition,	  an	  optional	  but	  commonly	  used	  criterion	  is	  that	  mature	  miRNA	  sequence	  
and	   predicted	   hairpin	   structure	   should	   be	   conserved	   in	   different	   species.	   An	   ‘ideal’	  
miRNA	  would	  meet	  all	  the	  above	  criteria.	  In	  practice,	  variations	  are	  possible,	  but	  at	  the	  
very	  minimum	  expression	  of	  a	  ∼18-­‐24	  nt	  form	  and	  the	  presence	  of	  a	  hairpin	  precursor	  
need	  to	  be	  demonstrated	  to	  classify	  a	  sequence	  as	  an	  miRNA.	  
MiRNAs	  are	  antisense	  RNA	  molecules	  that	  ,	  thanks	  to	  their	  characteristics	  ,	  they	  work	  
by	  guiding	  elements	  in	  post-­‐	  transcriptional	  gene	  silencing.	  Indeed	  matching	  to	  target	  
mRNAs	   it	   promotes	   their	   degradation	   or	   as	   happens	   more	   frequently,	   block	   its	  
translation.	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2.4.2	  THE	  DISCOVERY	  OF	  MIRNAS.	  
MiRNAs	  control	  the	  expression	  of	  genes	  involved	  in	  several	  biologic	  processes	  such	  as	  
apoptosis,	  proliferation,	  differentiation	  and	  metastasis	  .	  
Two	  decades	  ago,	  the	  existence	  and	  importance	  of	  miRNAs	  was	  completely	  unknown.	  
Until	  then,	  the	  scientific	  community	  was	  focused	  on	  genes	  that	  codify	  for	  protein.	  The	  
classical	  dogma	  that	  DNA	  is	  transcribed	  into	  RNA	  which	  then	  is	  translated	  into	  protein	  
put	   aside	   the	   study	   of	   all	   the	   non-­‐protein	   coding	   sequences.	   Only	   in	   1993	   the	  
importance	  of	  miRNAs	  started	  to	  be	  revealed.	  In	  fact,	  in	  December	  1993,	  in	  the	  same	  
issue	   of	   Cell,	   Ambros	   and	   Ruvkun	   independently	   reported	   that	   the	   small	   and	   non-­‐
protein	   coding	   transcript	   lin-­‐4	   in	   the	  Caenorhabditis	   elegans	   regulates	   lin-­‐14	   through	  
its	  3’	  UTR	  region	  (Lee	  et	  al.,1993;	  Wigthman	  et	  al.,1993):	  Lin-­‐4	  was	  the	  first	  miRNA	  to	  
be	  discovered.	  For	  some	  years	  Lin-­‐4	  appeared	  to	  be	  an	  isolated	  case	  until	  the	  discovery	  
of	  another	  miRNA	  gene,	  again	  in	  C.	  elegans,	  known	  as	  let-­‐7.	  	  The	  discovery	  that	  let-­‐7	  is	  
conserved	  across	  species	  triggered	  a	  revolution	  in	  the	  research	  of	  a	  new	  class	  of	  small	  
ncRNAs,	  called	  miRNAs.	  Presently,	  thousands	  of	  miRNAs	  had	  been	  identified	  in	  humans	  
and	   other	   species,	   and	   miRNA	   online	   sequences	   repositories,	   such	   as	   the	   miRbase	  
database,	  are	  available	  (Griffiths	  et	  al.,2004;	  Griffiths	  et	  al.,	  2006;	  Griffiths	  et	  al.,	  2008).	  
Also,	   current	   tools	   and	   software	   developed	   for	   miRNA	   target	   prediction	   facilitate	  
studies	  of	  miRNAs	  functional	  network	  (Xia	  et	  al.,	  2009;	  Huang	  et	  al.,	  2009).	  
2.4.3	  MIRNA	  BIOGENESIS.	  	  
The	  biosynthesis	  of	  miRNAs	   is	  a	   tightly	   regulated	  multistep	  process	   that	  starts	   in	   the	  
nucleus	   of	   the	   cell,	   following	   transcription,	   and	   continues	   through	   the	   cytoplasm	  
where	  finally	  the	  mature	  miRNA	  molecule	  exerts	   its	  main	  function.	  miRNA	  genes	  can	  
be	  grouped	  on	  the	  basis	  of	  their	  genomic	  locations:	  	  
1)	   exonic	  miRNA	   in	   non-­‐coding	   transcription	   units;	   2)	   intronic	  miRNA	   in	   non-­‐coding	  
transcription	  units;	  and	  3)	  intronic	  miRNA	  in	  protein-­‐coding	  transcription	  units.	  Mixed	  
miRNA	   genes	   can	   be	   assigned	   to	   one	   of	   the	   above	   groups	   depending	   on	   the	   given	  
splicing	  pattern.	  The	  biogenesis	  process	  begins	  with	  the	  synthesis	  of	  a	  long	  transcript	  




	  	  	  	  	  	  	  	  	  	  	  Fig.9:	  Pri-­‐miRna	  structure.	  
	  
Pri-­‐miRNAs	  are	   typically	   (although	  not	  exclusively)	   transcribed	  by	  RNA	  polymerase	   II,	  
which	  generates	   the	  pri-­‐miRNA	  that	  consists	  of	  one	  or	  more	  hairpin	  structures,	  each	  
composed	   of	   a	   stem	   and	   a	   terminal	   loop.	   Pri-­‐miRNAs	   are	   structurally	   analogous	   to	  
mRNAs;	   they	  are	  5ʹ′-­‐capped	  and	  spliced	  and	  bear	  a	  3ʹ′	  poly-­‐A	   tail,	   and	   they	  often	  can	  
produce	  more	  than	  one	  functional	  miRNA	  (Carthew	  et	  al.,	  2009;	  Kim	  et	  al.,	  2009;	  Cai	  et	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al.,	  2004;	  Lee	  et	  al.,	  2004	  ).	  However,	  other	  pathways	  generate	  a	  minor	  set	  of	  miRNAs,	  
especially	  from	  genomic	  repeats	  (i.e.,	  Alu	  repeats)	  whose	  transcription	  is	  carried	  out	  by	  
RNA	  polymerase	  III.	  (Borchert	  et	  al.,	  2006	  ).	  
In	  the	  canonical	  miRNA	  biogenesis	  pathway	  the	  first	  step	  of	  miRNA	  maturation	  starts	  
in	  the	  nucleus	  where	  the	  pri-­‐miRNA	  is	  “cropped”	  into	  a	  ~70	  nt	  hairpin	  structured	  pre-­‐
miRNA.	   This	   phenomenon	   is	   catalyzed	   by	   a	   multiprotein	   complex	   called	   the	  
microprocessor.	   The	   core	   components	   of	   this	   complex	   are	   Drosha,	   an	   RNase	   III	  
enzyme,	   together	   with	   its	   interacting	   partner	   DGCR8	   (DiGeorge	   syndrome	   critical	  
region	   gene	   8),	   a	   double-­‐stranded	   RNA-­‐binding	   domain	   (dsRBD)	   protein (Lee	   et	   al.,	  
2003;	  Denli	  et	  al.,	  2004;	  Gregory	  et	  al.,	  2004). The	  microprocessor	  appears	  to	  represent	  
a	   heterotetramer	   consisting	   of	   two	   Drosha	   and	   two	   DGCR8	   molecules.	   	   Following	  
nuclear	  processing	  by	  Drosha	  the	  pre-­‐miRNA	  is	  recognized	  by	  exportin-­‐	  5	  and	  transits	  
to	  the	  cytoplasm	  to	  be	  further	  processed	  (Lund	  et	  al.,	  2004;	  Yi	  et	  al.,	  2003).	  Owing	  to	  
compartmentalization	   of	   the	   processing	   events,	   nuclear	   export	   of	   pre-­‐miRNAs	   is	   a	  
crucial	  step	  in	  miRNA	  biogenesis.	  
Following	   its	   export	   from	   the	   nucleus,	   the	  
pre-­‐miRNA	   is	   cleaved	   by	   another	   RNase	   III	  
DICER,	   which	   results	   in	   a	   18-­‐24	   nucleotide	  
miRNA:	   miRNA*	   duplex	   (Bernstein	   et	   al.,	  
2001).	  The	  duplex	  is	  then	  unwound	  and	  one	  
strand	   is	   associated	   with	   the	   Argonaute	  
family	   of	   proteins	   which	   is	   the	   central	  
component	   of	   the	   RNA	   induced	   silencing	  
complex	   (RISC).	  Once	   incorporated	   into	   the	  
RISC,	  the	  single-­‐stranded	  mature	  miRNA	  will	  
guide	   the	   RISC	   to	   interact	   with	   the	   target	  
mRNA	   via	   the	   latter’s	   3ʹ′-­‐untranslated	  	  	  	  	  
region	   (Fig.10).	   Recently,	   DROSHA-­‐
independent	   or	   DICER-­‐independent	  
production	  of	  miRNAs	  has	  been	  reported	  
(Ruby	  et	  al.,	  2007;	  Cheloufi	  et	  al.,	  2010;	  Cifuentes	  et	  al.,	  2010).	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2.4.4	  	  MICRORNA–OFFSET	  RNAS	  (MORNAS).	  
Recent	   studies	   have	   exponentially	   increased	   the	   number	   of	   known	   noncoding	   RNA	  
categories	   and	   short	  RNA	   sequencing	   led	   to	   the	  discovery	  of	   a	  novel	   type	  of	  miRNA	  
related	  small	  RNA,	  miRNA–offset	  RNA	  (moRNA),	  whose	  function	  is	  currently	  unknown.	  
MoRNAs	  were	   first	   reported	   in	   a	   simple	   chordate,	   the	   ascidian	   Ciona	   intestinalis,	   as	  
∼20-­‐nt-­‐long	   RNAs	   derived	   from	   the	   ends	   of	   pre-­‐miRNAs,	   possibly	   by	   RNAse	   III-­‐like	  
processing.	   moRNAs	   can	   originate	   from	   either	   end	   of	   the	   pre-­‐miRNA,	   but	   they	   are	  
prevalently	   derived	   from	   the	   5ʹ′	   arm,	   regardless	   of	   the	   major	   miRNA	   position.	   This	  
suggests	  that	  moRNA	  and	  miRNA	  biogenesis	  might	  be	  linked	  but	  not	  interdependent.	  
The	  expression	  levels	  of	  moRNAs	  seem	  to	  be	  regulated	  in	  different	  developmental	  	  
stages	   of	   Ciona,	   and	   their	   abundance	   can	   exceed	   that	   of	   the	   corresponding	  mature	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Fig.	  10:	  Biogenesis	  of	  miRnas.	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miRNA	  (Bortoluzzi	  et	  al.,	  2011).	  
In	   addition,	   short	  RNA	   sequencing	   led	   to	   the	  discovery	  of	  moRNAs,	  which	  were	   first	  
reported	   in	   a	   simple	   chordate,	  
the	   ascidian	   Ciona	   intestinalis	  
(Shi	  et	  al.,	  2009),	  as	  ~20-­‐nt-­‐long	  
RNAs	  derived	  from	  the	  ends	  of	  
pre-­‐miRNAs,	  possibly	  by	  RNAse	  
III-­‐like	  processing	  (Fig.	  11).	  
MoRNAs	   can	   originate	   from	  
either	   end	   of	   the	   pre-­‐miRNA,	  
but	   they	   are	   prevalently	  
derived	   from	   the	   5ʹ′arm,	  
regardless	   of	   the	   major	   miRNA	   position.	   This	   suggests	   that	   moRNA	   and	   miRNA	  
biogenesis	  might	  be	  linked	  but	  not	   interdependent.	  The	  expression	  levels	  of	  moRNAs	  
seem	  to	  be	  regulated	  in	  different	  developmental	  stages	  of	  Ciona,	  and	  their	  abundance	  
can	  exceed	  that	  of	  the	  corresponding	  mature	  miRNA.	  
Initially,	   moRNAs	   were	   considered	   as	   by-­‐products	   of	   potentially	   atypical	   miRNA	  
processing	   (Shi	  et	  al.,	  2009).	   Later,	  moRNAs	  were	  also	   found	   in	  human	  cells	  by	  deep	  
sequencing	  data	  analysis.	  Langerberger	  et	  al.	  reported	  that	  moRNAs	  from	  78	  genomic	  
loci	   are	  weakly	   expressed	   in	   the	   prefrontal	   cortex	   (Langenberger	   et	   al.,	   2009).	   They	  
also	   observed	   that	   some	   moRNAs	   are	   as	   conserved	   as	   miRNAs,	   and	   that	   miRNA	  
precursors	   that	   also	   contain	   moRNAs	   are	   typically	   old	   from	   an	   evolutionary	  
perspective	  (Langenberger	  et	  al.,	  2009).	  Furthermore,	  some	  weakly	  expressed	  moRNAs	  
have	  been	  found	  in	  solid	  tumors,	  together	  with	  other	  small	  RNAs	  (Meiri	  et	  al.,	  2010).	  
moRNAs	  are	  generally	  included	  in	  the	  miRNA	  hairpin	  precursor,	  and	  in	  some	  cases	  the	  
moRNA	  overlaps	  the	  miRNA	  position	  by	  a	  few	  nucleotides	  (Langenberger	  et	  al.,	  2009).	  
Other	  moRNAs	   that	   overhang	   the	  miRNA	   hairpin	   can	   be	   produced	   by	   non-­‐canonical	  
Drosha	  processing	   (Berezikov	  et	  al.,	   2011).	   Thus,	   it	   is	  not	   clear	  how	   the	   two	  ends	  of	  
moRNAs	   arise	   and	   if	   or	   how	   Drosha	   and	   Dicer	   are	   involved.	   moRNAs	   seem	   to	   be	  
conserved	  across	  species,	  the	  conservation	  extent	  correlates	  with	  expression	  level	  (Shi	  
et	   al.,	   2009)	   and	   expression	   levels	   of	   certain	   moRNAs	   are	   greater	   than	   for	   their	  
corresponding	   miRNA	   (Umbach	   et	   al.,	   2010).	   In	   addition,	   moRNAs	   are	   prevalently	  
produced	  by	  the	  5ʹ′	  arm	  of	  the	  precursor,	  independent	  of	  which	  arm	  produces	  the	  most	  
expressed	   mature	   miRNA	   (Langenberger	   et	   al.,	   2009;	   Umbach	   et	   al.,	   2010).	   This	  
evidence	  suggests	  that	  moRNAs	  might	  be	  miRNA	  co-­‐products,	   representing	  a	  distinct	  
functional	  class	  of	  miRNA-­‐related	  agents	  (Berezikov	  et	  al.,	  2011).	  The	  hypothesis	  that	  
moRNAs	  are	  a	  new	  class	  of	   functional	   regulators	  whose	  qualitative	  alteration	  and/or	  
expression	  dysregulation	  might	   impact	  on	  human	  diseases	   is	   intriguing,	  but	  evidence	  
regarding	  possible	  moRNA	  functions	  is	  still	  fragmentary.	  
	  
2.4.5	  ROLE	  OF	  MICRORNAS	  IN	  HEMATOPOIESIS	  
In	   hematopoiesis	   a	   limited	   number	   of	   multipotent	   hematopoietic	   stem	   cell	  
differentiate	   into	   cells	   of	   all	   lineages	   that	   constitute	   the	   blood.	   This	   process	   of	  
Fig.11:	   moRNAs.	   Two	   miRNAs	   and	   two	   moRNAs	   can	   be	  
produced	   by	   transcription	  and	   processing	   of	  a	   single	  miRNA	  
locus.	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differentiation	   is	   well	   characterised	   and	   involves	   intermediate	   progenitors	   with	  
decreasing	   self-­‐renewal	   ability	   and	   increasing	   lineage	   commitment.	   Lineages	   are	  
defined	   functionally	   and	   morphologically	   and	   lineage	   commitment	   is	   controlled	   by	  
complex	  network	  of	  transcription	  factors	  that	  define	  specific	  gene	  expression	  patterns	  
for	  every	   cell	   type.	  There	  are	   several	  miRNAs	   that	  appear	   to	  play	  a	   role	   in	   the	  most	  




Fig.	   12:	   A	   diagram	   showing	   miRna	   and	   their	   targets	   that	   play	   a	   role	   in	   the	   development	   of	   the	   hematopoietic	  
system.	  The	  diagram	  lists	  the	  various	  miRnas	  and	  their	  targets	  that	  are	  involved	  in	  hematopoiesis.	  
Upregulation	  or	  downregulation	  of	  a	  specific	  miRna	  is	  represented	  by	  an	  upward	  (black)	  or	  a	  downward	  (red)	  arrow,	  
respectively.	   The	   changes	   in	   the	   expression	   levels	   of	   a	   validated	   target	   gene	   inversely	   correlate	  with	   that	   of	   the	  
targeting	  miRna	  and	  are	  similarly	  represented	  by	  an	  up	  or	  down	  arrow.(Sayed	  et	  al.,	  2011).	  
	  
The	   miR-­‐125	   family	   (consisting	   of	   three	   members,	   miR-­‐125a,	   miR-­‐125b1	   and	   miR-­‐
125b2)	   is	   crucial	   for	   the	  maintenance	  of	   self-­‐renewal	   and	  differentiation	  balance.	  As	  
shown	   by	   several	   groups	   (Gerrits	   et	   al.,2012;	   Guo	   et	   al.,	   2010;	   Ooi	   et	   al.,	   2010),	  
members	   of	   the	   miR-­‐	   125	   family	   are	   highly	   expressed	   in	   Hematopoietic	   Stem	   and	  
Progenitor	  Cells	  (HSPCs)	  and	  their	  expression	  decreases	  upon	  differentiation.	  Enforced	  
expression	   of	   these	  miRNAs	   in	   HSPCs	   provides	   a	   proliferative	   advantage	   and	   skews	  
differentiation	  towards	  the	  myeloid	  lineage	  (Guo	  et	  al.,	  2010;	  Chauduhuri	  et	  al.,	  2012)	  
Most	   recent	   data	   clearly	   show	   that	   all	   miR-­‐125	   family	  members	   promote	   increased	  
stem	  cell	  self-­‐renewal,	  but	  their	  exact	  targets	  are	  still	  unknown	  (Chaudhuri	  et	  al.,	  2012;	  
Wojtowicz	   et	   al.,	   2014).	   The	   phenotypes	   induced	   by	   miR-­‐125s	   maybe	   partially	  
explained	   by	   the	   inhibition	   of	   apoptosis,	   as	   miR-­‐125	   targets	   several	   pro	   apoptotic	  
genes	  and	  genes	   involved	   in	  p53	  pathway	   (Bousquet	  et	  al.,	  2012;	  Unoli	  et	  al.,	  2001).	  
Many	  miRNAs	  reside	  at	  introns	  or	  within	  close	  proximity	  of	  protein	  coding	  genes	  and	  
are	   often	   co-­‐expressed	   with	   these	   genes	   (Isik	   et	   al.,	   2010;	   Li	   et	   al.,	   2012).	   A	   good	  
example	  is	  the	  cluster	  of	  HOX	  genes,	  which	  encodes	  members	  of	  the	  miR-­‐196	  family.	  
The	  HOX	   family	  of	   transcription	   factors	   is	   essential	   for	   the	  development	   and	   several	  
HOX	   genes	   play	   an	   important	   role	   in	   hematopoiesis.	   In	   the	   mouse	   and	   human	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genomes	  miR-­‐196	   bis	   positioned	   between	   HoXA9	   and	   HoXA10	   genes.	   Expression	   of	  
miR-­‐196b	  correlates	  with	  the	  expression	  pattern	  of	  HOXA9,	  and	  is	  highly	  expressed	  in	  
HSPCs.	   MiR-­‐196b	   regulates	   transcription	   of	   genes	   involved	   in	   cell	   survival	   and	  
proliferation	   (Li	  et	  al.,	   2012)	  but	  also	  maintains	  primitive	   cells	  at	  an	  undifferentiated	  
state	  by	  repressing	  genes	  involved	  indifferentiation	  (Yekta	  et	  al.,	  2004).	  The	  balanced	  
expression	  of	  HOX	  genes	   is	   controlled	  by	  miR-­‐196b	  which	   represses	  HOX	  genes	   that	  
are	   normally	   upregulated	   during	   myeloid	   differentiation	   (Yekta	   et	   al.,	   2004).	   Other	  
HOX	  genes	  involved	  in	  hematopoietic	  differentiation	  such	  as	  HOXA7	  and	  HOXC8	  were	  
found	  to	  contain	  sequences	  complementary	  to	  the	  miR-­‐196b	  seed	  sequence	  and	  have	  
been	  confirmed	  as	  direct	   targets	   (Yekta	  et	  al.,	  2004).	  More	   	  evidence	   for	  miR-­‐196b's	  
role	  in	  suppressing	  differentiation	  comes	  from	  the	  observation	  that	  the	  transcriptional	  
repressor	   Gfi1	   required	   for	  myeloid	   differentiation	   down-­‐regulates	  miR-­‐196b	   during	  
myelopoiesis	  (Velu	  et	  al.,	  2009).	  The	  miR-­‐17–92	  cluster	  is	  transcribed	  as	  a	  single	  non-­‐
coding	   RNA	   that	   is	   subsequently	   processed	   into	   seven	   mature	   miRNAs:	   miR-­‐17-­‐5p,	  
miR-­‐17-­‐3p,	   miR-­‐18a,	   miR-­‐19a,	   miR-­‐19b,	   miR-­‐20a	   and	  miR-­‐92a.	   Some	  miRNAs	   in	   the	  
miR-­‐17-­‐92	  cluster	  share	  expression	  patterns	  which	  is	  often	  the	  case	  for	  miRNA	  clusters	  
as	  they	  are	  typically	  under	  control	  of	  the	  same	  promoter	  (Baskerville	  et	  al.,	  2005;	  Jin	  et	  
al.,2008).	   It	  has	  been	  shown	  that	   four	  of	   the	  eight	  miRNAs	  were	  higher	  expressed	   in	  
hematopoietic	  stem	  cells	  compared	  to	  mature	  blood	  cells	  (miR-­‐19a,miR-­‐19b,	  miR-­‐20a	  
and	  miR-­‐20b)	  (	  Jin	  et	  al.,	  2008)	  and	  overexpression	  of	  the	  entire	  cluster	  leads	  to	  stem	  
cell	  expansion	  (Li	  et	  al.,	  2012)	  .	  As	  expected,	  transcription	  factors	  targeted	  by	  miR-­‐17-­‐
92	  miRNAs	  are	   involved	  in	  differentiation	  and	  cell	  cycle	  regulation	  (Xiao	  et	  al.,	  2008).	  
Yet	  overexpression	  of	  individual	  miRNAs	  induced	  various	  blood	  malignancies	  (Li	  et	  al.,	  
2012)	   high	   lighting	   the	   importance	  of	   the	   coordinated	   regulation	   of	  multiple	   targets	  
involved	  in	  similar	  pathways	  for	  normal	  HSPC	  maintenance	  and	  self-­‐renewal.	  	  
-­‐MicroRNAs	  involved	  in	  the	  regulation	  of	  erythropoiesis	  and	  
megakaryopoiesis.	  
Several	  miRNAs	  have	  been	  implicated	  in	  the	  regulation	  of	  erythropoiesis,	  among	  which	  
are	   miR-­‐15a,	   mir-­‐24,	   miR-­‐144	   and	   miR-­‐451.	   In	   order	   to	   enable	   erythroid	  
differentiation,	   suppression	   of	   the	   self-­‐renewal	   of	   HSPCs	   and	   a	   switch	   in	   gene	  
expression	   to	   an	   erythroid	   signature	   pattern	   are	   imperative.	   Many	   of	   the	   miRNAs	  
upregulated	   in	   erythroid	   cells	   target	   genes	   that	   normally	   promote	   myeloid	   lineage	  
differentiation.	  These	  include	  GATA-­‐1	  and	  GATA-­‐2,	  which	  are	  regulated	  by	  miRNA-­‐24,	  
miR-­‐27a	  (Wang	  et	  al.,	  2008;	  Wang	  et	  al.,	  2014)	  and	  miR-­‐451	  (Pase	  et	  al.,	  2009).	  Their	  
interaction	   with	   PU.1	   is	   a	   bifurcation	   point	   between	   myeloid	   and	   erythroid	   lineage	  
commitment	   (Nerlov	   et	   al.,	   2000).	   During	   erythropoiesis,	   GATA-­‐1	   progressively	   out	  
competes	  GATA-­‐2,	  and	   this	  particular	  GATA	  switch	   is	  mediated	  by	  miR-­‐144	  and	  miR-­‐
451	   (Dore	  et	  al.,	  2008).	  MiR-­‐144	  and	  miR-­‐451	  are	  both	  upregulated	  during	  erythroid	  
differentiation	  and	  are	  transcribed	  as	  a	  single	  pri-­‐miRNA	  transcript	  (Dore	  et	  al.,	  2008).	  
GATA-­‐1	   and	   GATA-­‐2	   are	   both	   able	   to	   bind	   upstream	   of	   miR-­‐144/miR-­‐451	   but	   their	  
ability	  to	  activate	  transcription	  differs:	  only	  GATA-­‐1	  activates	  transcription	  of	  miR-­‐144/	  
miR-­‐451	  pri-­‐miRNA.In	  all	  reports	  GATA-­‐1	  is	  involved	  in	  a	  positive	  regulatory	  loop	  with	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the	  miRNAs	  that	  regulate	  the	  GATA-­‐switch:	  GATA-­‐1	  activates	  transcription	  of	  miRNAs	  
that	   repress	  GATA-­‐2	  and	   facilitate	  binding	  and	   transcriptional	   activation	  of	   erythroid	  
genes	   by	  GATA-­‐1.	  One	  of	   the	   suggested	   targets	   of	  miR-­‐451	   is	   c-­‐Myc,	   a	   transcription	  
factor	   and	   oncogene	   involved	   in	  HSC	   self-­‐renewal.	  Consequently,	   its	   downregulation	  
may	   allow	   for	   differentiation	   of	   progenitors	   into	   the	   erythroid	   lineage.	   Interestingly,	  
although	  initially	  believed	  to	  be	  primarily	  expressed	  in	  lymphocytes	  (Xiao	  et	  al.,	  2007)	  
miR-­‐150	  appears	  to	  also	  be	  important	  for	  megakaryopoiesis.	  One	  of	  its	  targets	  is	  c-­‐myb	  
that	  regulates	  transcription	  factors	  such	  as	  Kruppel	  Like	  Factor(Klf1)	  and	  Lmo2,	  which	  
enhance	   erythropoiesis	   (Lorenzo	   et	   al.,	   2011)	   .	   MiR-­‐150	   is	   up	   regulated	   during	  
megakaryopoiesis	   but	   downregulated	   in	   erythropoiesis	   suggesting	   that	   its	   level	   of	  
expression	  regulates	  cell	  lineage	  commitment	  towards	  differentiating	  megakaryocyte–
erythrocyte	  progenitors.	  
-­‐MicroRNAs	  important	  for	  granulopoiesis.	  
As	   discussed	   above,	   miRNAs	   can	   actin	   positive	   regulatory	   loops	   but	   additionally,	  
miRNAs	   are	   also	   able	   to	   actin	   negative	   feedback	   regulatory	   pathways	   and	   this	  
characteristic	   aids	   in	   the	   regulation	   of	   lineage	   commitment.	   An	   exemplary	   case	   is	  
provided	   by	   miR-­‐223	   (Fazi	   et	   al.,	   2005).	   During	   granulopoiesis	   miR-­‐223	   acts	   in	   a	  
negative	  cascade	  pathway	  to	  both	  repress	   the	  erythroid	   transcription	   factor	  NFI-­‐A	  at	  
the	  RNA	  level	  (Starnes	  et	  al.,	  2009)	  while	  at	  the	  same	  time	  associating	  with	  Ying	  Yang1	  
(YY1),	   a	   member	   of	   Polycomb	   Repressive	   Complex1	   (PRC1).	   This	   is	   quitean	   atypical	  
association	   for	   miRNAs,	   as	   they	   rarely	   associate	   with	   proteins	   outside	   of	   the	   RISC	  
complex.	   This	  provides	  a	   good	  example	  of	  how	  miRNA	   regulation	   can	  occur	   through	  
binding	  with	  other	  proteins,	  to	  form	  complexes	  able	  to	  repress	  gene	  transcription.	  All	  
of	   the	  above	  proteins	  bindin	  proximity	  of	   the	  NFI-­‐A	   locus	   to	   repress	   it	   stranscription	  
(Zardo	   et	   al.,	   2012)	   and	   collectively	   lead	   to	   enhanced	   granulopoiesis	   induced	   by	  
C/EBP/α	  (Fazi	  et	  al.,	  2005).	  While	  miR-­‐223	  transcription	  is	  activated	  by	  the	  binding	  of	  
either	   NFI-­‐AorC/EBP/α	   to	   its	   promoter,C/EBP/α	   is	   the	   more	   potent	   activator.	   Both	  
transcription	   factors	  compete	   for	  binding	  at	   the	  miR-­‐223	  promoter	  but	   they	  differ	   in	  
their	   degree	   of	   transcriptional	   activation.	   During	   granulopoiesis,	   however,	   NFI-­‐A	   is	  
unable	   to	   compete	   with	   C/EBP/α	   resulting	   in	   increasing	   miR-­‐223	   transcription	   and	  
sustained	  NFI-­‐A	  repression	  (Fazi	  et	  al.,	  2005).	  
2.4.6	  MIRNA	  AND	  CANCER.	  
Three	  important	  observations	  early	  in	  the	  history	  of	  miRNAs	  suggested	  a	  potential	  role	  
in	   human	   cancer.	   Firstly,	   the	   earliest	   miRNAs	   discovered	   in	   the	   roundworm	  C.	  
elegans	  and	   the	   fruit	   fly	  Drosophila	  were	   shown	   to	   control	   cell	   proliferation	   and	  
apoptosis	  (Lee	  et	  al.,	  1993;	  Brennecke	  et	  al.,	  2003).	  Their	  deregulation	  may	  therefore	  
contribute	   to	   proliferative	   diseases	   such	   as	   cancer.	   Secondly,	   when	   human	  miRNAs	  
were	  discovered,	  it	  was	  noticed	  that	  many	  miRNA	  genes	  were	  located	  at	  fragile	  sites	  in	  
the	  genome	  or	  regions	  that	  are	  commonly	  amplified	  or	  deleted	  in	  human	  cancer	  (Calin	  
et	   al.,	   2004).	   Thirdly,	   malignant	   tumors	   and	   tumor	   cell	   lines	   were	   found	   to	   have	  
widespread	   deregulated	  miRNA	   expression	   compared	   to	   normal	   tissues	   (Calin	   et	   al.,	  
2006;	  Gaur	  et	  al.,	  2007;	  Lu	  et	  al.,	  2005).	  The	  question	  remained	  whether	   the	  altered	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miRNA	   expression	   observed	   in	   cancer	   is	   a	   cause	   or	   consequence	   of	   malignant	  
transformation.	   In	   2002,	   the	   first	   direct	   evidence	   for	   an	   involvement	   of	   miRNAs	   in	  
cancer	  was	  reported	  (Calin	  et	  al.,	  2002).	  Calin	  et	  al.	  studied	  a	  well-­‐known	  deletion	  on	  
chromosome	   13,	   which	   is	   the	   most	   frequent	   chromosomal	   abnormality	   in	   chronic	  
lymphocytic	   leukemia	   (CLL).	   This	   deletion	   had	   long	   been	   suspected	   to	   contribute	   to	  
leukemogenesis.	  However,	  extensive	  studies	  had	  failed	  to	  identify	  a	  causal	  gene.	  Calin	  
et	  al.	  (Calin	  et	  al.,	  2002)	  found	  that	  two	  miRNA	  genes,	  mir-­‐15	  and	  mir-­‐16,	  were	  located	  
within	  this	  30-­‐kb	  deletion.	  They	  subsequently	  analyzed	  the	  expression	  of	  miR-­‐15	  and	  
miR-­‐16	   in	   blood	   samples	   from patients	   with	   CLL.	   Both	   miRNAs	   were	   absent	   or	  
downregulated	   in	   the	   majority	   (68%)	   of	   cases	   when	   compared	   to	   normal	   tissue	   or	  
lymphocytes.	  This	  finding	  suggested	  that	  these	  two	  miRNAs	  were	  causally	  involved	  in	  
the	  pathogenesis	  of	  chronic	  lymphocytic	  leukemia.	  In	  2005,	  three	  reports	  provided	  the	  
first	   mechanistic	   insight	   into	   how	   miRNAs	   might	   contribute	   to	   carcinogenesis.	   Two	  
independent	   studies	   described	   the	   relationship	  between	  a	  miRNA	   cluster,	  mir-­‐17-­‐92,	  
and	   the	   Myc	   oncogenic	   pathway	   (He	   et	   al.,	   2005;	  O’	   Donnell	   et	   al.,	   2005).	   A	   third	  
report	  demonstrated	  an	  interaction	  between	  let-­‐7	  miRNA	  and	  the	  RAS	  proto-­‐oncogene	  
(Johnston	  et	  al.,	  2003).	  
-­‐	  Abnormal	  expression	  of	  miRNA	  in	  cancer.	  
Tumor	  tissues	  and	  cultured	  tumor	  cells	  often	  exhibit	  significantly	   reduced	  expression	  
levels	   of	   mature	   miRNAs	  (Krutzfeldt	   et	   al.,	   2005).	   Different	   mechanisms	   for	   the	  
aberrant	   expression	   of	   miRNA	   were	   documented.	   Three	   of	   them,	   	   (i)	   genetic	  
alterations	  and	  single	  nucleotide	  polymorphism	  (SNP),	  (ii)	  epigenetic	  silencing	  and	  (iii)	  
defects	  in	  the	  miRNA	  biogenesis	  pathway,	  are	  discussed	  below.	  
(i) Genetic	   alterations	  and	  SNP:	  Complete	  mapping	  of	  human	  miRNA	  genes	   revealed	  
that	  a	  great	  majority	  of	  the	  miRNAs	  were	  associated	  with	  fragile	  sites,	  cancer-­‐specific	  
translocation	  breakpoints,	  repetitive	  sequences	  and	  CpG	  islands	  (Kumar	  et	  al.,	  2007).	  
However,	   some	   studies	   have	   indicated	   such	   association	   is	   not	   straight-­‐forward	   and	  
appears	  to	  be	  dependent	  on	  the	  specific	  type	  of	  cancer	  (Lagos-­‐Quintana	  et	  al.,	  2001).	  
Furthermore,	   the	   existence	   of	   polymorphism	   in	   single	   nucleotides	   (SNPs)	   is	   widely	  
known	  and,	  evidence	  has	  been	  presented	  suggesting	  the	  influence	  of	  SNPs	  on	  miRNA	  
targets	  in	  cancer-­‐related	  pathways	  (Lai	  et	  al.,	  2005).	  A	  gain	  in	  function	  due	  to	  SNP	  may	  
enhance	   its	   interaction	  with	  miRNA	   target	   and	   thus,	   enhance	   its	   regulatory	   function	  
such	  as	  a	  tumor	  suppressor	  gene.	  In	  contrast,	  loss	  in	  function	  due	  to	  SNP	  may	  result	  in	  
increased	   expression	   of	   miRNA,	   which	   then	   acts	   as	   an	   oncogene	  (Lau	   et	   al.,	   2001).	  
Additionally,	   SNPs	   in	   target	   sites	   of	   miRNAs	   may	   also	   result	   in	   the	   escape	   of	  
degradation	  by	  miRNA	  (Lee	  et	   al.,	   2001).	  All	   these	  observations	   suggested	   that	   SNPs	  
may	  be	  one	  of	  the	  contributing	  factors	  in	  the	  regulation	  of	  biogenesis	  and	  functionality	  
of	  miRNAs.	  
(ii) Epigenetic	   regulation	   of	   miRNA	   expression:	   Several	   research	   groups	   have	  
investigated	  whether	   epigenetics,	   i.e.,	   hyper-­‐	   or	  hypo-­‐methylation	   (an	  early	   event	   in	  
carcinogenesis),	  play	  a	  role	  and	  influence	  the	  activity	  of	  miRNA	  genes	  (Lee	  et	  al.,	  1993;	  
Lee	  et	  al.,	  2003;	  Lee	  et	  al.,	  2007)	  since	  the	  expression	  of	  miRNA	  genes,	  especially	  those	  
located	   near	   CpG	   islands,	   tends	   to	   be	   affected	   more	   readily	   by	   methylation	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processes	  (Lee	  et	   al.,	   1993;	   Lee	  et	   al.,	   2003;	   Lee	  et	   al.,	   2005).	   In	   scientific	   literature,	  
there	  were	  several	  examples	  of	  DNA	  methylation	  processes	  influencing	  the	  activity	  of	  
miRNAs.	   In	  addition	  to	  DNA	  methylation,	  histone	  acetylation	  was	  also	  reported	  to	  be	  
another	  epigenetic	  phenomenon	  in	  deregulated	  cancers.	  In	  breast	  cancer	  cells,	  histone	  
deacetylase	   inhibition	   was	   shown	   to	   result	   in	   alteration	   in	   miRNA	   levels	  (Lu	   et	   al.,	  
2005).	   In	  bladder	   cancer	   cells,	   a	   combined	   treatment	  with	  5-­‐aza-­‐2ʹ′-­‐deoxycytidine	   (5-­‐
Aza-­‐CdR)	   and	   histone	   deacetylase	   (HDAC)	   inhibitor	   4-­‐phenylbutyric	   acid	   (PBA)	   had	   a	  
significant	   effect	   on	  multiple	  miRNAs	   among	  which	  miR-­‐127	   was	  most	   differentially	  
expressed	  (Lee	  et	  al.,	  2005).	  Specific	   induction/activation	  of	  miRNA-­‐127	  by	  5-­‐Aza-­‐CdR	  
and	  PBA	  suppressed	  the	  transcription	  of	  the	  zinc-­‐finger	  repressor	  BCL6	  gene	  and	  thus	  
induced	  apoptosis	  in	  human	  cancer	  cells	  (Lee	  et	  al.,	  2005).	  
iii)	  Defects	  in	  the	  miRNA	  pathway:	  In	  humans,	  the	  majority	  of	  miRNAs	  are	  encoded	  by	  
introns	  of	  non-­‐coding	  or	  coding	  transcripts.	  However,	  some	  miRNAs	  were	  reported	  to	  
be	  encoded	  by	  exonic	   regions.	   The	  genes	   controlling	  miRNA	  are	  often	   clustered	  and	  
transcribed	   as	   polycistronic	   messages	   or	   excised	   from	  mRNAs	  (Lu	   et	   al.,	   2005).	   The	  
precise	   locations	  of	  promoters	   for	  most	  miRNA	  genes	  are	  not	   yet	  mapped	  but,	   they	  
can	  be	  inferred	  from	  collective	  analysis	  of	  CpG	  islands,	  RNA	  sequencing	  and	  chromatin	  
immune-­‐precipitation	  followed	  by	  ChIP-­‐sequencing	  (Lujambio	  et	  al.,	  2007)	  .	  Numerous	  
Pol-­‐II	   associated	   transcription	   factors	   were	   reported	   to	   activate	   or	   repress	   several	  
miRNA	  genes.	  The	  abundance	  of	  some	  miRNAs	  were	  also	  shown	  to	  be	  regulated	  at	  the	  
RNA	  stability	  level	  (Ma	  et	  al.,	  2007).	  
2.4.7	  CIRCULATING	  MIRNAS	  AND	  ROLE	  IN	  CANCER.	  	  
Previous	  studies	  have	  demonstrated	  that	  miRNAs	  are	  stable	  also	  in	  serum	  and	  plasma	  
and	  that	  their	  expression	  profile	  responds	  to	  changes	  under	  different	  physiological	  and	  
pathological	  conditions	  (Chim	  et	  al.,	  2008;	  Gutwain	  et	  al.,	  2005)	  .	  Although	  circulating	  
miRNAs	   may	   serve	   as	   biomarkers	   for	   various	   types	   of	   cancers	   (Lodes	   et	   al.,	   2009;	  
Lawrie	  et	  al.,	   2008),	   the	   isolation	  and	  measurement	  of	   circulating	  miRNAs	   remains	  a	  
challenging	   task.	   In	   addition,	   although	  many	   studies	   have	   attempted	   to	   explain	   the	  
origin	  and	   function	  of	   circulating	  miRNAs	   in	   cancer	  patients,	   no	  definitive	   source	   for	  
these	   molecules	   has	   been	   proposed.	   Some	   cell-­‐free	   miRNAs	   in	   body	   fluids	   may	   be	  
packaged	   in	   exosomes,	   microvesicles	   or	   RNA	   binding-­‐proteins,	   which	   provide	  
protection	  from	  RNases	  (Huan	  et	  al.,	  2013;	  Arroyo	  et	  al.,	  2011;	  	  Gibbings	  et	  al.,	  2009;	  
Hunter	   et	   al.,	   2008;	   Zhang	   et	   al.,	   2010	   )	   and	   enable	   their	   transfer	   from	   one	   cell	   to	  
another	   during	   diverse	   biological	   processes.	   By	   defining	   tumors	   as	   relatively	  
homogeneous	   cancer	   cells	   formed	   in	   an	   independent	  microenvironment,	   circulating	  
miRNAs	  may	  play	  a	  novel	  role	  as	  regulators	  of	  cell-­‐cell	  communications	  during	  cancer	  
formation	   (Hergenreider	   et	   al.,	   2012;	   Chen	   et	   al.,	   2014	   ).	   Circulating	   miRNAs	   have	  
numerous	  advantages	  including	  stably	  existing	  in	  almost	  all	  body	  fluids,	  cancer-­‐specific	  
or	  tightly	  correlating	  with	  physiological	  and	  pathological	  changes	  and	  easily	  detectable.	  
Consequently,	   a	   number	   of	   studies	   have	   proposed	   that	   circulating	  miRNAs	   could	   be	  
ideal	  biomarkers	   for	   the	  prediction	  and	  prognosis	  of	  cancer.	  The	  first	  comprehensive	  
analysis	  of	  circulating	  miRNAs	  in	  cancer	  patients	  was	  performed	  by	  Lawrie	  et	  al.	  They	  
compared	  the	  expression	  levels	  of	  tumor	  associated	  miR-­‐155,	  miR-­‐210	  and	  miR-­‐21	  in	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serum	   from	   patients	   with	   diffuse	   large	   B-­‐cell	   lymphoma	   with	   levels	   in	   serum	   from	  
healthy	  controls	  and	  observed	  higher	  levels	  in	  patients	  compared	  with	  controls	  (Lawrie	  
et	   al.,	   2008).	   	   Mitchell	   et	   al.	   established	   an	   important	   approach	   when	   measuring	  
tumor-­‐derived	  miRNAs	  in	  serum	  or	  plasma	  and	  suggested	  that	  serum	  level	  of	  miR-­‐141	  
can	   distinguish	   patients	   with	   prostate	   cancer	   from	   healthy	   controls	   (Michell	   et	   al.,	  
2008).	   In	   hepatocellular	   cancer,	   based	  on	  microarray	   and	  qRT-­‐PCR,	   seven	   circulating	  
miRNAs	  (miR-­‐21,	  -­‐26a,	  -­‐27a,	  -­‐122,	  -­‐192,	  -­‐223,	  and	  -­‐801)	  were	  reported	  to	  differentiate	  
HCC	  patients	  from	  healthy	  controls,	  patients	  with	  chronic	  hepatitis	  B	  or	  patients	  with	  
cirrhosis	  (Zhou	  et	  al.,	  2011).	  Table	  7	  summarizes	  recently	  described	  circulating	  miRNAs	  
that	  may	  be	  used	  as	  non-­‐invasive	  biomarkers	  for	  cancer	  detection.	  In	  further	  examples	  
of	   the	   differentiation	   of	   diseased	   patients	   from	   healthy	   controls,	   circulating	  miRNAs	  
have	   also	   been	   demonstrated	   as	   biomarkers	   for	   early-­‐stage	   cancer	   diagnosis.	   For	  
example,	   Roth	   et	   al.	   noted	   that	   the	   concentration	   of	  miR-­‐155	   in	   serum	   significantly	  
discriminated	  M0-­‐	  breast	  cancer	  patients	  from	  healthy	  women	  (Roth	  et	  al.,	  2010).	  Zhu	  
et	  al.	  also	  identified	  five	  miRNAs	  (miR-­‐16,	  miR-­‐25,	  miR-­‐92a,	  miR-­‐451	  and	  miR-­‐486-­‐5p)	  
as	   potential	   markers	   for	   the	   early-­‐stage	   gastric	   non-­‐cardia	   adenocarcinoma	   (GNCA)	  
(stage	   I)	   (Zhu	   et	   al.,	   2014).	   It	   has	   been	   reported	   that	   circulating	   miR-­‐92a	   was	  
dysregulated	   in	   non-­‐metastatic	   and	   metastatic	   colorectal	   cancer	   (CRC)	   patients	   and	  
showed	   potential	   as	   a	   non-­‐invasive	   biomarker	   for	   the	   early	   detection	   of	   liver	  
metastasis	  in	  CRC	  patients	  	  (Wang	  et	  al.,	  2014)	  .	  
	  
	  
Tab.7:	  	  Summary	  of	  the	  circulating	  miRNAs	  that	  may	  be	  used	  as	  non-­‐invasive	  biomarkers	  
for	  the	  detection	  of	  cancer.	  
Finally,	  in	  	  a	  study	  conducted	  by	  Zhi	  et	  al.,	  	  6	  miRNAs,	  miR-­‐10a-­‐5p,	  miR-­‐93-­‐5p,	  miR-­‐129-­‐
5p,	  miR-­‐155-­‐5p,	  miR-­‐	  181b-­‐5p	  and	  miR-­‐320d,	  were	  found	  to	  have	  significantly	  different	  
expression	   levels	   in	   AML	   compared	   with	   control	   serum	   samples.	   Furthermore,	  
unsupervised	  clustering	  analysis	  revealed	  the	  remarkable	  ability	  of	  the	  6-­‐miRNA	  profile	  
to	  differentiate	  between	  AML	  patients	  and	  normal	  controls.	   	  More	   importantly,	  miR-­‐
181b-­‐5p	  levels	  in	  serum	  were	  significantly	  associated	  with	  overall	  survival.	  These	  data	  
demonstrated	  that	  the	  expression	  patterns	  of	  circulating	  miRNAs	  were	  systematically	  
altered	  also	   in	  AML	  and	  miR-­‐181b-­‐5p	  may	  serve	  as	  a	  predictor	   for	  overall	   survival	   in	  
AML	  patients	  (Zhi	  et	  al.,	  2013).	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2.4.8	  	  MIRNAS	  IN	  HEMATOLOGICAL	  DISEASE.	  	  
The	   general	   importance	   of	   miRNA	   dysregulation	   to	   the	   pathogenesis	   of	   myeloid	  
disorders	  is	  implied	  by	  the	  fact	  that	  more	  than	  70%	  of	  all	  human	  miRNAs	  are	  encoded	  
within	   regions	   of	   recurrent	   copy-­‐number	   alterations	   in	   myelodysplastic	   syndrome	  
(MDS)	   and	   acute	   myeloid	   leukemia	   (AML)	   cell	   lines	   (Starczynowski	   et	   al.,	   2011).	  
Furthermore,	   a	   functional	   role	   in	   the	   pathology	   of	   these	   diseases	   has	   been	  
demonstrated	   recently	   by	   several	   in	   vivo	   mouse	   models.	   For	   example,	   targeted	  
deletion	   of	  Dicer1	  in	   osteoprogenitor	   cells	   resulted	   in	   abnormal	   hematopoiesis,	  MDS	  
and	   eventual	   AML	   (Raaijmakers	   et	   al.,	   2010).	   Deletion	   of	  murine	   HSC-­‐encoded	  miR-­‐
145	  and	  miR-­‐146a,	  miRNAs	   encoded	   on	   the	   5q	   locus,	   a	   frequently	   deleted	   region	   in	  
myeloid	   disorders,	   caused	  mild	   neutropenia,	   megakaryocytic	   dysplasia	   and	   eventual	  
fatal	   myeloid	   malignancy	   (Starczynowski	   et	   al.,	   2010).	   Over-­‐expression	   of	  miR-­‐
125b	  resulted	  in	  the	  development	  of	  leukemia,	  (Bousquet	  et	  al.,	  2010)	  mirroring	  what	  
occurs	   in	  MDS	   and	   AML	   patients	   that	   harbor	   the	   t(2,11)	   translocation	   involving	   the	  
encoding	  locus	  for	  this	  miRNA	  (Bousquet	  et	  al.,	  2008).	  Finally,	  over-­‐expression	  of	  miR-­‐
155	  (O’	   Connell	   et	   al.,	   2008)	   or	  miR-­‐29a	   (Han	   et	   al.,	   2010)	   in	   mouse	   HSC	   results	   in	  
myeloproliferative	  disorders	  that	  can	  progress	  to	  AML.	  
Many	   studies	   have	   demonstrated	   that	  miRNAs	   are	   abnormally	   expressed	   in	  myeloid	  
malignancies	  compared	  to	  counterpart	  controls;	  most	  commonly	  in	  AML	  (	  Marcucci	  et	  
al.,	  2011),	  but	  also	  in	  MDS	  (	  Rhyasen	  et	  al.,	  2012)	  and	  chronic	  myeloid	  leukemia	  (CML).	  
However	  it	  should	  be	  noted	  that	  the	  reliability	  of	  much	  of	  this	  data	  is	  still	  contentious	  
as	  the	  miRNA	  signatures	  show	  little	  overlap	  between	  studies.	  These	  discrepancies	  are	  
probably	  due	  to	  the	  use	  of	  different	  control	  populations	  (unsorted	  PMBCs,	  BM-­‐derived	  
CD34+	  or	   in	  vitro	  expanded	  CD34+),	  as	  well	  as	  technical	  variability	  (e.g.	  differing	  array	  
platforms,	  statistical	  analyses	  and	  varying	  cytogenetic/molecular	  profiling	  techniques)	  
between	   studies.	   Consequently,	   the	   need	   to	   validate/standardize	   these	   data	   is	   a	  
prerequisite	  to	  translate	  these	  findings	  into	  routine	  clinical	  practice.	  
Of	   particular	   interest,	   profiling	   studies	   have	   revealed	   marked	   differences	   in	   miRNA	  
expression	  between	  common	  cytogenetic	  subtypes	  of	  AML	   including	  those	  harboring	  
favorable-­‐risk	  abnormalities	  such	  as	  t(8,21),	  (Jongen	  et	  al.,	  2008;	  Li	  et	  al.,	  2008;	  Dixon	  
et	   al.,	   2008;	  Cammarata	  et	   al.,	   2010)	   inv(16),	   t(15,17),	   (Jongen	  et	   al.,	   2008;	   Li	   et	   al.,	  
2008;	  Dixon	  et	  al.,	  2008)	  and	  inv(16),	  and	  those	  with	  less	  favorable-­‐risk	  subtypes	  such	  
as	  t(11q23)/MLL	  	  (	  Jongen	  et	  al.,	  2008;	  Li	  et	  al.,	  2008;	  Dixon	  et	  al.,	  2008)	  and	  trisomy	  8	  
cases	  (Garzon	  et	  al.,	  2008).	  Additionally,	  karyotype	  normal	  AML	  patients	  (i.e.	  CN-­‐AML)	  
also	  have	  distinctive	  miRNA	  expression	  patterns	  associated	  with	   recurrent	  molecular	  
abnormalities	   including	  FLT3-­‐ITD	  (Jongen	  et	  al.,	  2008;	  Cammarata	  et	  al.,2010;	  Garzon	  
et	  al.,	  2008)	  and	  MLL	  duplications,	  mutations	  in	  WT1,IDH1,	  IDH2,	  NPM1	  (Jongen	  et	  al.,	  
2008;	  Garzon	  et	  al.,	  2008)	  	  and	  CEPBA	  (Jongen	  et	  al.,	  2008)	  as	  well	  as	  high	  expression	  
of	  BAALC	  (Langer	  et	  al.,	  2008)	  ERG	  and	  MN1	  (Langer	  et	  al.,	  2009)	  genes.	  In	  addition	  to	  
chromosomal	  alterations	  causing	  aberrant	  miRNA	  expression,	  epigenetic	  dysregulation	  
of	  miRNA	  plays	  an	  important	  role	  in	  myeloid	  pathogenesis	  (and	  in	  other	  hematological	  
malignancies),	   and	   many	   are	   hypermethylated	   including	  miR-­‐124a,	   associated	   with	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regulation	  of	  EVI1,	  CEBPA	  and	  CDK6,	  miR-­‐193a	   (targeting	  KIT)	  and	  miR-­‐34b	  (targeting	  
CREB)	   (Agirre	   et	   al.,	   2012).	   Conversely	   miRNAs	   can	   target	   components	   of	   the	  
epigenetic	   machinery	   such	   as	   DNA	   methyltransferases	   (Benetti	   et	   al.,	   2008)	   and	  
histone	  deacetylases	  (Roccaro	  et	  al.,	  2010).	  	  
The	   use	   of	   miRNA	   as	   novel	   classifiers	   of	   myeloid	   malignancies	   has	   drawn	   a	   lot	   of	  
attention	   recently.	   In	   MDS,	   for	   example	   twelve	   miRNAs	   were	   identified	   as	   being	  
differentially	  expressed	  between	  high	  and	  low	  risk	  MDS	  patients,	  although	  numbers	  in	  
this	  study	  were	  small	  (n	  =	  25)	  (Erdogan	  et	  al.,	  2011).	  Another	  study	  of	  52	  MDS	  patients	  
correlated	   high	  miR-­‐150	  levels	   with	   good	   cytogenetic-­‐risk	   groups	   (Roccaro	   et	  
al,2010).	  Microarray	  analyses	  of	  samples	  from	  122	  AML	  patients	  were	  used	  to	  define	  
signatures	   associated	   with	   cytogenetically	   favorable-­‐risk	   groups	   (Garzon	   et	   al.,	  
2008).	  Importantly,	   these	   findings	  were	   tested	   in	   an	   independent	   cohort	   of	   60	   AML	  
patients	   using	   qRT-­‐PCR	   and	   levels	   of	  miR-­‐191	  and	  miR-­‐199a	  were	   found	   to	   be	  
independent	   predictors	   of	   prognosis	   by	   multivariate	   analysis.	   More	   recently,	   high	  
levels	   of	  miR-­‐181a	  were	   correlated	  with	   better	   prognostic	   outcome	   for	   187	   CN-­‐AML	  
patients	  (Schwind	  et	  al.,	  2010).	  
Like	  AML	  and	  MDS,	  miRNAs	  are	  also	  aberrantly	  expressed	  in	  CML	  tumor	  cells	  (Agirre	  et	  
al.,	   2008).	   Interestingly,	   up-­‐regulation	   of	   the	  miR-­‐17-­‐92	  cluster	   was	   found	   to	   be	  
associated	  with	  chronic	  phase	  but	  not	  blast	  crisis	  CML	  patients	  (Venturini	  et	  al.,	  2007).	  
The	  same	  study	  demonstrated	  that	  K562	  cells	  treated	  with	  either	  imatinib	  or	  anti-­‐BCR-­‐
ABL	  siRNA	  caused	  down-­‐regulation	  of	   these	  miRNAs.	  A	  miRNA	  signature	  was	  derived	  
that	   could	  distinguish	  between	  CML	  patients	   that	  were	   responsive	   and	   refractory	   to	  
imatinib	  treatment	  (San	  Jose	  et	  al.,	  2009).	  	  The	  association	  of	  miRNAs	  with	  BCL-­‐ABL	  has	  
been	  further	  illustrated	  by	  the	  finding	  that	  miR-­‐203,	  an	  epigenetically	  silenced	  miRNA	  
in	   CML,	   can	   regulate	   BCL-­‐ABL	   expression	   (Bueno	   et	   al.,	   2008)	   Additionally,	  miR-­‐138,	  
down-­‐regulated	   in	   CML	   tumor	   cells	   but	   restored	   in	   response	   to	   imatinib	   treatment,	  
was	   recently	   shown	   to	  act	  as	  a	   tumor	   suppressor	   in	  CML	  cells	   thorough	   targeting	  of	  
BCR-­‐ABL	  expression	  as	  well	  as	  enhancing	  GATA1	  activity	  (Xu	  et	  al.,	  2013).	  
	  	  	  	  	  	  2.4.9	  MICRORNAS	  	  IN	  MYELOPROLIFERATIVE	  DISORDERS:	  STATE	  OF	  ART.	  
In	   recent	   studies	   abnormally	   expressed	  microRNAs	   in	  CD34+	   and	  blood	   cells	   of	  MPN	  
patients	   have	   been	   identified,	   some	   of	   which	   have	   a	   JAK2-­‐dependent	   pattern	   of	  
expression	   (Guglielmelli	   et	   al.,	   2007).	  Guglielmelli	   et	   al.	   has	  published	  a	   comparative	  
analysis	  of	  miRNA	  expression	  profile	   in	  granulocytes	   from	  PMF	  patients	  compared	  to	  
healthy	   subjects	   and	   PV	   or	   ET	   patients	   (Guglielmelli	   et	   al.,	   2007).	   A	   general	   down-­‐
regulation	  of	  miRNAs	  is	  observed,	  as	   in	  other	  tumors,	  although	  a	  minority	  of	  miRNAs	  
showed	   increased	   expression	   levels	   (Guglielmelli	   et	   al.,	   2007).	   Interestingly,	   the	  
abnormally	  increased	  level	  of	  over-­‐expressed	  miR182-­‐	  and	  183	  linearly	  correlated	  with	  
JAK2V617F	  allelic	  burden;	  finally,	  miRNA	  panel	  analysis	  pointed	  to	  discrete	  differences	  
in	  49	  miRNAs	  between	  JAK2	  mutated	  and	  wild-­‐type	  patients	  (Guglielmelli	  et	  al.,	  2007).	  
Bruchova	   and	   colleagues	   performed	   a	   gene	   expression	   profiling	   of	   micro-­‐RNAs	  
(miRNAs)	   in	   granulocytes	   from	   PV	   patients	   (Bruchova	   et	   al.,	   2007)	   and	   the	   miRNA	  
signature	   observed	   was	   clearly	   different	   from	   that	   of	   normal	   granulocytes,	   and	  
allowed	   the	   identification	   of	   a	   number	   of	  miRNAs	   (40	   out	   of	   a	   total	   of	   326)	   whose	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abnormal	   expression	   was	   either	   correlated	   or	   independent	   from	   the	   JAK2V617F	  
mutation.	   It	   is	   of	   interest,	   and	   probably	   not	   unexpected,	   that	   at	   least	   some	   of	   the	  
abnormally	  regulated	  miRNAs	  found	  in	  PV	  had	  been	  detected	  in	  PMF	  granulocytes	   in	  
the	  study	  of	  Guglielmelli	  et	  al.,	  and	  that	  they	  were	  also	  detected	  in	  ET	  or	  PMF	  patients	  
by	   Bruchova	   et	   al.	   Furthermore,	   Guglielmelli	   et	   al.	   have	   obtained	   considerable	  
evidence	   for	   a	   significant	   contribution	   of	   deranged	   miR-­‐16-­‐2	   expression	   to	   the	  
pathogenesis	  of	  PV	  (Guglielmelli	  et	  al.,	  2011).	  Finally,	  Bortoluzzi	  et	  al.	  performed	  short	  
RNA	   massive	   sequencing	   and	   extensive	   bioinformatic	   analysis	   in	   the	   JAK2V617F-­‐
mutated	   SET2,	   a	   factor-­‐independent	   megakaryoblastic	   cell	   line.	   Overall,	   652	   known	  
mature	   miRNAs	   were	   detected,	   of	   which	   21	   were	   highly	   expressed,	   thus	   being	  
responsible	   of	   most	   of	   miRNA-­‐mediated	   gene	   repression	   (Bortoluzzi	   et	   al.,	   2012).	  
Overall,	   these	   data	   point	   to	   a	   complex	   pattern	   of	   aberrant	   miRNA	   expression	   that	  
might	   contribute	   to	   the	   molecular	   complexity	   of	   MPNs	   through	   transcriptional	  
regulation,	   and	   provide	   a	   framework	   for	   hypothesizing	   a	   direct	   involvement	   of	  
aberrant	   miRNA	   regulation	   in	   MPNs,	   whose	   deciphering	   could	   be	   of	   help	   in	   better	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3	  	  AIM	  OF	  THE	  STUDY	  
The	   molecular	   basis	   of	   MPN	   has	   been	   appreciated	   recently	   with	   the	   description	   of	  
mutations	   in	   JAK2,	  MPL	   and	   CALR,	   but	   several	   aspects	   of	   their	   pathogenesis	   remain	  
elusive.	  In	  particular,	  the	  mechanisms	  and/or	  the	  molecules	  involved	  in	  the	  phenotypic	  
mimicry	   of	   these	   disorders,	   on	   the	   basis	   of	   an	   unique	  mutational	   event,	   are	   largely	  
unknown.	  To	  this	  end,	  I	  have	  been	  interested	  in	  studying	  microRNAs,	  a	  novel	  class	  of	  
short	  non-­‐protein	  coding	  RNAs	  that	  regulate	  gene	  expression	  through	  imperfect	  base	  
pairing	  with	  the	  3’UTR	  of	  target	  mRNAs,	  in	  patients	  with	  PMF.	  Infact,	  micro-­‐RNAs	  have	  
been	   shown	   to	   contribute	   significantly	   to	   oncogenesis	   in	   different	   cellular	   models,	  
including	  chronic	  and	  acute	  leukemias.	  	  
The	  main	  objectives	  of	  this	  study	  were:	  	  
(i) to	  describe	  abnormally	  expressed	  genes	  and	  microRNAs	  in	  CD34+	  cells,	  granulocytes	  
and	  plasma;	  
(ii) to	  discover	  novel	  miRNAs	  and	  moRNAs	  that	  are	  specifically	  associated	  with	  the	  PMF	  
and	  the	  other	  MPNs;	  	  
(iii)	   to	   address	   and	   functionally	   characterize	   the	   mechanistic	   correlates	   of	  
abnormalities	   of	   selected	   miRNA	   expression	   and/or	   sequence	   in	   the	   uncontrolled	  
proliferation	  of	  MPN	  hematopoietic	  cells;	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4	  MATERIAL	  AND	  METHODS	  
4.1	  	  	  SAMPLES	  COLLECTION	  	  AND	  PREPARATION.	  
4.1.1	  PATIENTS	  
Patients	   diagnosed	   with	   PMF	   according	   to	   World	   Health	   Organization	   (WHO)	   and	  
International	   Working	   Group	   for	   Myelofibrosis	   Research	   and	   Treatment	   (IWGMRT)	  
criteria,	   respectively,	   were	   recruited	   for	   this	   study	   from	   the	   database	   at	   Florence	  	  
hematology	  unit.	  Patients	  provided	  informed	  consent	  for	  the	  use	  of	  archival	  material	  
for	   mutational	   analysis,	   and	   the	   study	   was	   performed	   under	   a	   Florence	   University	  
Institutional	  Review	  Board–approved	  protocol	   in	  referring	   institutions.	  The	  study	  was	  
conducted	  in	  accordance	  with	  the	  Declaration	  of	  Helsinki.	  Samples	  had	  been	  collected	  
at	   diagnosis	   of	   PMF	   or	   no	   later	   than	   1	   year	   afterward	   provided	   the	   patient	   had	  
remained	  free	  of	  cytotoxic	  treatment.	  
4.1.2	  MONONUCLEAR	  AND	  GRANULOCYTE	  CELLS	  PREPARATION.	  
In	   order	   to	   carry	   out	   molecular	   testing,	   it	   was	   necessary	   starting	   from	   20	   ml	   of	  
peripheral	   blood	   (or	   5-­‐8	   ml	   of	   bone	   marrow	  
blood	  )	  to	  obtain	  	  samples	  of	  mononuclear	  cells	  
and	  granulocytes.	  
Briefly,	  whole	   blood	  were	   collected	   into	   EDTA-­‐
containing	   polypropylene	   tubes	   an	   processed	  
within	   4	   hours.	   Blood	   was	   diluted	   1:1	   with	  
Ca2+/Mg2+	   free	   phosphate-­‐buffered	   saline,	  
carefully	  layered	  over	  15	  ml	  of	  Ficoll-­‐Hypaque	  in	  
a	  50-­‐ml	  tube,	  and	  centrifuged	  at	  800	  x	  g	  at	  room	  	  
temperature	   for	  20	  minutes	   (Fig	   13).	   Initially	   it	  
was	   recovered	   the	   ring	   of	   mononuclear	   cells,	  
which	   were	   washed	   in	   sterile	   PBS	   at	   4°	   and	  
centrifuged	  at	  1000	  rpm	  for	  10	  minutes	  at	  8°	  C	  
for	   two	   times.	   The	   cells	   were	   counted	   using	   a	  
Burker	  chamber	  with	  a	  dilution	  factor	  of	  1	  :	  200.	  	  
After,	  the	  Ficoll	  layer	  were	  carefully	  removed	  and	  the	  lower	  fraction	  was	  collected	  and	  
transferred	  to	  a	  fresh	  tube.	  Lysis	  of	  red	  blood	  cells	  was	  performed	  by	  the	  addition	  of	  a	  
10X	  volume	  of	  1X	  BD	  PharmLyse	  solution	  (Becton	  Dickinson	  BD®),	  centrifugation	  of	  the	  
tube	   after	   a	   15-­‐minute	   incubation	   at	   room	   temperature,	   and	   removal	   of	   the	  
supernatant.	   This	   step	   was	   repeated	   twice.	   After	   two	   washes	   in	   Ca2+/Mg2+	   free	  
phosphate-­‐buffered	   saline,	   the	   dry	   granulocyte	   pellet	   was	   stored	   at	   −20°C	   until	  
processed.	  
Density	  gradient–separated	  mononuclear	  cells	  were	  processed	  through	  two	  sequential	  
steps	   of	   immunomagnetic	   CD34+	   selection	   (Miltenyi®);	   final	   purity	  was	   evaluated	   by	  
flow	   cytometry	   after	   labeling	   with	   PE-­‐HPCA2	   anti-­‐CD34	   monoclonal	   antibody	   (BD	  
Biosciences®),	  and	  found	  to	  be	  >	  97%	  in	  all	  instances.	  
Fig.	  13:	  Separation	  of	  human	  
blood	  cells	  by	  Ficoll-­‐Paque	  centrifugation. 
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4.1.3	  CD34+	  	  ISOLATION.	  
The	   purification	   of	   CD34+	   cells	   was	   performed	   starting	   from	  mononuclear	   obtained	  
from	  peripheral	  blood	  or	  bone	  marrow	  aspirates	  through	  immunomagnetic	  separation	  
according	  to	  the	  procedure	  Mltenyi®(Fig.	  14).	  For	  this	  procedure	  it	  took	  some	  reagents	  
such	  as:	  	  
•	  Buffer	  1	  (Wash	  buffer	  and	  dilution):	  Ca2+-­‐Mg2+	  free	  PBS,	  EDTA	  2mM;	  	  
•	  Buffer	  2	  (separation	  pad):	  Ca2+	  -­‐Mg2+	  free	  PBS,	  0.5%	  BSA,	  2	  mM	  EDTA;	  	  
•	  FcR	  blocking	  reagent	  Human	  IgG	  (Miltenyi®);	  	  
•	  MACS	  CD34	  microbeads	  (Miltenyi®):	  Microbeads	  super-­‐paramagnetic	  conjugated	  to	  
monoclonal	  murine	  anti-­‐human	  CD34+	  (isotype:	  mouse	  IgG1).	  	  
Once	   prepared	   the	   reagents,	   the	   pellet	   of	   mononuclear	   cells	   was	   subjected	   to	   two	  
washings	  with	  buffer	  1,	  centrifuged	  at	  1000	  rpm	  for	  10	  minutes	  and	  then	  resuspended	  
in	   buffer	   2	   to	   a	   final	   volume	   of	   300	   μl	   containing	   108	   mononuclear	   cells.	   To	   the	  
suspension	  in	  buffer	  2	  were	  then	  added	  100	  μl	  of	  FcR	  blocking	  reagent	  (Miltenyi®)	  and	  
100	   μl	   of	   CD34+	  microbeads	   (Miltenyi®)	   for	   each	   108	   total	   cells	   and	   the	   whole	   was	  
incubated	   for	  30	  minutes	  at	  4°C	  and	  periodically	  agitated	   .	  After	   incubation	  buffer	  2	  
was	   added	   up	   to	   a	   volume	   of	   10	   ml	   and	  
centrifuged	   at	   1000	   rpm	   for	   10	   minutes	   at	   8°C;	  
removed	  very	  carefully	  the	  supernatant,	  the	  pellet	  
was	   resuspended	   in	   a	   final	   volume	   of	   500	   μl	   of	  
buffer	   2	   per	   108	   total	   cells.	   After	   washing	   the	  
column	  MACS	  MS+	  (Miltenyi®)	  separation	   inserted	  
into	   the	  magnetic	   holder	  with	   500	  μl	   of	   buffer	   2,	  
the	   cells	   suspension	   was	   applied	   to	   the	   column	  
which	   was	   then	   allowed	   to	   drain	   by	   gravity	  
recovering	   the	   fraction	   CD34-­‐,	   subsequently	   they	  
have	   been	   performed	   3	   washes	   of	   each	   column	  
with	  500	  μl	  of	  buffer	  2	  and	   they	  were	  allowed	   to	  
flow	  still	  collecting	  them	  as	  a	  fraction	  CD34-­‐.	  It	  was	  
then	   added	   a	   further	   500	   μl	   of	   buffer	   2	   in	   the	  
column,	   which	   was	   quickly	   detached	   from	   the	  
magnetic	  media	   to	   recover	   the	   fraction	   of	   CD34+	  
cells	  by	  means	  of	  pressure	  with	  a	  piston-­‐column.	  In	  
some	  cases	  it	  was	  necessary	  to	  perform	  additional	  
steps	   of	   purification	   of	   the	   CD34+	   fraction	  
recovered	  in	  a	  new	  column	  up	  to	  a	  maximum	  of	  3	  
purifications	   (additional	   steps	  do	  not	   increase	   the	  
purity).	  
Purity	  of	  the	  isolated	  CD34+	  cell	  population	  was	  evaluated	  by	  flow	  cytometry	  after	  
labeling	  with	  PE-­‐HPCA2	  anti-­‐CD34+	  monoclonal	  antibody	  (BD	  Biosciences®)	  and	  was	  
always	  >95%.	  CD34+	  cells	  (3	  *105)	  were	  immediately	  lysed	  in	  Qiazol	  (Qiagen®)	  and	  
were	  stored	  at	  -­‐80°C.	  
Fig.14:	  Purification	  of	  CD34+	  cells	  
procedure.	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4.1.4	  RNA	  EXTRACTION.	  
RNA	  extraction	  was	  carried	  out	  from	  the	  pellet	  of	  granulocytes	  and	  CD34+	  resuspended	  
in	  Trizol	   (Invitrogen-­‐Life	  Technolgies,	   Inc.	  ®)	   (guanidine	  thiocyanate	  /	  phenol	  that	  can	  
lyse	   the	   cells	   and	   inhibit	   the	   RNase)	   following	   the	   directions	   of	   the	   company.	   Each	  
pellet	  resuspended	  in	  Trizol,	  was	  incubated	  at	  room	  temperature	  for	  2-­‐3	  minutes	  after	  
adding	  0.2	  ml	  of	  chloroform	  and	  centrifuged	  at	  12000	  rpm	  for	  15	  min	  at	  4°C.	  They	  have	  
been	  obtained	  so	  three	  phases:	  a	  upper	  aqueous	  phase,	  an	  interface	  and	  a	  whitish	  red	  
phase	  represented	  by	  Trizol.	  It	   is	  the	  upper	  aqueous	  phase	  was	  recovered	  and	  added	  
to	   2	   μl	   of	   glycogen	   and	   0.5	   ml	   of	   isopropanol	   to	   allow	   the	   precipitation	   of	   RNA.	  
Following	  what	  has	  been	  done	  incubation	  at	  room	  temperature	  for	  10	  min	  with	  stirring	  
for	   inversion	  and	  centrifugation	  at	  12000	   rpm	  for	  10	  min	  at	  4°C.	  At	   this	  point	   it	  was	  
obtained	  an	  RNA	  pellet	  which	  was	  washed	  with	  75%	  ethanol	  and	  finally	  centrifuged	  at	  
7500	  rpm	  for	  5	  min	  at	  4°C.	  The	  pellet	  was	  dried	  for	  5	  min	  and	  resuspended	  in	  20	  μl	  of	  
water	   DNAse-­‐free	   RNAse.	   Finally,	   it	   was	   gone	   to	   quantify	   and	   analyze	   RNA	   samples	  
obtained.	  
	  4.1.5	  QUANTIFICATION	  AND	  EVALUATION	  OF	  THE	  RNA	  QUALITY.	  	  
	  
RNA	  obtained	  was	  initially	  quantified	  by	  spectrophotometric	  absorption	  at	  260	  nm	  and	  
it	  was	  determined,	  in	  the	  first	  instance,	  the	  value	  of	  purity	  whereas	  the	  ratio	  between	  
the	  absorbance	  at	  260	  nm	  and	  that	  at	  280	  and	  230	  nM	  (Technology	  	  
Nanodrop®).	   In	  order	   to	  establish	   the	  quality	  and	   integrity	  of	  each	  sample	  of	  RNA,	   it	  
has	   been	   made	   an	   analysis	   with	   the	  
Agilent	   2100	   Bioanalyzer	   (Fig.15).	  
These	  technology	  consists	  of	  an	  actual	  
capillary	   electrophoresis.	   Each	   chip	  
used	   for	   this	   instrument	   contains	   a	  
series	   of	   tightly	   interconnected	  
microchannels:	   the	   nucleic	   acid	  
fragments	   are	   well	   separated	  
according	  to	  their	  molecular	  weight	  as	  
in	   a	   standard	   electrophoresis	   in	  
agarose	   gel.	   The	   microchannels	   of	  
each	  chip	  are	   filled	  with	  a	  matrix	  and	  
a	   fluorochrome	   for	  which,	   at	   the	  end	  
of	  the	  electrophoretic	  run,	  the	  samples	  are	  read	  on	  the	  basis	  of	  their	  fluorescence	  and	  
this	   information	   is	   translated	   into	   a	   typical	   image	   of	   gel	   electrophoresis	   and	   in	  
electropherograms.	  Specifically,	  to	  make	  the	  race	  has	  been	  used	  a	  chip	  of	  type	  "Nano"	  
(range	  50-­‐500	  ng	  of	   total	  RNA	  /uL)	  and	  at	   the	  end	  of	   it	  has	  been	  possible	   to	   	  obtain	  
from	  the	  instrument	  to	  a	  defined	  	  value	  RIN	  (RNA	  Integrity	  Number)	  that	  allows	  you	  to	  
assign	  a	  quality	   index	   total	  RNA	  examined.	  This	  parameter	  has	  a	   scale	  of	  10,	  RNA	  of	  
excellent	   quality,	   in	   which	   0	   indicates	   completely	   degraded	   RNA.	   The	   RNA	   samples	  
used	  showed	  a	  RIN	  greater	  than	  8.	  
Fig.15:	  A	  typical	  electropherogram	  of	  RNA	  sample	  
obtained	  by	  Agilent	  	  2100	  bioanalyzer.	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4.2	  ANALISYS	  OF	  GENES	  AND	  MIRNAS	  EXPRESSION	  PROFILE	  OF	  
CD34+	  	  CELLS	  FROM	  PMF	  PATIENTS	  AND	  CONTROLS.	  	  
4.2.1	  MICROARRAY	  DATA	  ANALYSIS	  
To	   obtain	   gene-­‐	   and	   miRNA-­‐	   expression	   profiles	   (GEP	   and	   miEP,	   respectively)	  
CD34+cells	  were	  performed	  on	  the	  same	  RNA	  isolated	  from	  CD34+	  cells	  of	  42	  PMF	  and	  
24	  ET	  patients	  and	  31	  healthy	  donors	  (n=15	  BM,	  n=16	  PB).	  
With	   regard	   to	   GEP,	   cDNA	   synthesis,	   as	   well	   as	   biotin-­‐labeled	   target	   synthesis,	   was	  
performed	   using	   the	   GeneAtlas	   3´	   IVT	   Express	   Kit	   (Affymetrix®)	   according	   to	   the	  
standard	   protocol	   supplied	   by	   Affymetrix.	   The	   HG-­‐U219	   Array	   Strip	   hybridization,	  
staining,	  and	  scanning	  were	  performed	  by	  using	   the	  GeneAtlas	  Platform.	  To	  perform	  
miEP,	  total	  RNA	  (100	  ng)	  was	  labeled	  using	  the	  FlashTag®	  Biotin	  HSR	  kit	  (Affymetrix®)	  
and	   hybridized	   to	   the	   Affymetrix	   Genechip	   miRNA	   array	   2.0	   according	   to	   the	  
manufacturer's	   recommendations.	   miRNA	   arrays	   were	   processed	   using	   the	  
Affymetrix®	  GeneChip	  instrument	  platform.	  The	  probe	  level	  data	  were	  normalized	  and	  
converted	   into	   expression	   values	   using	   the	   robust	   multiarray	   average	   (RMA)	  
procedure.	   Quality	   control	   assessment	   was	   performed	   using	   different	   Bioconductor	  
packages	   such	   as	   R-­‐AffyQC	   Report,	   R-­‐Affy-­‐PLM,	   R-­‐RNA	   degradation	   Plot,	   and	   QC	  
procedures	  included	  in	  the	  Partek	  GS.	  6.6	  Software	  Package	  (http://www.partek.com).	  
Before	  analysis,	  a	  variance	  filter	  was	  applied	  to	  remove	  flat	  genes	  with	  low	  variation	  in	  
expression	  over	   the	  samples.	  An	  exploratory	  principal	  component	  analysis	   (PCA)	  was	  
performed	  using	  the	  PCA	  module	  implemented	  in	  Partek	  GS™.	  Differentially	  expressed	  
genes	  (DEGs)	  and	  DEMs	  were	  then	  selected	  following	  a	  supervised	  approach	  with	  the	  
analysis	  of	  variance	  (ANOVA)	  module	  included	  in	  the	  Partek	  GS	  package.	  In	  particular,	  
it	  was	  selected	  all	  the	  probe	  sets	  with	  a	  fold	  change	  contrast	  ≥2	  for	  DEGs	  or	  ≥1.5	  for	  
DEMs	  in	  the	  pairwise	  comparison	  of	  PMF	  vs	  controls	  and	  a	  false	  discovery	  rate	  (q	  value	  
<	  0.05).	  
4.2.2	  VALIDATION	  GENE	  EXPRESSION	  MICROARRAY	  DATA	  	  
To	  validate	  the	  Gene	  expression	  array	  data,	  at	  first	  it	  was	  performed	  a	  QRT-­‐PCR	  	  in	  an	  
independent	  cohort	  of	  CD34+	  cells	  from	  10	  PMF	  patients	  and	  8	  healthy	  subjects	  (n=4	  
BM,	  n=4	  PB)	  and,	  after,	  also	  in	  an	  granulocytes	  of	  PMF	  patients	  (n=32)	  compared	  with	  
healthy	  controls	  (n=	  12).	  
-­‐	  Reverse	  transcription	  PCR	  	  
cDNA	  was	  synthesized	  from	  total	  RNA	  using	  TaqMan®	  High	  capacity	  cDNA	  reverse	  
transcription	  kit	  	  (Applied	  Biosystems®).	  
The	  composition	  of	  	  reagents	  	  mix	  for	  these	  reverse	  transcription	  PCR	  and	  a	  kinetic	  of	  
reaction	  are	  reported	  below	  (See	  Tab.	  8	  and	  Tab.9).	  
	  
	  












	  	  	  	  	  	  






Tab.	  9	  :	  Reaction	  kinetics.	  
	  
-­‐	  Taqman	  Real	  time	  PCR	  	  
To	  validate	  the	  array	  data	   in	  CD34+	  cells	   it	  was	  designed	  a	  TaqMan	  low-­‐density	  array	  
containing	  63	  +	  GAPDH	  TaqMan	  gene	  expression	  assays.	   The	   selection	  of	   genes	  was	  
based	  on	  either	  the	  highest	  absolute	  fold-­‐change	  contrast	  and/or	  their	  putative	  role	  in	  
PMF	   pathogenesis.	   TaqMan	   PCR	   was	   carried	   out	   in	   duplicate	   using	   either	   Custom	  
TaqMan	   Array	   384-­‐well	   Cards	   by	   using	   an	   AB	   7900HT	   Fast	   Real-­‐Time	   PCR	   System	  
(Applied	  Biosystems®).	  	  
The	   composition	  of	   the	  mix	  of	   the	   reagents	  which	  has	  been	  used	   for	   the	  process	  of	  	  









	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  






of	  reaction	  	  
Volume	  (µL)	  	  	  
for	  one	  sample	  
10X	  RT	  Buffer	  	   2	  
25X	  dNTP	  Mix	  (100	  mM)	   0,8	  
5X	  RT	  Random	  Primer	   2	  




RNA	  (~350ng)	  +	  H2O	   13,2	  
TOT	   20	  
	   STEP	  1	   STEP	  2	   STEP	  3	   STEP	  4	  
Temperature	   25°C	   37°C	   85°C	   4°C	  
	  	  	  	  	  	  Duration	  	   10	  min	   120	  min	   5	  min	   ∞	  
Components	  	  
of	  reaction	  	  
Volume	  (µL)	  	  	  
Per	  Fill	  reservoir	  	  
Taqman	  Universal	  PCR	  
Master	  Mix	  2x	  
50	  
cDNA	  sample	  and	  RNAse	  free	  
water	  
50	  
TOT	   100	  
	   48	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Tab.	  11:	  kinetic	  of	  Taqman	  real	  time	  PCR	  reaction.	  
	  
	  
	  	  	  	  	  	  	  	  	  	  	  -­‐	  Gene	  expression	  in	  granulocytes	  samples	  
After,	  among	  the	  validates	  genes	  in	  previously	  in	  CD34+	  cells,	  	  it	  was	  	  selected	  a	  set	  of	  7	  





GENE	   PROTEIN	  	  	  	  NAME	   Taqman	  Assay	  ID	  
OLFM4	   Olfactomedina	  4	   Hs00197437_m1	  
LCN2	   Lipocalin	  2	   Hs01008571_m1	  
LEPR	   Leptin	  receptor	   Hs00174497_m1	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  FGR	   Gardner-­‐Rasheed	  feline	  sarcoma	  
viral	  (v-­‐fgr)	  oncogene	  homolog	  
	  	  	  	  	  	  	  Hs00178340_m1	  
ANXA3	   Annexin	  A3	   Hs00974395_m1	  
CEACAM8	   Carcinoembryonic	  antigen-­‐related	  
cell	  adhesion	  molecule	  8	  
Hs00266198_m1	  
DEFA1	   Defensin,	  alpha	  1	   Hs00234383_m1	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Tab.	  12:	  List	  of	  selected	  genes	  validated	  in	  PMF	  granulocytes.	  
	  
In	   these	   case,	   each	   generated	   cDNA	   of	   granulocyte	   cells	   was	   amplified	   by	   QRT-­‐PCR	  
with	  sequence-­‐specific	  primers	  from	  the	  TaqMan	  gene	  expression	  assays	  by	  means	  of	  
StepOne	  real-­‐time	  PCR	  system	  (Applied	  Biosystems®).	  
The	   composition	  of	   the	  mix	  of	   the	   reagents	  which	  has	  been	  used	   for	   the	  process	  of	  	  



















	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Tab.	  13:	  	  Composition	  of	  	  Taqman®	  Real	  time	  PCR	  mix.	  
	  
The	  kinetics	  of	  this	  reaction	  is	  the	  same	  as	  that	  described	  previously.	  Gene	  expression	  
relative	  quantification	   (RQ)	  was	   achieved	  using	   the	   comparative	   cycle	   threshold	   (CT)	  
method	   using	   glyceraldehyde-­‐3-­‐phosphate	   dehydrogenase	   (GAPDH)	   as	   the	  
housekeeping	  gene.	  To	  normalize	  the	  data,	  ΔΔCT	  was	  calculated	  for	  each	  sample	  using	  
the	  mean	  of	  its	  ΔCT	  values	  subtracted	  from	  the	  mean	  ΔCT	  value	  measured	  in	  the	  entire	  
population	  of	  healthy	  subjects,	  considered	  as	  a	  calibrator;	  the	  RQ	  value	  was	  expressed	  
as	   2−ΔΔCT.	   To	  make	   the	   RQ	   value	   symmetric	   for	   up-­‐	   and	   down-­‐regulated	   genes,	   fold	  
change	  (FC)	  was	  used	  in	  the	  Tables	  for	  ease	  of	  interpretation	  (for	  RQ	  >	  1,	  FC	  =	  RQ;	  for	  
RQ	  <	  1	  FC	  =	  −1/RQ).	  
4.2.3	  VALIDATION	  MIRNAS	  EXPRESSION	  MICROARRAY	  DATA.	  
To	  validate	  the	  miRna	  expression	  array	  data,	  it	  was	  used	  TaqMan®	  single	  miRNA	  assays	  
to	  assess	  the	  expression	  of	  46	  DEMs	  ,	  which	  were	  selected	  based	  on	  either	  their	  
relatively	  high	  differential	  expression	  or	  their	  biological	  role	  in	  cancer-­‐related	  
processes	  or	  myeloid	  differentiation.	  TaqMan®	  assays	  were	  carried	  out	  in	  an	  
independent	  cohort	  of	  CD34	  +	  cells	  from	  10	  PMF	  patients	  and	  8	  healthy	  subjects	  (n=4	  
BM,	  n=	  4	  PB).	  
For	  miRNA	  cDNA	  synthesis,	  800	  ng	  of	  total	  RNA	  	  was	  reverse-­‐transcribed	  using	  the	  
Taqman®	  microRNA	  Reverse	  Transcription	  Kit	  and	  the	  miRNA-­‐specific	  looped-­‐primers	  
included	  in	  Megaplex	  Primer	  Pool	  A	  (Life	  Technologies®),	  except	  for	  five	  miRNAs	  (i.e.,	  
miR-­‐1246,	   miR-­‐378a-­‐3p,	   miR-­‐543,	   miR-­‐766-­‐3p,	   miR-­‐409-­‐3p)	   out	   of	   the	   above-­‐
mentioned	  pool,	  which	  were	  carried	  on	  as	  individual	  retro-­‐transcriptions.	  
The	   composition	   of	   retrotrascription	   reaction	   mix	   is	   reported	   in	   Tab.14	   and	   the	  








of	  reaction	  	  
Volume	  (µL)	  	  	  
for	  one	  sample	  
2X	  Taqman	  Gene	  Expression	  
Master	  Mix	  
10	  
20X	  Gene	  expression	  assay	   1	  
20x	  RNAse	  P	  assay	   1	  
cDna	  	   2	  
H2O	   6	  
TOT	   20	  














	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Tab.	  14:	  Megaplex	  RT	  Reaction	  Mix	  Components.	  
	  








Tab.	  15:	  	  Megaplex	  RT	  Reaction	  Thermal-­‐cycling	  conditions.	  
	  
	  
qRT-­‐PCR	  was	  performed	  using	  TaqMan	  ®MicroRNA	  array	  (Life	  Technologies®)	  and	  the	  










Tab.	  16:	  TaqMan®	  MicroRNA	  Array	  reaction	  mix.	  
	  
The	  thermal	  cycling	  condition	  for	  Taqman®	  microRNA	  real	  time	  PCR	  	  are	  the	  same	  as	  








RT	  Reaction	  Mix	  
Components	   0.8	  
dNTPs	  with	  dTTP	  (100	  mM)	   0.2	  
MultiScribe™	  Reverse	  
Transcriptase	  (50	  U/μL)	   1.5	  
10✕	  RT	  Buffer	   0.8	  
MgCl2	  (25	  mM)	   0.9	  
RNase	  Inhibitor	  (20	  U/μL)	   0.1	  
Nuclease-­‐free	  water	   0.2	  
RNA	  (~800	  ng)	  +	  H2O	   3	  
Total	   7.5	  
	  
40	  CYCLES	  
STEP	  3	   STEP	  4	  
STEP	  1	   STEP	  2	  
	  	  	  	  	  	  STEP	  
3	  
Temperature	   16°C	   42°C	   50°C	   85°C	   4°C	  
	  	  	  	  	  	  Time	  	   2	  min	   1	  min	   1	  sec	   5	  min	   ∞	  
Components	  	  
of	  reaction	  	  
Volume	  (µL)	  	  	  
Per	  Fill	  reservoir	  	  
Taqman	  Universal	  PCR	  
Master	  Mix	  2x	  
50	  
Megaplex™	  RT	  product	  and	  
RNAse	  free	  water	  
50	  
TOT	   100	  
	   51	  
	  -­‐	  miRna	  expression	  in	  granulocytes	  samples	  
Among	  the	  validated	  miRNAs	  in	  PMF	  CD34+	  cells,	  it	  was	  selected	  the	  24	  (Tab	  19)	  most	  
upregulated	   ones	   to	   test	   their	   expression	   in	   the	   granulocytes	   from	   the	   same	   PMF	  
patients	   (n=30)	   and	   healthy	   donors	   (n	   =8)	   previously	   used	   for	   mRNA	   expression	  
validation.	  	  
Even	   this	   time,	   cDNA	   was	   synthesized	   from	   total	   RNA	   using	   TaqMan®	   MicroRNA	  
Reverse	   Transcription	   Kit	   (Applied	   Biosystems®)	   but	   the	   composition	   of	   the	  
reagents	   mix	   and	   a	   kinetics	   of	   reaction	   are	   different	   than	   the	   previous	   reverse	  













	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  








	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Tab.18:	  	  Reaction	  Kinetics.	  
	  
	  
Each	  generated	  cDNA	  was	  amplified	  by	  QRT-­‐PCR	  with	  sequence-­‐specific	  primers	  from	  
the	  TaqMan®microRNA	  Assays	  on	  	  Step	  one	  plus	  PCR	  system	  (Applied	  Biosystems®).	  
The	   composition	  of	   the	  mix	  of	   the	   reagents	  which	  has	  been	  used	   for	   the	  process	  of	  	  




of	  reaction	  	  
Volume	  (µL)	  	  	  
for	  one	  sample	  
10X	  RT	  Buffer	  	   1.5	  
25X	  dNTP	  Mix	  (100	  mM)	   0.15	  
5X	  RT	  miRna	  Primer	   3	  




RNA	  (~10ng)	  +	  H2O	   9.16	  
TOT	   15	  
	   STEP	  1	   STEP	  2	   STEP	  3	   STEP	  4	  
Temperature	   16°C	   42°C	   85°C	   4°C	  
	  	  	  	  	  	  Duration	  	   30	  min	   120	  min	   5	  min	   ∞	  
	   52	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  












	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Tab.	  20:	  Composition	  of	  a	  QRT-­‐PCR	  mix.	  
Components	  	  
of	  reaction	  	  
Volume	  (µL)	  	  	  
for	  one	  sample	  
2X	  Taqman	  Universal	  Master	  
mix,	  No	  AmpErase	  UNG	  
8	  
20X	  miRNA	  assay	   0,8	  
cDNA	   2	  
H2O	   5,2	  
TOT	   16	  
	   53	  
	  
	  
	  	  	  	  	  Tab.	  21:	  Reaction	  kinetics.	  
	  
Relative	   quantities	   were	   calculated	   by	   using	   the	   control	   group.	   Quantification	   of	  
relative	  miRNA	  expression	  on	  the	  validation	  set	  was	  performed	  with	  the	  comparative	  
CT	  method	  using	  the	  formula	  2-­‐DDCT,	  where	  DDCT	  =	  [(CT	  miRna	  of	  interest-­‐CT	  reference	  
snRNA)	   PMF	   sample	   –	   mean	   of	   (CT	   miRna	   of	   interest-­‐CT	   reference	   snRna)	   control	  
goup]	  by	  using	  snRNAU6	  as	  the	  reference	  miRNA	  .	  
4.2.4	  ENZYME-­‐LINKED	  IMMUNOSORBENT	  ASSAY	  (ELISA).	  
Serum	   levels	   of	   LCN2	   (NGAL)	   and	   OLFM4	   secreted	   proteins	   in	   PMF	   patients	   and	  
healthy	  donors	  were	  evaluated	  by	  ELISA	  using	  two	  commercial	  kits	  (NGAL	  rapid	  ELISA	  
kit;	  BioPorto	  Diagnostics®;	  Gentofte,	  and	  OLFM4	  ELISA	  kit;	  Antibodies-­‐online	  GmbH®),	  
according	   to	   the	   manufacturer’s	   instructions.	   The	   results	   are	   expressed	   as	   mean	  
concentration	  (ng/mL)	  with	  each	  sample	  assayed	  in	  triplicate.	  
4.2.5	  CD34+	  CELL-­‐CULTURE	  CONDITIONS	  AND	  ELECTROPORATION.	  	  
After	   immunomagnetic	   separation,	   CD34+	   cells	   were	   seeded	   in	   24-­‐well	   plates	   at	  
5*105/mL	   in	   Iscove’s-­‐modified	  Dulbecco	  medium	   (IMDM;	   Euroclone)	   containing	   20%	  
human	   serum	   (Bio-­‐Whittaker),	   stem	   cell	   factor	   (SCF;	   50	   ng/mL),	   Fms-­‐like	   tyrosine	  
kinase	  3	  ligand	  (Flt3L;	  50	  ng/mL),	  thrombopoietin	  (TPO;	  20	  ng/mL),	  interleukin-­‐6	  (IL-­‐6;	  
10	  ng/mL),	  and	  interleukin-­‐3	  (IL-­‐3;	  10	  ng/mL;	  all	  from	  Miltenyi).	  	  
The	   electroporation	   program	   of	   CD34+	   cells	   was	   based	   on	   a	   previously	   published	  
protocol	   (Salati	   et	   al.,	   2008)	   which	   was	   optimized	   to	   be	   performed	   on	   the	   4D-­‐
Nucleofector	  System	   (Lonza®).	  Briefly,	  each	   sample	  was	  electroporated	  3	   times	  once	  
every	  24	  hours	  with	  a	  mix	  of	  3	  Silencer	  Select	  small	  interfering	  RNAs	  (siRNAs)	  targeting	  
human	  JARID2	  (see	  Tab.22)	  (Life	  Technologies®),	  starting	  from	  the	  day	  after	  CD34+	  cell	  
purification.	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  Tab.	  22:	  Silencer	  select	  small	  interfering	  RNAs	  (siRNAs)	  targeting	  human	  JARID2.	  
	  
For	  each	  electroporation,	  4*105	  CD34+	  cells	  were	  resuspended	  in	  100	  mL	  of	  P3	  Primary	  
Cell	   Solution	   (Lonza®),	   containing	   3	  mg	   of	   siRNA	  mix,	   and	   pulsed	  with	   the	   program	  
DS112.	  To	  exclude	  nonspecific	  effects	  caused	  by	  interfering	  RNA	  (RNAi)	  nucleofection,	  
a	   sample	   transfected	   with	   a	   nontargeting	   siRNA	   negative	   control	   (NegCTR;	   Silencer	  
Select	  Negative	  Control	  #2	  siRNA;	  Life	  Technologies®)	  was	   included.	  As	  described	   for	  
siRNA	   transfections,	   the	   number	   of	   nucleofections	   and	   the	   quantities	   of	   miRNA	  
mimics/inhibitors	  were	  modified	  from	  a	  previously	  described	  protocol	  (Tenedini	  et	  al.,	  
2010)	  to	  best	  fit	  the	  properties	  of	  the	  second-­‐generation	  of	  miRNA	  mimics/inhibitors	  
(Life	  Technologies®).	  Briefly,	  CD34+	  cells	  were	  nucleofected	  twice,	  once	  every	  24	  hours,	  
with	  3	  mg	  of	  mirVana	  miR-­‐155-­‐5p	  mimic	  or	  mirVana	  miRNA	  mimic	  Negative	  Control	  #1	  
(Neg-­‐mimic),	  by	  using	  the	  previously	  mentioned	  electroporation	  protocol	  DS112.	  PMF	  
and	   CB	   CD34+	   cells	   were	   nucleofected	   4	   times,	   once	   every	   24	   hours,	   with	   3	   mg	   of	  
mirVana	   miR-­‐155-­‐5p	   inhibitor	   or	   mirVana	   miRNA	   inhibitor	   Negative	   Control	   #1	  
(NegINH),	  by	  using	  the	  electroporation	  protocol	  DS112.	  Cells	  were	  analyzed	  24	  and	  48	  
hours	   after	   the	   last	   nucleofection	   for	   both	   cell	   viability	   and	   JARID2	   or	   miR-­‐155-­‐5p	  
expression.	  
After	  each	  transfection,	  CD34+	  cells	  were	  transferred	  into	  pre-­‐warmed	  fresh	  medium	  in	  
24-­‐well	   plates	   (Euroclone®)	   and	   maintained	   in	   the	   same	   culture	   conditions	   as	  
described	   above.	   For	   liquid	   culture	   differentiation	   assays,	   CD34+	   cells	   were	   plated	  
(5*105/mL)	   in	   IMDM	   with	   the	   addition	   of	   20%	   BIT	   9500	   serum	   substitute	   (bovine	  
serum	   albumin,	   insulin,	   and	   transferrin;	   StemCell	   Technologies)	   24	   h	   after	   the	   last	  
nucleofection,	   in	  order	   to	  set	  up	  a	  multilineage	  cell	   culture	   (SCF,	  50	  ng/mL;	  Flt3L,	  50	  
ng/mL;	  TPO,	  20	  ng/mL;	   IL-­‐3,	  10	  ng/mL;	   IL-­‐6,	  10	  ng/mL;	  all	   cytokines	   from	  Miltenyi	  ®)	  
and	   megakaryocyte	   (MK)	   unilineage	   culture(TPO,	   100	   ng/mL)	   (Guglielmelli	   et	   al.,	  
2009).	  
4.2.6	  METHYLCELLULOSE	  AND	  COLLAGEN	  CLONOGENIC	  ASSAYS.	  
The	  methylcellulose	  assay	  was	  carried	  out	  by	  plating	  CD34+	  cells	   in	  MethoCultTM	  GF	  
H4434	   (StemCell	   Technologies	   Inc.®),	   as	   previously	   described	   (Zini	   et	   al.,2012).	   MK	  
colony	   forming	   units	   (CFU-­‐MK)	   were	   assayed	   in	   collagen-­‐based	   medium,	   using	   a	  
commercial	   MK	   assay	   detection	   kit	   (MegaCult-­‐C;	   StemCell	   Technologies	   Inc.®)	   as	  
previously	  reported	  (Zini	  et	  al.,	  2012).	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4.2.7	  MORPHOLOGICAL	  AND	  IMMUNOPHENOTYPIC	  ANALYSIS.	  	  
Differentiation	   of	   CD34+	   cells	   was	   monitored	   by	   morphological	   analysis	   of	   May–
Grunwald–Giemsa-­‐stained	   cytospins	   and	   by	   flow	   cytometric	   analysis	   of	   CD34,	   CD14,	  
CD66b,	   CD163,	  Glycophorin	   A	   (GPA),	   and	   CD41	   surface	   antigen	   expression	   at	   day	   0,	  
3,5,	  8,	  10,	  and	  12	  after	  the	  last	  nucleofection.	  Images	  were	  captured	  by	  using	  an	  Ax10	  
Scope.A1	   microscope	   equipped	   with	   an	   AxioCam	   ERc	   5S	   Digital	   Camera	   and	   Axion	  
software	  4.8	  (all	  Carl	  Zeiss	  MicroImaging	  Inc.®).	  The	  images	  were	  then	  processed	  with	  
Adobe	   Photoshop	   7.0	   software.	   The	   following	  monoclonal	   antibodies	   (MoAbs)	  were	  
used	   for	   flow	   cytometric	   analysis:	   phycoerythrin	   (PE)-­‐conjugated	  mouse	   anti-­‐human	  
CD14	   MoAb,	   fluorescein	   isothiocyanate	   (FITC)-­‐conjugated	   mouse	   anti-­‐human	   CD34	  
MoAb,	   FITC-­‐conjugated	  mouse	   anti-­‐human	   CD66b	  MoAb	   (all	   from	  Miltenyi	   Biotech;	  
Auburn,	  CA,	  USA),	  FITC-­‐conjugated	  mouse	  antihuman	  CD41	  MoAb,	  and	  PE-­‐conjugated	  
mouse	  anti-­‐human	  GPA	  MoAb	  (all	  from	  Dako®).	  After	  staining,	  cells	  were	  analyzed	  by	  
using	  a	  BD	  FACSCan	  to	  II	  (BD	  Biosciences	  ®).	  At	   least	  10,000	  events	  were	  counted	  for	  
each	  sample	  to	  ensure	  statistical	  relevance.	  
4.2.8	  LUCIFERASE	  REPORTER	  ASSAYS.	  
Full-­‐length	   and	   empty	   3´untranslated	   region	   (3´UTR)	   luciferase	   reporter	   constructs	  
were	  all	  purchased	  from	  Labomics®).	  	  Every	  plasmid	  contains	  the	  firefly	  luciferase	  gene	  
upstream	  of	  a	  given	  3´UTR,	  and	  the	  Renilla	  luciferase	  gene	  acting	  as	  a	  normalizer	  gene.	  
Mutant	  3'UTR	  luciferase	  assays	  were	  obtained	  from	  the	  above-­‐mentioned	  plasmids	  by	  
changing	   nucleotides	   3-­‐5	   in	   the	   miRNA	   seed	   binding	   site	   regions	   (all	   from	  
Genecopoeia®).	   K562	   cells	   were	   electroporated	   by	   means	   of	   the	   Amaxa	   4D-­‐
Nucleofector™	  System,	  according	  to	  the	  manufacturer's	  instructions.	  Briefly,	  K562	  cells	  
were	  subcultured	  at	  a	  density	  of	  3*105	  cells/mL	  2	  days	  before	  nucleofection.	  Cells	  were	  
then	  transiently	  co-­‐nucleofected	  with	  either	  a	  miRNA	  mimic	  or	  miRNA	  mimic	  negative	  
control	  (NEG-­‐mimic)	  at	  a	  concentration	  of	  3.6	  μM	  and	  with	  either	  3´UTR-­‐less	  luciferase	  
or	   a	   full-­‐length	   3´UTR	   construct	   at	   a	   concentration	   of	   200	   ng/sample.	   For	   each	  
electroporation,	  106	  cells	  were	  resuspended	  in	  100	  μL	  of	  SF	  Cell	  line	  Solution	  (Lonza®)	  
and	   pulsed	   with	   the	   program	   FF120.	   Firefly	   and	   Renilla	   luciferase	   activities	   were	  
measured	  48	  h	  after	  electroporation	  using	  the	  Dual-­‐Luciferase	  Reporter	  Assay	  System	  
(Promega),	   and	   luminescence	   was	   recorded	   on	   a	   GloMax®-­‐Multi+	   Detection	   System	  
with	  Intinct™	  Software	  (Promega®),	  according	  to	  the	  manufacturer’s	  protocol.	  In	  order	  
to	   analyze	   the	   data,	   three	   levels	   of	   normalization	   were	   performed:	   first,	   firefly	  
luciferase	  activity	  was	  normalized	   to	   that	  of	  Renilla	   luciferase	  as	   the	   internal	   control	  
for	   nucleofection	   efficiency;	   second,	   the	   data	   were	   normalized	   to	   the	   effect	   of	   the	  
miRNA	  mimic	  on	  the	  3ʹ′UTR-­‐less	  control	  reporter;	  lastly,	  the	  luminescence	  signals	  were	  
normalized	   to	   the	   effect	   of	   the	   Neg-­‐mimic	   on	   the	   corresponding	   3´UTR	   full-­‐length	  
construct.	  
4.2.9	  RETROVIRAL	  VECTORS	  PACKAGING.	  
The	  human	   JARID2	   cDNA	   (NM_004973.3)	  was	   synthesized	   and	   cloned	   into	   retroviral	  
vector	  LXIΔN	  6	  by	  GeneArt	  service	  (Life	  Technologies®).	  Packaging	  line	  for	  LJARID2IΔN	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was	   generated	   by	   transinfection	   in	   the	   ecotropic	   Phoenix	   and	   amphotropic	  
GP+envAm12	   cells,	   as	   previously	   described	   (Grande	   et	   al.,1999.	   Viral	   titers	   were	  
assessed	  by	  flow	  cytometry	  analysis	  of	  a	  truncated	  version	  of	  low-­‐affinity	  nerve	  growth	  
factor	   receptor	   (ΔLNGFR)	   expression	   percentage	   upon	   infection	   of	   KG1	   cells	   or	   CB	  
CD34+	  cells.	  
4.2.10	  HEMATOPOIETIC	  CELL	  TRANSDUCTION	  AND	  PURIFICATION.	  
After	  24	  h	  of	  culture,	   cells	  were	  electroporated	  as	  previously	  described	   in	  paragraph	  
4.2.5.	   Each	   sample	  was	   electroporated	   twice,	   once	   every	   24	   h,	  with	  mirVana™	  miR-­‐
155-­‐5p	   mimic	   or	   mirVana™	   miRNA	   mimic	   Negative	   Control	   #1	   (Neg-­‐mimic)	   (Life	  
Technologies®).	   Transduction	   of	   CB	   CD34+	   cells	   was	   performed	   after	   12	   h	   from	   the	  
second	  nucleofection	  in	  24-­‐wells	  plates	  at	  a	  density	  of	  5x105/ml	  in	  IMDM	  (Euroclone®)	  
containing	  20%	  HS	  (Bio-­‐Whittaker),	  SCF	  (50	  ng/ml),	  Flt3-­‐ligand	  (Flt3-­‐l)	  (50	  ng/ml),	  TPO	  
(20	  ng/ml),	  IL-­‐6	  (10	  ng/ml)	  and	  IL-­‐3	  (10	  ng/ml)	  (Miltenyi®)	  (Salati	  et	  al.,	  2008).	  
Retroviral	  transduction	  was	  performed	  by	  four	  cycles	  of	  infection	  (12	  h	  each	  one)	  with	  
viral	   supernatant	   with	   the	   addition	   of	   polybrene	   (8	   μg/ml),	   20%	   HS	   and	   human	  
cytokines	   (SCF,	   Flt3-­‐l,	   TPO,	   IL-­‐6	   and	   IL-­‐3	   as	   already	   described	   in	   CD34+	   cell-­‐culture	  
conditions)	   in	   retronectin-­‐coated	  plates.	  Untreated	  24-­‐wells	  plates	  were	  coated	  with	  
retronectin	   (106	   μg/cm2)	   (Takara	   Bio	   Inc®)	   following	   the	   protocol	   supplied	   by	   the	  
manufacturer.	   To	   achieve	   an	   optimal	   expansion	   and	   infection	   of	   the	   primary	   CD34+	  
cells,	  the	  retronectin	  coated	  plates	  were	  pre-­‐incubated	  with	  retroviral	  supernatant	  for	  
4	  h,	  then	  CD34+	  cells	  were	  seeded	  in	  24-­‐wells	  plate	  at	  a	  density	  of	  3*105/ml	  (1ml/well)	  
in	   fresh	  viral	   supernatant.	  After	   transduction,	  CB	  CD34+	  cells	  were	  maintained	   in	   the	  
already	   described	   liquid	   culture	   conditions	   for	   36	   h.	   Transduced	   CD34+	   cells	   were	  
subsequently	   purified	   by	   an	   immunomagnetic	   procedure	   (EasySep	   “Do-­‐It-­‐Yourself”	  
Selection	  Kit®)	  by	  means	  of	  an	  antihuman	  p75-­‐NGFR	  mouse	  monoclonal	  antibody	  (BD	  
Biosciences®)	  and	  seeded	  in	  the	  liquid	  culture	  conditions	  as	  reported	  above.	  Cells	  were	  
analyzed	  after	  the	  purification	  of	  NGFR+cells	  for	  JARID2	  expression	  by	  QRT-­‐PCR.	  Purity	  
of	  the	  isolated	  NGFR+	  cells	  was	  evaluated	  by	  flow	  cytometry	  after	  labeling	  with	  PE	  anti-­‐
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4.3	  CHARACTERIZATION	  THE	  NEW	  MIRNA	  AND	  MORNA	  
EXPRESSION	  IN	  CD34+	  	  USING	  MASSIVE	  SMALL	  RNA-­‐SEQ.	  
	  
4.3.1	  SMALL	  RNA-­‐SEQ	  LIBRARY	  CONSTRUCTION	  AND	  SEQUENCING.	  
For	  each	  sample,	  a	  small	  RNA	  library	  was	  prepared	  starting	  from	  1	  μg	  total	  RNA,	  using	  
the	  TruSeq	  Small	  RNA	  Sample	  Preparation	  Kits	  and	  protocols	  (Illumina®,	  San	  Diego,	  CA,	  
USA,	  http://www.illumina.com).	  Library	  quality	  was	  checked	  using	  High	  Sensitivity	  DNA	  
chip	   (Agilent	   Technologies®).	   The	   purified	   cDNA	   libraries	   was	   used	   for	   cluster	  
generation	   on	   Illumina's	   Cluster	   Station	   and	   sequenced	   on	   an	   Illumina	   HiSeq2000	  
instrument,	  producing	  single	  reads	  from	  49	  to	  57	  bp.	  
4.3.2	  SMALL	  RNA	  DATA	  ANALYSIS.	  
The	  data	  analysis	  of	  small	  RNA	  seq	  was	  conducted	  in	  collaboration	  with	  the	  group	  of	  
University	  of	  Padua	  directed	  by	  Prof.	  Bortoluzzi.	  
It	   was	   performed	   a	   differential	   expression	   analysis	   using	   DESeq	   R/Bioconductor	  
package.	   It	  was	   	  considered	  those	  short	  RNAs	  that	  had	  a	  total	  expression	  throughout	  
all	   samples	   higher	   than	   the	   median.	   It	   was	   performed	   a	   multiple	   test	   correction	  
according	  to	  the	  Benjamini	  Hochberg	  method	  (FDR).	   It	  was	  considered	  a	  corrected	  p-­‐
value	  of	  0.05	  as	  threshold	  to	  identify	  differentially	  expressed	  elements.	  
4.3.3	  	  VALIDATION	  OF	  SRNAS	  CONSIDERED	  DIFFERENTIALLY	  EXPRESSED	  	  
BY	  RNAseq.	  
It	   was	   performed	   individual	   miRNAs	   assay	   by	   Taqman®	   quantitative	   real-­‐time	   PCR	  
(QRT-­‐PCR)	   for	   quantification	   of	   abnormally	   expressed	   miRNAs	   in	   PMF	   and	   control	  
granulocytes	  and	  in	  CD34+	  cells.	  cDNA	  was	  synthesized	  from	  total	  RNA	  using	  TaqMan®	  
MicroRNA	   Reverse	   Transcription	   Kit	   (Applied	   Biosystems®).The	   composition	   of	  
the	  mix	  of	  the	  reagents	  which	  has	  been	  used	  for	  the	  process	  of	  reverse	  transcription	  
and	   the	   kinetics	   of	   reaction	   are	   described	   previously	   (See	   par.	   4.2).	   Each	   generated	  
cDNA	   was	   amplified	   by	   QRT-­‐PCR	   with	   sequence-­‐specific	   primers	   from	   the	   TaqMan	  
microRNA	   Assays	   on	   Step	   one	   plus	   PCR	   system	   (Applied	   Biosystems®).	   Relative	  
quantities	  were	  calculated	  by	  using	  the	  control	  group.	  Quantification	  of	  relative	  miRNA	  
expression	  on	  the	  validation	  set	  was	  performed	  with	  the	  comparative	  CT	  method	  using	  
the	   formula	   2^-­‐DDCT,	   where	   DDCT	   =	   [(CT	   gene	   of	   interest-­‐CT	   reference	   gene)	   PMF	  
sample	  –	  mean	  of	   (CT	  miRna	  of	   interest-­‐CT	   reference	  miRna)	   control	   goup]	  by	  using	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4.3.4	   TARGET	   PREDICTION	   OF	   VALIDATED	   sRNAS	   AND	   FUNCTIONAL	  
ENRICHMENT.	  
The	   complexity	   of	   miRNA-­‐mRNA	  
interactions	   causes	   ambiguity	   in	   target	  
prediction	  results.	  
It	   was	   chose	   to	   perform	   a	   target	  
prediction	  using	   two	  different	  programs,	  
miRanda	   and	   PITA,	   which	   implement	  
orthogonal	   target	   prediction	   strategies.	  
Our	  choice	  was	  determined	  also	  by	  code	  
availability,	   which	   allowed	   us	   to	   make	  
custom	   predictions	   using	   as	   query	  
sequences	   also	   isomiRs	   and	   moRNA	  
sequences.	  
	   It	   was	   performed	   a	   target	   prediction	  
using	   both	   miRanda	   3.3a	   and	   PITA	  
executable	   version	   6.	   It	   was	   applied	  
default	  parameters	  of	  miRanda	  to	  predict	  
target	   of	   selected	   miRNAs	   and	   moRNA	  
sequences	   since	   these	   settings	   are	  
reported	   to	   optimize	   the	   dynamic	  
programming	   miRanda	   algorithm.	   It	   was	   used	   default	   parameters	   for	   PITA	   target	  
prediction	  too.	  According	  to	  PITA	  documentation,	  it	  was	  considered	  a	  binding	  site	  with	  
score	  	  </=	  -­‐10	  likely	  to	  be	  functional	  in	  endogenous	  microRNA	  expression	  levels.	  It	  was	  
performed	  a	  hypergeometric	  test	  using	  an	  in	  house	  modified	  version	  of	  the	  R	  Category	  
package	   of	   Bioconductor,	   which	   supports	   Reactome	   annotation	   maps	   via	   the	  
reactome.db	  R	  package.	  
4.3.5	  QRT-­‐PCR	  ANALYSIS	  OF	  TARGET	  GENE	  EXPRESSION.	  
After	  identifying	  the	  target	  genes	  of	  miRNAs,	  It	  was	  analized	  the	  expression	  of	  some	  of	  
them	  considered	  most	  relevant	  (See	  Tab.	  23)	  using	  the	  RNA	  extracted	  from	  CD34+	  cells	  	  
of	  PMF	  patients	  and	  crontrols.	  CDNA	  was	  synthesized	  from	  total	  RNA	  using	  TaqMan®	  
High	   capacity	   cDNA	   reverse	   transcription	   kit	   	   (Applied	   Biosystems®).	  
Subsequently	   cDNA	   was	   amplified	   by	   QRT-­‐PCR	   with	   sequence-­‐specific	   primers	   from	  
the	   TaqMan	   gene	   expression	   assays	   by	   means	   of	   StepOne	   real-­‐time	   PCR	   system	  
(Applied	  Biosystems®).	  Gene	  expression	  profiling	  was	  achieved	  using	   the	  RQ	  method	  





	  	  	  	  	  	  	  	  Tab.	  23:	  Target	  genes	  of	  miRnas	  whose	  it	  
was	  analyzed	  the	  expression.	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4.4	  	  EVALUATION	  OF	  PLASMA	  MIRNAS	  EXPRESSION	  PROFILE	  IN	  
PMF	  PATIENTS.	  
	  4.4.1	  PLASMA	  SAMPLES	  COLLECTION.	  	  
All	  samples	  were	  collected	  in	  EDTA	  vacutainer	  tubes	  were	  centrifuged	  at	  1,800	  x	  g	  	  	  (at	  
temperature	  4	  	  ̊C)	  	  for	  15	  min,	  	  and	  subsequently	  were	  centrifuged	  at	  	  7,000	  x	  g	  for	  5	  
min	   to	   remove	   a	   cellular	   debris.	   In	   all	   processing	   steps,	  measures	  were	   be	   taken	   to	  
prevent	  lysis	  of	  cells	  to	  do	  so	  may	  lead	  to	  contamination	  of	  the	  samples	  with	  RNA	  from	  
intact	  cells.	  Once	  prepared	  plasma	  samples	  may	  be	  stored	  at	  -­‐80°	  C.	  
4.4.2	  RNA	  EXTRACTION	  AND	  PURIFICATION	  FROM	  PLASMA	  SAMPLES.	  
Total	   RNA	   was	   extracted	   from	   200	   μl	  of	   plasma	   using	   miRNeasy	   Serum/Plasma	   Kit	  
(Qiagen®).	  Because	  plasma	  samples	  contain	  only	  small	  amounts	  of	  RNA	  which	  means	  
that	   there	   is	   a	   high	   risk	   that	   a	   significant	   proportion	   of	   the	   RNA	   is	   lost,	   during	  
extraction,	  1	  μg	  of	  MS2	  carrier	  RNA	  	  (0,8	  μg/	  μl)	  (Roche	  Applied	  Science®)	  for	  200	  μl	  of	  
plasma	   was	   added	   to	   the	   QIAzol	   Lysis	   Reagent	   (Qiagen®)	   prior	   to	   RNA	   purification.	  
Purified	  RNA	  was	  resuspended	  in	  20	  μl	  of	  nuclease-­‐free	  water	  and	  stored	  at	  -­‐80°C	  prior	  
to	  assaying	  miRNA.	  The	  use	  of	  a	  carrier	  ensures	  the	  highest	  and	  most	  consistent	  yield	  
from	   plasma	   samples.	   A	   source	   of	   MS2	   carrier	   is	   guaranteed	   to	   be	   free	   from	  
microRNAs.	  	  
4.4.3	  MIRNA	  QUANTIFICATION	  IN	  PLASMA	  BY	  QRT-­‐PCR.	  
The	  concentration	  of	  purified	  RNA	  from	  plasma	  or	  serum	  is	  usually	  very	   low	  and	   it	   is	  
difficult	   to	   carry	  out	  a	  measurement,	   then,	   it	  was	  decided	   to	  use	  a	   fixed	  volumes	  of	  
eluted	  RNA	  (8	  μl)	  for	  miRNA	  expression	  assays	  as	  previously	  reported	  (MacLellan	  et	  al.,	  
2012).	  RNA	  was	  reverse	  transcribed	  using	  the	  miRCURY	  LNA	  Universal	  RT	  miRNA	  PCR,	  
Polyadenylation	  and	   cDNA	   synthesis	   kit	   (Exiqon®).	   The	  miRNA	  detection	  experiments	  
were	  performed	  on	   Serum/Plasma	   Focus	  micro-­‐RNA	  polymerase	   chain	   reaction(PCR)	  
Panel	   (V1)	   by	   using	   SYBR	   Green	   master	   mix	   (Exiqon®)	   as	   recommended	   by	   the	  
manufacturer.	  This	  panel	  covers	  the	  analysis	  of	  168	  human	  miRNAs.	  	  
All	   qRT-­‐PCR	   reactions	   were	   carried	   out	   on	   384-­‐well	   plates	   in	   the	   presence	   of	   ROX	  
Reference	  Dye	  (Life	  Technologies®)	  and	  analyzed	  with	  the	  Applied	  Biosystems	  7900HT	  
Fast	  Real-­‐Time	  PCR	  System	  (Life	  Technologies®).	  Relative	  quantities	  were	  calculated	  by	  
using	  the	  control	  group.	  Quantification	  of	  relative	  miRNA	  expression	  on	  the	  validation	  
set	  was	  performed	  with	  the	  comparative	  CT	  method	  using	  the	  formula	  2^-­‐DDCT,	  where	  
DDCT	  =	  [(CT	  miRna	  of	  interest-­‐CT	  reference	  miRna)	  PMF	  sample	  –	  mean	  of	  (CT	  miRna	  
of	  interest-­‐CT	  reference	  miRna)	  	  control	  goup]	  by	  using	  hsa-­‐miR-­‐93-­‐5p	  as	  the	  reference	  
miRNA	  .	  
4.4.4	  STATISTICAL	  ANALYSIS.	  	  
	  Unpaired	   two-­‐tailed	   T-­‐test	   of	   independent	   samples	   as	   well	   as	   one-­‐way	   analysis	   of	  
variance	   (ANOVA)	   was	   performed,	   comparing	   PMF	   patients	   and	   control	   groups.	  
GraphPad	  software	  (San	  Diego®)	  was	  employed	  for	  t-­‐test	  statistical	  analysis.	  
In	   the	   discovery	   set,	   candidate	   miRNAs	   were	   selected	   if	   they	   were	   found	   to	   be	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significantly	  different	  expressed	   in	  the	  PMF	  patients	  versus	  control	  group.	  Exclusively	  
miRNAs	   that	  were	   found	   to	  be	  up-­‐or	  down-­‐regulated	   in	  each	   individual	  PMF	  patient	  
were	   selected	   or	   the	   validation	   set	   analysis.	   Statistical	   significance	  was	   defined	   as	   P	  
value	  ≤	 0.05.	  	  
	  
4.5	  MIRNA	  EXPRESSION	  PROFILE	  IN	  JAK2V617F	  KI	  MOUSE	  
MODEL.	  
4.5.1	  	  JAK2V617F	  KI	  MOUSE	  MODEL.	  
	  
The	   analysis	   of	   miRNA	   expression	   profile	   was	   performed	   on	   cells	   purified	   from	  
JAK2V617F	  KI	  animals	  kindly	  concessed	  Dr.	  Jean	  Luc	  Villeval	   (Mouse	  Clinical	   Institute,	  
Illkirch,	  France)	  where	  the	  model	  was	  generated.	  The	  animal	  model	  was	  developed	  as	  
follows:	   a	   fragment	   encompassing	   JAK2	   exon	   13	  was	   amplified	   by	   polymerase	   chain	  
reaction	   (PCR)	   on	   129S2/SvPas	   mouse	   embryonic	   stem	   (ES)	   cell	   genomic	   DNA	   to	  
introduce	  the	  GTC	  >	  TTC	  point	  mutation	  (617V	  >	  F)	  and	  subcloned	   in	  a	  vector	  with	  a	  
floxed	   neomycin	   resistance	   (NeoR)	   cassette	   resulting	   in	   a	   step	   1	   plasmid.	   A	   5	  
homologous	  arm	  was	  amplified	  by	  PCR	  and	  subcloned	  in	  step	  1	  plasmid	  to	  generate	  a	  
step	   2	   plasmid.	   Finally,	   a	   3	   homologous	   arm	   was	   subcloned	   in	   step	   2	   plasmid	   to	  
generate	  the	  final	  targeting	  construct.	  Targeted	  129S2/SvPas	  ES	  clones	  were	  confirmed	  
by	  PCR	  and	  Southern	  blot	  and	  injected	  into	  C57BL/6J	  blastocysts	  to	  generate	  chimeric	  
mice.	   Chimeras	   (L2)	  were	   crossed	  with	   flippase	   (FLP)	   TG	  C57BL/6	  mice	   to	   excise	   the	  
FRT	   siteflanked	   NeoR	   cassette	   on	   F1	   progenies	   (L-­‐).	   Finally,	   F1	   animals	   (L-­‐)	   were	  
crossed	  with	  129Sv	  mice	  to	  generate	  F2	  animals.	  	  
4.5.2	  	  ISOLATION	  OF	  	  TER119+	  AND	  GR1+	  CELLS.	  
Mice	   belonging	   to	   L-­‐	   progenies	   (JAK2wtmice)	   (n=2)	   and	   L2	   progenies	   (JAK2V617F	  mice)	  
(n=2)	  were	  sacrified	  and	  then	  bone	  marrow	  cells	  were	  purified	  from	  both	  femour	  and	  
tibia.	  Bones	  were	  transfered	  to	  50	  mL	  Falcon	  tube	  containing	  sterile	  PBS.	  Immediately	  
after,	   it	   was	   removed	   a	   bone	   from	   the	   PBS	  with	   tweezers	   and	   cut	   the	   ends.	   It	   was	  
flushed	  out	  the	  bone	  marrow	  into	  the	  50	  mL	  Falcon	  tube	  by	  inserting	  a	  20	  mL	  syringe	  
filled	  with	  PBS	  at	  the	  knee	  side	  of	  both	  types	  of	  bone.	  After	  passing	  the	  PBS	  through	  
the	   bone,	   the	   colour	   of	   the	   bone	   turned	   from	   red	   to	   white,	   indicating	   that	   all	   the	  
marrow	  was	  expelled.	  When	  all	  bones	  were	  washed	  of	  marrow,	  it	  was	  centrifuged	  cells	  
at	  1500	  rpm	  for	  5	  minutes.	  TER119+	  and	  GR1+	  cells	  were	  obtained	  by	  immunomagnetic	  
separation	   using	   anti-­‐TER119-­‐mouse	   and	   anti-­‐GR1-­‐mouse	   antibodies	   (Milteny	  
Biotec®).	   In	   adult	  mice,	   Anti-­‐TER-­‐119	   reacts	  with	   20–25%	   of	   bone	  marrow	   cells	   and	  
approximately	  50%	  of	  spleen	  cells,	  but	  not	  with	  thymocytes	  or	  lymphonode	  cells.	  The	  
mouse	  Anti-­‐GR-­‐1	  antibody	   reacts	  with	   Ly-­‐6G,	  a	  21-­‐25	  kDa,	  GPI-­‐anchored	  cell	   surface	  
protein,	  previously	  defined	  as	  the	  granulocyte-­‐differentiation	  antigen-­‐1	  (GR-­‐1).	  GR-­‐1	  is	  
expressed	  on	  mature	  granulocytes	   in	  bone	  marrow	  and	  peripheral	   tissues.	   The	  Anti-­‐
GR-­‐1	   antibody	   also	   stains	  monocytes	   transiently	   during	   their	   differentiation	   in	   bone	  
marrow	  and	  at	  low	  levels	  plasmacytoid	  dendritic	  cells	  in	  lymphoid	  tissues.	  The	  quality	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of	  purified	  TER119+	  and	  GR1+	  populations	  was	  evaluated	  by	  flow	  citometer.	  	  	  	  	  
4.5.3	  RNA	  EXTRACTION	  AND	  MIRNA	  QUANTIFICATION	  BY	  QRT-­‐PCR.	  
Total	  RNA	  was	  prepared	  with	  a	  Tripure	  isolation	  reagent	  (Roche®	  )	  as	  described	  by	  the	  
manufacturer.	  It	  was	  added	  	  20	  mg	  Glycogen	  (Roche	  ®)	  	  to	  each	  sample	  as	  a	  carrier.	  
RNA	  	  purity	  and	  concentration	  were	  evaluated	  by	  spectrophotometry	  using	  NanoDrop	  
ND-­‐1000.	  Quality	  and	  related	  size	  of	  total	  and	  small	  RNA	  was	  assessed	  by	  the	  Agilent	  
2100	   Bioanalyzer	   microfluidics-­‐based	   platform	   (Agilent	   Technoogies®)	   with	   Agilent	  
Small	  Rna	  Kit	  for	  low	  molecular	  weight	  RNA.	  Electropherograms	  were	  visualized	  using	  
the	  Agilent	  2100	   	  Expert	  software	   	  wich	   included	  data	  collection,	  peak	  detection	  and	  
interpretation	   	   of	   the	   different	   profile	   (See	   par	   4.1.5).	   RNA	  was	   reverse	   transcribed	  
using	  the	  miRCURY	  LNA	  Universal	  RT	  miRNA	  PCR,	  Polyadenylation	  and	  cDNA	  synthesis	  
kit	   (Exiqon®)	  and	  the	  analysis	  of	  miRNA	  was	  performed	  using	  that	   includes	   	  miRCURY	  
LNATM	  Universal	  RT	  microRNA	  PCR,	  Ready-­‐to	  –use	  Mouse	  and	  Rat	  Panel	  I	  (Exiqon®).	  All	  
qRT-­‐PCR	   reactions	   were	   carried	   out	   on	   384-­‐well	   plates	   in	   the	   presence	   of	   ROX	  
Reference	  Dye	  and	  analyzed	  with	  the	  Applied	  Biosystems	  7900HT	  Fast	  Real-­‐Time	  PCR	  
System	  (Life	  Technologies®).	  
Relative	  quantities	  were	  calculated	  by	  using	  the	  	  L2	  and	  L-­‐	  mice	  	  cells.	  Quantification	  of	  
relative	  miRNA	  expression	  on	  the	  validation	  set	  was	  performed	  with	  th	  e	  comparative	  
CT	  method	  using	  the	  formula	  2^-­‐DDCT,	  where	  DDCT	  =	  [(CT	  gene	  of	  interest-­‐CT	  reference	  
gene)	  L2	  GR1/TER119	  –	  mean	  (CT	  gene	  of	  interest-­‐CT	  reference	  gene)	  L-­‐	  GR1/TER119]	  .	  
The	  reference	  miRNA	  used	  was	  been	  U6	  snRNA.	  
4.5.4	  VALIDATION	  RESULTS	  DEREGULATED	  MIRNAS.	  	  
To	   validate	   results	   deregulated	   miRnas,	   RNA	   extracted	   from	   L2	   (N=6)	   and	   L-­‐	   (N=6)	  
GR1/TER119	   cells	   was	   reverse	   transcribed	   using	   miRna	   reverse	   transcription	   kit	  
(Lifetech®)	   and	   a	   Real-­‐time	   PCR	   	   was	   performed	   by	   TaqMan®	   miRna	   assays	   as	  
described	  by	  the	  manufacturer.	  All	  qRT-­‐PCR	  reactions	  were	  analyzed	  with	  the	  Step-­‐one	  
Plus	   Real-­‐Time	   PCR	   System	   (Life	   Technologies®).	   Quantification	   of	   relative	   miRNA	  
expression	  on	   the	  validation	   list	  was	  performed	  with	   the	   comparative	  CT	  method	  as	  
previously	  described.	  
4.5.5	  STATISTICAL	  ANALYSIS.	  
Unpaired	   two-­‐tailed	   T-­‐test	   of	   independent	   samples	   as	   well	   as	   one-­‐way	   analysis	   of	  
variance	  (ANOVA)	  was	  performed,	  comparing	  miRnas	  expression	  of	  L2	  mouse	  GR1+	  or	  
TER119+	   versus	   a	   control	   groups	   consisting	   of	   L-­‐	   mouse	   corrispondent	   cells.	   In	   the	  
discovery	  set,	  candidate	  miRNAs	  were	  selected	   if	   they	  were	   found	  to	  be	  significantly	  
different	   expressed	   in	   the	   L2	  mouse	   	   cells	   versus	   L-­‐	   control	   group.	   Subsequently,	   a	  
group	  of	  miRNAs	   that	  were	   found	   to	  be	  up-­‐or	  down-­‐regulated	   in	   	  L2	  mouse	   	   cells	  at	  
first	  analisys,	  were	  further	  validated.	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5	  RESULTS 
5.1	  ANALISYS	  OF	  GENE	  AND	  MIRNA	  EXPRESSION	  PROFILE	  OF	  
CD34+	  CELLS	  AND	  GRANULOCYTES	  FROM	  PMF	  PATIENTS	  AND	  
CONTROLS.	  
Norfo	  R,	  Zini	  R,	  Pennucci	  V,	  Bianchi	  E,	  Salati	  S,	  Guglielmelli	  P,	  Bogani	  C,	  Fanelli	  T,	  
Mannarelli	  C	  et	  al.	  (2014)	  Blood.	  124(13):e21-­‐32.	  	  	  	  
5.1.1	  GENE	  EXPRESSION	  PROFILE	  OF	  CD34+	  CELLS	  FROM	  PMF	  PATIENTS.	  
	  
It	  was	  performed	  mRNA	  expression	  profiling	   in	  CD34+	  cells	   from	  42	  PMF	  patients	  (n=	  
23	  JAK2V617F-­‐positive	  and	  n=19	  wild-­‐type	  JAK2)	  and	  31	  healthy	  donors	  (n=15	  from	  the	  
BM	   and	   n=16	   from	   the	   PB).	   After	   data	   preprocessing,	   using	   an	   ANOVA-­‐based	  
supervised	  approach	  for	  comparing	  PMF	  samples	  with	  both	  BM	  and	  PB	  controls,	  it	  was	  
identified	  718	  DEGs.	   	  Array	  data	  confirmed	  the	  abnormal	  expression	  of	  several	  genes	  
(ie,	  WT1,	  NFE2,	   CXCR4,	   and	   CD9)	   previously	   identified	   as	   deregulated	   in	   PMF	  CD34+	  
cells	  by	  our	  group	  in	  a	  different	  cohort	  of	  PMF	  patients	  (Guglielmelli	  et	  al,	  2007).	  	  
Moreover,	  PMF	  samples	  exhibited	  increased	  levels	  of	  several	  putative	  cancer	  markers,	  
such	   as	  ANGPT1,	   CEACAM8,	   and	  CP,	   previously	   reported	   to	   be	   associated	  with	  poor	  
prognosis	   in	   hematologic	   and	   solid	   neoplasms,	   as	  well	   as	   genes	   associated	  with	   BM	  
fibrosis	  (LEPR,	  MMP9,	  and	  TIMP3)	  and	  aberrant	  migration	  (TM4SF1,	  RHOB,	  ARHGAP18,	  
and	  MMP8).	  	  In	  addition,	  PMF	  samples	  showed	  a	  deregulated	  expression	  pattern	  of	  a	  
number	  of	  transcription	  factors	  and	  chromatin	  remodelers	  involved	  in	  myeloid	  and	  MK	  
commitment,	   either	   downregulated	   (ie,	   JARID2,	   RUNX2,	   KLF3,	   and	   AFF3)	   or	  
upregulated	   (ie,	   FHL2,	   MAF,	   and	   IKZF2).	   A	   selected	   list	   of	   DEGs	   chosen	   for	   their	  
biological	   significance	   is	   presented	   in	   Table	   24.	   To	   validate	   the	   array	   data,	   it	   was	  
designed	   a	   TaqMan®	   low-­‐density	   array	   containing	   63	   and	   GAPDH	   TaqMan®	   gene	  
expression	   assays.	   The	   selection	   of	   genes	  was	   based	   on	   either	   the	   highest	   absolute	  
fold-­‐change	  contrast	  and/or	  their	  putative	  role	  in	  PMF	  pathogenesis.	  TaqMan®	  assays	  
were	  carried	  out	  in	  an	  independent	  cohort	  of	  CD34+	  cells	  from	  10	  PMF	  patients	  and	  8	  
healthy	  subjects	  (n=4	  BM,	  n=4	  PB)	  and	  enabled	  validation	  of	  the	  expression	  of	  50	  out	  
of	  63	  genes	  (79.4%).	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Tab.24:	  DEGs	  selected	  by	  biological	  significance.	  
	  
5.1.2	  MIRNA	  EXPRESSION	  PROFILE	  OF	  CD34+	  CELLS	  FROM	  PMF	  PATIENTS.	  
	  
To	   draw	   a	   comprehensive	   picture	   of	   miRNA	   deregulation	   and	   its	   relationship	   with	  
differential	  gene	  expression	   in	  PMF	  cells,	   it	  was	  performed	  miEP	   in	  the	  same	  sample	  
set,	  using	  the	  Affymetrix	  miRNA	  2.0	  arrays.	  	  
Next,	  by	  using	  an	  ANOVA-­‐based	  supervised	  approach	  as	  described	  in	  paragraph	  4.2.1,	  
it	   was	   selected	   76	   DEMs.	   In	   particular,	   it	   was	   found	   several	   upregulated	   miRNAs	  
associated	   with	   hematologic	   malignancies,	   or	   known	   as	   oncomiRs	   (ie,	   miR-­‐155-­‐5p,	  
miR-­‐21-­‐5p,	  miR-­‐29a-­‐3p,	  and	  miRNAs	  belonging	  to	  the	  miR-­‐17-­‐92	  cluster)	  (Schotte	  et	  al,	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2012).	  By	  contrast,	  among	  the	  downregulated	  miRNAs,	  it	  was	  found	  miR-­‐378c,	  which	  is	  
described	   as	   a	   tumor	   suppressor	   gene	   in	   gastric	   cancer	   (Deng	   et	   al.,	   2013).	  
Furthermore,	   overexpressed	   miRNAs	   previously	   identified	   as	   being	   involved	   in	   MK	  
commitment	  were	  also	   found	   (ie,	  miR-­‐146b-­‐5p	  and	  miR-­‐34a-­‐5p)	   (Li	  et	  al.,	  2011).	   	   To	  
validate	   the	   array	   data,	   it	   was	   used	   TaqMan®	   single	   miRNA	   assays	   to	   assess	   the	  
expression	   of	   46	   DEMs,	   which	   were	   selected	   based	   on	   either	   their	   relatively	   high	  
differential	   expression	  or	   their	   biological	   role	   in	   cancer-­‐related	  processes	  or	  myeloid	  
differentiation.	  TaqMan®	  assays	  were	  carried	  out	   in	  an	   independent	  cohort	  of	  CD34+	  
cells	  from	  10	  PMF	  patients	  and	  8	  healthy	  subjects	  (n=4	  BM,	  n	  =4	  PB)	  and	  confirmed	  the	  
deregulated	  expression	  of	  34	  out	  of	  46	  miRNAs	  (73.9%).	  
	  
5.1.3	  VALIDATION	  OF	  A	  GENE	  SET	  ON	  GRANULOCYTES	  AND	  SERUM	  
FROM	  PMF	  PATIENTS.	  
	  
Among	   the	  50	  validated	  genes	  described	  previously,	   it	  was	  selected	  a	   set	  of	  7	  genes	  
(OLFM4,	   LCN2,	   LEPR,	   FGR,	   ANXA3,	   CEACAM8,	   and	   DEF1A)	   out	   of	   those	   most	  
upregulated	   to	   validate	   their	   expression	   in	   granulocytes,	   which	   represent	   a	   more	  
appropriate	  source	  for	  diagnostic/prognostic	  purposes.	  Using	  qRT-­‐PCR,	  it	  was	  observed	  
that	  OLFM4,	  LCN2,	  LEPR,	  FGR,	  and	  ANXA3	  mRNA	  levels	  were	  significantly	  increased	  in	  
PMF	  granulocytes	  (n=32)	  compared	  with	  healthy	  controls	  (n=	  12)	  (Fig	  16	  A),	  whereas	  
CEACAM8	  and	  DEF1A	  expression	  was	  not	  statistically	  modulated	  between	  the	  2	  groups	  
(data	  not	  shown).	  Because	  OLFM4	  and	  LCN2	  genes	  encode	  for	  2	  secreted	  proteins,	   it	  
was	  assessed	  OLFM4	  and	  LCN2	  protein	  levels	   in	  the	  serum	  of	  the	  same	  PMF	  patients	  
(n=32)	   and	   healthy	   donors	   (n=8)	   by	  means	   ofan	   ELISA.	   As	   shown	   in	   Figure	   16B,	   the	  
levels	  of	  OLFM4	  and	  LCN2	  secreted	  proteins	  were	  significantly	  higher	  in	  PMF	  patients	  
than	   in	  healthy	  donors.	  Of	  note,	   the	  median	   concentration	  of	  OLFM4	   serum	  protein	  
was	  five	  fold	  higher	  in	  PMF	  patients	  than	  in	  controls.	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Fig.	   16.	   Validation	   of	   the	   selected	   genes	   and	  miRNAs	   in	   granulocytes	   and	   plasma	   from	   PMF	   patients.	   (A)	   Expression	   of	   the	   7	  
selected	  genes	  in	  granulocytes	  from	  PMF	  patients	  and	  healthy	  donors.	  Gene	  expression	  levels	  were	  measured	  by	  qRT-­‐PCR	  starting	  
from	  granulocyte	  total	  RNA	  and	  were	  expressed	  as	  relative	  quantity	  (RQ).	  Boxes	  represent	  the	  inter	  quartile	  range	  that	  contains	  
50%	   of	   the	   subjects,	   the	   horizontal	   line	   in	   the	   box	   marks	   the	   median,	   and	   the	   bars	   show	   the	   range	   of	   values.	   Data	   are	  
representative	  of	  32	  PMF	  and	  12	  control	  (CTR)	  samples.	  (B)	  Serum	  levels	  of	  2	  secreted	  proteins	  (LCN2	  and	  OLFM4)	  in	  PMF	  patients	  
and	  healthy	  donors.	  Protein	  levels	  were	  measured	  by	  enzyme-­‐linked	  immunosorbent	  assay	  (ELISA)	  and	  were	  expressed	  as	  ng/mL.	  
Boxes	  represent	  the	  interquartile	  range	  that	  contains	  50%	  of	  the	  subjects,	  the	  horizontal	  line	  in	  the	  box	  marks	  the	  median,	  and	  the	  
bars	   show	   the	   range	   of	   values.	   Data	   are	   representative	   of	   30	   PMF	   and	   8	   CTR	   samples.	   (C)	   Expression	   levels	   of	   the	   8	   selected	  
miRNAs	  in	  granulocytes	  from	  PMF	  patients	  and	  healthy	  donors.	  The	  miRNA	  expression	  levels	  were	  measured	  by	  qRT-­‐PCR	  starting	  
from	  granulocyte	  total	  RNA	  and	  were	  expressed	  as	  RQ.	  Boxes	  represent	  the	  interquartile	  range	  that	  contains	  50%	  of	  the	  subjects,	  
the	  horizontal	  line	  in	  the	  box	  marks	  the	  median,	  and	  the	  bars	  show	  the	  range	  of	  values.	  Data	  are	  representative	  of	  32	  PMF	  and	  12	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5.1.4	  VALIDATION	  OF	  THE	  SELECTED	  MIRNAS	  IN	  THE	  GRANULOCYTES	  
FROM	  PMF	  PATIENTS.	  
	  
Among	   the	   validated	   miRNAs	   in	   PMF	   CD34+	   cells,	   it	   was	   selected	   the	   16	   most	  
upregulated	  ones	  (see	  Table	  19	  in	  “Material	  and	  methods”)	  to	  test	  their	  expression	  in	  
the	   granulocytes	   from	   the	   same	  
PMF	   patients	   (n=30)	   and	   healthy	  
donors	   (n=8)	   previously	   used	   for	  
mRNA	   expression	   validation.	   It	  
was	   demonstrated	   that	   the	   levels	  
of	   miR-­‐19a-­‐3p,	   miR-­‐335-­‐5p,	   miR-­‐
379-­‐5p,	   miR-­‐376c-­‐3p,	   miR-­‐487b-­‐
3p,	   and	   miR-­‐494-­‐3p	   were	  
significantly	   increased	   in	   PMF	  
granulocytes	   compared	   with	  
controls;	   whereas	   miR-­‐486-­‐3p	  
expression	   was	   significantly	  
decreased	  in	  PMF	  granulocytes,	  in	  
contrast	  to	  the	  results	  obtained	  in	  
CD34+cells	  (Figure	  15C).	  The	  levels	  
of	  the	  remaining	  miRNAs	  were	  not	  
statistically	   modulated	   between	  
PMF	  and	  controls.	  
5.1.5	  GEP	  AND	  MIEP	  
INTEGRATIVE	  ANALYSIS.	  
	  
Because	   each	   miRNA	   can	   target	  
many	  mRNAs	  while	  a	  single	  mRNA	  
can	   be	   targeted	   by	   multiple	  
miRNAs,	   it	   was	   performed	   IA	   by	  
means	   of	   IPA	   to	   untangle	   this	  
combinatorial	   complexity.	   Based	  
on	   IPA,	   it	   was	   selected	   DEM-­‐DEG	  
pairs	   with	   an	   anticorrelated	  
expression	   pattern.	   In	   particular,	  
56	   out	   of	   the	   76	   DEMs	   have	   at	  
least	  1	  anticorrelated	  target	  among	  DEGs;	  whereas	  445	  out	  of	   the	  718	  DEGs	  have	  at	  
least	   1	   anticorrelated	   targeting	   DEM.	   There	   were	   1167	   anticorrelated	  miRNA-­‐target	  
pairs	   finally	   generated.	   Among	   the	   interaction	   networks	   uncovered	   by	   IPA,	   it	   was	  
focused	  our	  attention	  on	  3	  of	  them	  because	  of	  their	  enrichment	  in	  genes	  and	  miRNAs	  
involved	   in	   myeloproliferative	   disorders	   and/or	   in	   hematopoietic	   differentiation.	  
Figure	  17A	  shows	  several	  miRNAs	  that	  are	  highly	  expressed	  in	  PMF,	  such	  as	  miR-­‐18a-­‐
Fig.	  17.	  Regulatory	  networks	  of	  mRNA-­‐miRNA	  interactions	  built	  
through	  IPA.Visualization	  of	  the	  regulatory	  networks	  enriched	  
for	  chromatin	  remodeling	  genes	  (A),	  myeloid	  transcription	  
factors	  (B),	  and	  myeloproliferative	  disorder-­‐related	  genes	  (C).	  
Red	  filling	  means	  upregulation,	  and	  green	  filling	  indicates	  
downregulation.	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5p,	  miR-­‐29a-­‐3p,	  miR-­‐433-­‐3p,	  miR-­‐19a-­‐3p,	  miR-­‐155-­‐5p,	  miR-­‐195-­‐5p,	  miR-­‐200c-­‐3p,	  and	  
miR-­‐152-­‐3p,	   and	   their	   downregulated	   targets	   (BRWD1,	   JARID2,	   PHC3,	   and	   HMGB3)	  
implicated	  in	  chromatin	  remodeling,	  a	  process	  severely	  impaired	  in	  MPNs.	  The	  second	  
network	   (Figure	   17B)	   displays	   several	   upregulated	   miRNAs	   involved	   in	   myeloid	  
differentiation	   (miR-­‐155-­‐5p,	  miR-­‐21-­‐5p,	   and	  miR-­‐29a-­‐3p)	   (	  O’Connelet	   al.,	   2011)	   and	  
their	  interactions	  with	  downregulated	  transcription	  factors,	  known	  as	  leukemic	  tumor	  
suppressors	   (TLE4,	   MLL5,	   and	   FOXO1)	   or	   myeloid	   commitment	   regulators	   (CEBPD,	  
CEBPG,	   MAFF,	   TCF4,	   and	  MXD1).	   Finally,	   through	   IA	   we	   could	   identify	   a	   regulatory	  
network	  gathering	  a	  high	  number	  of	  upregulated	  oncomiRs	  (ie,	  miR-­‐155-­‐5p,	  miR-­‐29a-­‐
3p,	  miR-­‐92b-­‐3p,	  miR-­‐19a-­‐3p,	  and	  miR-­‐18a-­‐5p)	  targeting	  anticorrelated	  mRNAs	  whose	  
downregulation	  or	  deletion	  has	  been	  related	  to	  hematopoietic	  disorders.	  In	  particular,	  
hypoallelic	   NR4A3	   or	   CDC42	   K/O	   in	   mice	   leads	   to	   a	   myeloproliferative	   disorder	  
(Ramirez-­‐Herrick	   et	   al.,	   2011;	   Yang	   et	   al.,	   2007)	   and	   JARID2	   is	   a	   frequently	   deleted	  
gene	   in	   leukemic	  transformation	  of	  chronic	  myeloid	  malignancies	   (Puda	  et	  al.,	  2012);	  
the	   other	   target,	   HMGB3,	   is	   instead	   described	   as	   a	   regulator	   of	   self-­‐renewal/	  
differentiation	  balance	  in	  murine	  HSCs	  (Nemeth	  et	  al.,	  2006)	  (Figure	  17C).	  
5.1.6	  MIRNA-­‐MRNA	  INTERACTION	  VALIDATION	  BY	  LUCIFERASE	  
REPORTER	  ASSAYS.	  	  
Because	  the	  network	  shown	  in	  Figure	  17C	  contained	  the	  highest	  number	  of	  oncomiRs	  
and	  targets	  involved	  in	  malignant	  hematopoiesis,	   in	  collaboration	  with	  the	  laboratory	  
directed	  by	  Prof.ssa	  R.	  Manfredini	   	   in	   the	  University	  of	  Modena	  and	  Reggio	  Emilia,	   it	  
was	   selected	   to	   validate	   every	   putative	   miRNA/target	   pair	   by	   assessing	   3’UTR	  
luciferase	  activity	  upon	  miRNA	  overexpression;	  K562	  cells	  were	  selected	  as	  an	  in	  vitro	  
system	  providing	  a	  hematopoietic	  background.	  	  
	  
Fig.	   18.	  Validation	  of	  3’UTR-­‐miRNA	   interactions.	   (A)	  Normalized	   luciferase	  activity	  of	  K562	  cells	  nucleofected	  with	  
the	  indicated	  miRNA	  mimics	  and	  3’UTR	  luciferase	  reporter	  vectors.	  Firefly	  luciferase	  activity	  was	  measured	  48	  hours	  
after	  nucleofection	  and	  normalized	  to	  Renilla	  luciferase	  activity.	  Values	  are	  reported	  as	  mean	  6	  SEM;	  *P<0.05	  
vs	   miRNA	   mimic	   negative	   control	   (Neg-­‐mimic).	   Results	   come	   from	   3	   independent	   experiments	   performed	   in	  
duplicate.	   (B)	   Graphical	   representation	   of	   mRNA-­‐miRNA	   interactions	   validated	   by	   means	   of	   3’UTR	   luciferase	  
reporter	  assays.	  Solid	  lines	  (validated	  interactions);	  dashed	  lines	  (not	  validated	  interactions).	  	  
	  
As	   shown	   in	   Figure	   18A,	   the	   data	   demonstrated	   that	   the	   following	   3’UTR-­‐miRNA	  
interactions	   were	   statistically	   significant:	   JARID2	   3’UTR	   by	   miR-­‐152-­‐3p,	   miR-­‐195-­‐5p,	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and	  miR-­‐155-­‐5p;	  CDC42	  3’	  UTR	  by	  miR-­‐29a-­‐3p	  and	  miR-­‐18a-­‐5p;	  HMGB3	  3’UTR	  by	  miR-­‐
152-­‐3p,	  miR-­‐200c-­‐3p,	  miR-­‐433-­‐3p,	   andmiR-­‐155-­‐5p;	   NR4A3	   3’UTR	   by	  miR-­‐335-­‐5p	   and	  
miR-­‐92b-­‐3p.	  Conversely,	  the	  interactions	  between	  the	  remaining	  miRNA-­‐3’	  UTR	  target	  
pairs	  were	  not	   confirmed.	   Figure	  18B	  graphically	   recapitulates	  all	   the	   confirmed	  and	  
non	  confirmed	  interactions	  of	  the	  IA	  network	  previously	  shown.	  	  
	  
	  
Fig.	  19:	  Results	  of	  the	  luciferase	  reporter	  assays	  performed	  with	  wild-­‐type	  and	  mutant	  3’UTR.	  Assays	  were	  carried	  
out	  only	  for	  the	  3’UTR-­‐miRNA	  interactions	  previously	  validated	  (Fig.	  18A).	  Each	  bar	  represents	  the	  luciferase	  activity	  
upon	   miRNA	   overexpression	   normalized	   on	   the	   value	   of	   the	   same	   3’UTR	   luciferase	   vector	   upon	   Neg-­‐mimic	  
transfection.	   Values	   are	   reported	   as	  mean	   6	   SEM;	   *P<	   0.05	   vs	  mutant	   3’UTR.	   Results	   come	   from	  3	   independent	  
experiments	  performed	  in	  duplicate.	  
	  
Figure	   19	   clearly	   shows	   that	   mutations	   in	   the	   miRNA	   binding	   site	   of	   3’UTR	   targets	  
prevented	   the	   decrease	   in	   luciferase	   reporter	   activity	   by	   miRNAs,	   which	   conversely	  
occurs	   in	   their	  wild-­‐type	  counterparts.	  Collectively,	   the	   luciferase	  assay	  data	   support	  
the	   good	   predictive	   power	   by	   IA,	   as	   demonstrated	   by	   the	   11/17	   (64.7%)	   successful	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5.1.7	  SILENCING	  OF	  JARID2	  IN	  NORMAL	  CD34+	  CELLS.	  	  
Because	  the	  contribution	  of	  JARID2	  to	  PMF	  pathogenesis	  has	  never	  been	  investigated,	  
it	  was	   performed	   RNAi-­‐mediated	   gene	   silencing	   experiments	   on	   normal	   CD34+	   cells.	  
First,	  it	  was	  optimized	  
the	   CD34+	   cell	  
nucleofection	  
protocol	   for	   the	  
Amaxa	   4D-­‐
Nucleofector	   System	  
technology	   .	   CD34+	  
cells	  were	  transfected	  
with	   a	   mixture	   of	   3	  
Silencer	  Select	   siRNAs	  
targeting	   JARID2	  
mRNA	  and	  with	  a	  non	  
targeting	   siRNA	   as	  
NegCTR.	   The	  
expression	   level	   of	  
JARID2	   in	   control	  
samples	   and	   JARID2-­‐
siRNA	   cells	   was	  
assessed	   by	   qRT-­‐PCR	  
at	   24	   and	   48	   hours	  
after	   the	   last	  
nucleofection	   (Figure	  
20A).	  
Flow	   cytometric	  
analysis	   of	   the	   CD4+	  
MK	   marker	  
performed	   on	  
serum	   free	  
multilineage	  culture	  
at	   days	   8,	   10,	   and	  
12	   showed	   that	  
JARID2	   inhibition	  
induces	   a	   significant	   increase	   in	   the	  MK	   fraction	   compared	  with	   the	  NegCTR	   sample	  
(Figure	   20	   B).	   Unilineage	   MK	   differentiation	   culture	   experiments	   further	   confirmed	  
these	   results	   (Figure	   20C).	   Flow	   cytometric	   analysis	   of	   granulocytic,	   mono-­‐
macrophagic,	  and	  erythrocyte	  differentiation	  markers	  did	  not	  highlight	  any	  significant	  
modulation	   between	   JARID2-­‐siRNA	   CD34+	   cells	   and	   the	   NegCTR	   sample	   (data	   not	  
Fig.	  20:.	   Effect	  of	   JARID2	  silencing	  on	  normal	  CD34+	  cell	  differentiation.	  (A)	  Expression	   levels	  
of	   JARID2	   at	  24	   and	  48	   hours	  after	   the	   last	   nucleofection	  were	  measured	  by	  qRT-­‐PCR,	   and	  
data	  are	   reported	  as	  RQ.	   (B-­‐C)	  Results	  of	   the	  statistical	  analysis	  on	   the	  percentage	  of	  CD41+	  
cells	   performed	   by	   flow	   cytometry	   at	   days	   5,	   8,	   10,	   and	   12	   after	   the	   last	   nucleofection	   on	  
serum-­‐free	  multilineage	  and	  MK	  unilineage	  cultures.	  (D)	  Results	  of	   the	  statistical	  analysis	  of	  
collagen-­‐based	  clonogenic	  assay.	  The	  cells	  were	  plated	  24	  hours	  after	   the	  last	  nucleofection	  
and	  scored	  after	  12	   days.	   (E)	  Morphologic	   analysis	  of	  NegCTR	   (i-­‐ii)	   and	   JARID2-­‐siRNA	   (iii-­‐iv)	  
samples	   after	   May-­‐Grunwald-­‐Giemsa	   (MGG)	   staining	   at	   days	   8	   and	   10	   of	   MK	   unilineage	  
culture	   after	   the	   last	   nucleofection	   in	   a	   representative	   experiment.	   Values	   are	   reported	   as	  
mean	  6	  SEM.	  **P<0.01	  vs	  NegCTR;	  *P<0.05	  vs	  NegCTR.	  The	  results	  come	  from	  5	  independent	  
experiments.	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shown).	   The	   methylcellulose	   assay	   indicated	   a	   1.5-­‐fold	   increase	   in	   the	   clonogenic	  
efficiency	  of	   JARID2-­‐siRNA	  CD34+	   cells	   vs	   the	  NegCTR	   sample,	  whereas	   there	  was	  no	  
significant	   difference	   in	   the	   percentage	   of	   erythroid	   and	  myeloid	   colonies	   (data	   not	  
shown).	  Next,	   it	  was	  examined	   the	  effect	  of	   JARID2	  silencing	  on	  MK	  commitment	  by	  
plating	  NegCTR	  and	  JARID2-­‐siRNA	  CD34+	  cells	  in	  a	  collagen-­‐based	  serum-­‐free	  semisolid	  
culture	   medium	   that	   supports	   the	   growth	   of	   MK	   progenitors	   in	   vitro.	   The	   results,	  
reported	   in	   Figure	   20D,	   demonstrated	   that	   JARID2	   silencing	   induces	   a	   remarkable	  
increase	   in	  colony	  forming	  unit	  (CFU)-­‐MKs	  and	  a	  strong	  decrease	  of	  non-­‐MK	  colonies	  
(CFU	  non-­‐MK)	  compared	  with	  the	  NegCTR	  sample.	  Moreover,	  morphologic	  evaluation	  
of	  MGG-­‐stained	  cytospins	  of	   thrombopoietin-­‐treated	  cells	  at	  days	  8	  and	  10	  after	   the	  
last	   nucleofection	   clearly	   displayed	   a	   considerable	   enrichment	   in	   MK	   precursors	   at	  
different	   stages	   of	   maturation	   in	   JARID2-­‐siRNA	   cells	   compared	   with	   NegCTR	   (Figure	  
20E).	  Finally,	  to	  better	  characterize	  the	  changes	  in	  gene	  expression	  induced	  by	  JARID2	  
gene	   silencing,	   it	  was	  performed	  mRNA	  profiling	   in	  NegCTR	  and	   JARID2-­‐siRNA	  CD34+	  
cells.	  
	  
5.1.8	  MIR-­‐155-­‐5P	  OVEREXPRESSION	  AND	  SILENCING	  IN	  NORMAL	  AND	  
PMF	  CD34+	  CELLS.	  
Next,	   it	  was	  asked	  whether	  any	  JARID2-­‐targeting	  miRNA	  could	  reproduce	  its	  silencing	  
effects	   on	   MK	   differentiation.	   Thus,	   it	   was	   decided	   to	   overexpress	   miR-­‐155-­‐5p	   in	  
normal	  CD34+	  cells	  because	   it	  was	  highlighted	  by	  the	   luciferase	  reporter	  assay	  as	   the	  
strongest	   regulator	   of	   the	   JARID2	   3’UTR	   (Figure	   19A).	   Furthermore,	   a	   significant	  
negative	  correlation	  was	  observed	  between	  miR-­‐155-­‐5p	  and	  JARID2	  expression	  levels	  
across	   the	  whole	  microarray	  data	   set.	   CD34+	   cells	  were	   transfected	  either	  with	  miR-­‐
155-­‐5p	   mimic	   or	   with	   Neg-­‐mimic.	   By	   means	   of	   qRT-­‐PCR,	   it	   was	   observed	   that	   the	  
JARID2	  mRNA	  level	  was	  downregulated	  upon	  miR-­‐155-­‐5	  overexpression	  (RQ	  +/-­‐	  SEM,	  
34.7	  +/-­‐	  11.1,	  P<	  0.05)	  at	  24	  and	  48	  hours	  after	  the	  last	  nucleofection	  (Figure	  20Ai).	  
As	  observed	  for	  the	  JARID2	  knockdown,	  miR-­‐155-­‐5p	  overexpression	  led	  to	  a	  significant	  
increase	  of	  the	  percentage	  of	  CD41+	  cells	  at	  days	  10	  and	  12	  after	  the	  last	  nucleofection	  
in	  serum-­‐free	  multilineage	  culture	  (Figure	  21Aii).	  Similar	  results	  were	  obtained	  under	  
unilineage	   MK	   differentiation	   culture	   conditions	   (Figure	   21Aiii).	   Furthermore,	   the	  
collagen-­‐based	   assay	   showed	   that	   miR-­‐155-­‐5p	   overexpression	   causes	   a	   significant	  
increase	  in	  the	  CFU-­‐MKpercentage	  coupled	  with	  a	  strong	  decrease	  of	  non-­‐MK	  colonies	  
(Figure	  21Aiv).	  
Finally,	   the	   morphologic	   analysis	   of	   MGG-­‐stained	   cytospins	   showed	   a	   remarkable	  
enrichment	   in	   MK	   precursors	   at	   different	   stages	   of	   maturation	   in	   miR-­‐155-­‐5p	  
overexpressing	   cells	   compared	   with	   controls	   at	   days	   10	   and	   12	   after	   the	   last	  
nucleofection	   (Figure	  21Av).	  Furthermore,	   the	  study	  was	  aimed	  at	  assessing	  whether	  
miR-­‐155-­‐5p	   downregulation	   in	   PMF	   CD34+	   cells	   could	   reduce	   the	   expansion	   MK	  
lineage.	   First,	   we	   evaluated	   JARID2	   levels	   upon	   miR-­‐155-­‐5p	   silencing,	   observing	   a	  
statistically	  significant	  increase	  at	  24	  and	  48	  hours	  after	  the	  last	  nucleofection	  (Figure	  
21Bi).	   As	   observed	   for	   the	   JARID2	   knockdown,	   miR-­‐155-­‐5p	   overexpression	   led	   to	   a	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significant	   increase	   of	   the	   percentage	   of	   CD41+cells	   at	   days	   10	   and	   12	   after	   the	   last	  
nucleofection	   in	   serum-­‐free	   multilineage	   culture	   (Figure	   21Aii).	   Similar	   results	   were	  
obtained	  under	  unilineageMK	  differentiation	  culture	  conditions	  (Figure	  20Aiii).	  
	  
	  
Fig.	   21:	   Transfection	   of	  miR155-­‐5p	  mimic	   and	   inhibitor	   in	   normal	   and	   PMF	   CD34+	   cells.	   (A)	   Effect	   of	  miR155-­‐5p	  
mimic	  transfection	  on	  normal	  CD34+	  cell	  differentiation.	  (i)	  Expression	  levels	  of	  JARID2	  at	  24	  and	  48	  hours	  after	  the	  
last	  nucleofection,	  measured	  by	  qRT-­‐PCR	  and	  reported	  as	  RQ.	  (ii-­‐iii)	  Results	  of	  statistical	  analysis	  on	  the	  percentage	  
of	   CD41+	   cells	   performed	   by	   flow	   cytometry	   at	   days	   5,	   8,	   10,	   and	   12	   after	   the	   last	   nucleofection	   on	   serum-­‐free	  
multilineage	   and	  MK	   unilineage	   cultures.	   (iv)	   Results	   of	   the	   statistical	   analysis	   of	   the	   collagen-­‐based	   clonogenic	  
assay.	  The	  cells	  were	  plated	  24	  hours	  after	  the	  last	  nucleofection	  and	  scored	  after	  12	  days.	  (v)	  Morphologic	  analysis	  
of	  Neg-­‐mimic	  and	  miR-­‐155-­‐5p	  nucleofected	  cells	  after	  MGG	  staining	  at	  days	  8	  and	  10	  of	  MK	  unilineage	  serum-­‐free	  
liquid	   culture	   after	   the	   last	   nucleofection	   in	   a	   representative	   experiment.	   Values	   are	   reported	   as	   mean	   6	   SEM.	  
**P<0.01	   vs	   Negmimic;*P<0.05	   vs	   Neg-­‐mimic.	   The	   results	   come	   from	   5	   independent	   experiments.	   (B)	   Effect	   of	  
miR155-­‐5p	  downregulation	  in	  PMF	  CD34+	  cells.	  (i)Expression	  levels	  of	  JARID2	  in	  PMF	  CD34+	  cells	  at	  24	  and	  48	  hours	  
after	  the	  last	  nucleofection	  of	  miR-­‐155-­‐5p	  inhibitor.	  The	  JARID2	  expression	  was	  measured	  by	  qRT-­‐PCR,	  and	  data	  are	  
reported	  as	  RQ.	  (ii-­‐iii)	  Percentage	  of	  viable	  CD41+	  cells	  assessed	  by	  flow	  cytometry	  at	  days	  5,	  8,	  and	  10	  after	  the	  last	  
nucleofection	  on	  serum-­‐free	  multilineage	  and	  MK	  unilineage	  cultures.	   (iv)	  Results	  of	   the	  statistical	  analysis	  of	   the	  
collagen-­‐based	   clonogenic	   assay.	   The	   cells	  were	  plated	  24	  hours	   after	   the	   last	  nucleofection	  and	   scored	  after	   12	  
days.	   (v)	  Morphologic	   analysis	  of	  negative	   control	   inhibitor	   (NegINH)	  and	  miR-­‐155-­‐5p	   inhibitor	   treated	   cells	   after	  
MGG	   staining	   at	   days	   8	   and	   10	   of	   MK	   unilineage	   serum-­‐free	   liquid	   culture	   after	   the	   last	   nucleofection	   in	   a	  
representative	   experiment.	   Magnification	   X1000.	   Values	   are	   reported	   as	   mean	   6	   SEM.**P<	   0.01	   vs	   NegINH;	   *P	  
<0.05	  vs	  NegINH.	  The	  results	  come	  from	  4	  independent	  experiments.	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Furthermore,	  the	  collagen-­‐based	  assay	  showed	  that	  miR-­‐155-­‐5p	  overexpression	  causes	  
a	   significant	   increase	   in	   the	   CFU-­‐MK	   percentage	   coupled	   with	   a	   strong	   decrease	   of	  
non-­‐MK	   colonies	   (Figure	   21Aiv).	   Finally,	   the	   morphologic	   analysis	   of	   MGG-­‐stained	  
cytospins	   showed	   a	   remarkable	   enrichment	   in	  MK	   precursors	   at	   different	   stages	   of	  
maturation	  in	  miR-­‐155-­‐5p–overexpressing	  cells	  compared	  with	  controls	  at	  days	  10	  and	  
12	   after	   the	   last	   nucleofection	   (Figure	   21Av).	   Furthermore,	   the	   study	   was	   aimed	   at	  
assessing	  whether	  miR-­‐155-­‐5p	   downregulation	   in	   PMF	   CD34+	   cells	   could	   reduce	   the	  
expansion	  MK	  lineage.	  First,	  it	  was	  evaluated	  JARID2	  levels	  upon	  miR-­‐155-­‐5p	  silencing,	  
observing	   a	   statistically	   significant	   increase	   at	   24	   and	   48	   hours	   after	   the	   last	  
nucleofection	   (Figure	  20Bi).	  Strikingly,	  knockdown	  of	  miR-­‐155-­‐5p	   impaired	   the	  ability	  
of	  PMF	  CD34+	  cells	  to	  give	  rise	  to	  CD41+	  cells,	  in	  both	  multilineage	  and	  MK	  unilineage	  
cultures	   (Figure	  21Bii-­‐iii).	   Those	  observations	  were	   further	   confirmed	  by	  decrease	  of	  
CFU-­‐MK	   colonies	   in	   collagen-­‐based	   assays	   (Figure	   21Biv)	   and	   by	   decrease	   of	   MK	  
progenitors	  in	  MGG-­‐stained	  cytospins	  (Figure	  21Bv).	  	  
	  
5.1.9	  FUNCTIONAL	  VALIDATION	  OF	  THE	  MIR-­‐155-­‐5p/JARID2	  AXIS	  IN	  MK	  
LINEAGE	  EXPANSION	  
	  
In	   order	   to	   demonstrate	   that	  miR-­‐155-­‐5p	   affects	  megakaryocytopoiesis	   by	  means	   of	  
JARID2	   modulation,	   it	   was	   concurrently	   overexpressed	   JARID2	   and	   miR-­‐155-­‐5p	   in	  
normal	  CD34+	  cells.	  To	  this	  aim,	  CB	  CD34+	  cells	  were	  nucleofected	  twice	  with	  miR-­‐155-­‐
5p	   or	  Neg-­‐mimic	   and	   consecutively	   transduced	  with	   the	   retroviral	   vector	   expressing	  
JARID2	   gene	   (LJARID2IΔN)	   or	   empty	   vector	   (LXIΔN)	   (see	   timing	   flowchart	   in	   Figure	  
22Ai).	   To	   assess	   JARID2	   expression,	   qRT-­‐PCR	   was	   performed	   after	   NGFR+	   cell	  
purification	  (Figure	  21Aii).	  As	  shown	  in	  Figure	  21Aiii,	  the	  fraction	  of	  CD41+	  cells	  in	  the	  
MK	  unilineage	  culture	  decreased	   in	  miR-­‐155-­‐5p/LJARID2IΔN	  compared	  with	  miR-­‐155-­‐
5p/LXIΔN	   cells	   at	   days	   4,	   7,	   and	   11	   post	   	   purification.	  Moreover,	   the	   CFU-­‐MK	   assay	  
results	   showed	   that	   JARID2	   overexpression	   in	   miR-­‐155-­‐5p	   cells	   causes	   a	   significant	  
decrease	   in	   the	   CFU-­‐MK	   percentage	   compared	   with	   miR-­‐155-­‐5p/LXIΔN	   cells	   (Figure	  
22Aiv).	   Furthermore,	   to	   confirm	   that	   miR-­‐155-­‐5p–driven	   megakaryopoiesis	   depends	  
on	   JARID2	   mRNA	   levels,	   it	   was	   simultaneusly	   silenced	   miR-­‐155-­‐5p	   and	   JARID2	   in	  
normal	  CD34+	  cells	  (see	  timing	  flowchart	  in	  Figure	  22Bi).	  The	  expression	  level	  of	  JARID2	  
was	  assessed	  by	  qRT-­‐PCR	  at	  48	  hours	  after	  the	  last	  nucleofection	  (Figure	  22Bii).	  Flow	  
cytometric	   analysis	   of	   CD34+	   expression	   performed	   on	   the	  MK	   unilineage	   culture	   at	  
days	  8,	  10,	  and	  12	  after	  the	  last	  nucleofection	  showed	  a	  decrease	  in	  the	  MK	  fraction	  in	  
miR-­‐155-­‐5p-­‐silenced	  cells	  compared	  with	  NegCTR/negative	  control	   inhibitor	  (NegINH)	  
cells	  (Figure	  22Biii).	  As	  expected,	  the	  simultaneous	  JARID2	  knockdown	  could	  rescue	  the	  
MK	  differentiation	  unbalance	  in	  miR-­‐155-­‐5p	  silenced	  cells.	  In	  agreement	  with	  the	  flow	  
cytometry	   data,	   the	   results	   of	   MK	   assay	   highlighted	   that	   the	   concurrent	  
downregulation	   of	   miR-­‐155-­‐5p	   and	   JARID2	   could	   prevent	   the	   impairment	   of	   MK	  
differentiation	   observed	   in	   both	   independently	   silenced	   miR-­‐155-­‐5p	   and	   JARID2	  
samples	  (Figure	  22Biv).	  




	  Fig.	  22:	  Simultaneous	  overexpression	  or	  inhibition	  of	  JARID2	  and	  miR-­‐155-­‐5p	  in	  normal	  CD34+	  cells.	  (A)	  Rescue	  of	  
JARID2	   expression	   in	   miR-­‐155-­‐5p–overexpressing	   cells.	   (i)	   Flowchart	   listing	   the	   experiment	   timing	   (expressed	   in	  
days)	  after	  NGFR+	  cell	  purification.	   (ii)	  Expression	   levels	  of	   JARID2	   in	  CB	  CD34+	  cells	  after	  NGFR+	  cells	  purification.	  
The	  JARID2	  expression	  was	  measured	  by	  qRT-­‐PCR,	  and	  data	  are	  reported	  as	  RQ.	  (iii)	  Percentage	  of	  viable	  CD41+	  cells	  
in	   the	  MK	   unilineage	   culture	   assessed	   by	   flow	   cytometry	   at	   days	   4,	   7,	   and	   11	   after	   NGFR+	   cell	   purification.	   (iv)	  
Results	  of	  the	  statistical	  analysis	  of	  the	  collagen-­‐based	  clonogenic	  assay.	  The	  cells	  were	  plated	  24	  hours	  after	  NGFR+	  
cell	  purification	  and	  scored	  after	  12	  days.	  Values	  are	  reported	  as	  mean	  6	  SEM.	  **P<0.01;	  *P	  <0.05.	  The	  results	  come	  
from	  3	  independent	  experiments.	  (B)	  Simultaneous	  downregulation	  of	  JARID2	  and	  miR155-­‐5p	  in	  CB	  CD34+	  cells.	  (i)	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Flowchart	  reporting	  the	  experiment	  timing	  (expressed	  in	  days)	  after	  the	  last	  nucleofection.	  (ii)	  Expression	  levels	  of	  
JARID2	  in	  CB	  CD34+cells	  at	  48	  hours	  after	  the	  last	  nucleofection.	  The	  JARID2	  expression	  was	  measured	  by	  qRT-­‐PCR	  
and	  data	  are	  reported	  as	  RQ.	  	  
(iii)	  Percentage	  of	  viable	  CD41+	  cells	  in	  the	  MK	  unilineage	  culture	  assessed	  by	  flow	  cytometry	  at	  days	  8,	  10,	  and	  12	  
after	  the	  last	  nucleofection.	  (iv)	  Results	  of	  the	  statistical	  analysis	  of	  the	  collagen-­‐based	  clonogenic	  assay.	  The	  cells	  
were	  plated	  24	  hours	  after	   the	   last	  nucleofection	  and	  scored	  after	  12	  days.	  Values	  are	   reported	  as	  mean	  6	  SEM.	  
**P<	  0.01;	  *P<0.05.	  The	  results	  come	  from	  3	  independent	  experiments.	  
	  
All	   the	   results	   obtained	   in	   this	   first	   part	   of	   study,	   and	   reported	   in	   this	   thesis,	   were	  
published	  in	  Plos	  One:	  Norfo	  R.,	  Zini	  R.,	  Pennucci	  V.,	  Bianchi	  E.,	  Salati	  S.,	  Guglielmelli	  P.,	  
Bogani	   C.,	   Fanelli	   T.,	  Mannarelli	   C.	  et	   al. (2014) miRNA-­‐mRNA	   integrative	   analysis	   in	  
primary	   myelofibrosis	   CD34+cells:	   role	   of	   miR-­‐155/JARID2	   axis	   in	   abnormal	  
megakaryopoiesis.	  Blood.	  2014	  Sep	  25;124(13):e21-­‐32. 
	  
5.2	  	  CHARACTERIZATION	  THE	  NEW	  MIRNA	  AND	  MORNA	  
EXPRESSION	  IN	  CD34+	  CELLS	  OF	  PMF	  PATIENTS.	  
Guglielmelli	  P,	  Bisognin	  A,	  Saccoman	  C,	  Mannarelli	  C,	  et	  al.	  (2015).	  PLoS	  ONE	  10(10):	  
e0140445.	  
	  
5.2.1	  SMALL	  RNA	  EXPRESSION	  IN	  CD34+	  CELLS	  OF	  PATIENTS	  WITH	  PMF.	  
	  
It	   was	   considered	   small	   RNA	   sequencing	   data	   of	   6	   CD34+	   cells	   samples,	   including	   3	  
samples	  collected	  from	  3	  pools	  of	  bone	  marrow	  CD34+	  cells	  of	  healthy	  subjects	  (CTR),	  
and	  3	  samples	  of	  circulating	  CD34+	  cells	  of	  patients	  affected	  by	  primary	  myelofibrosis	  
(PMF),	   two	  of	  which	  were	  from	  individual	  patients	  while	  the	  third	  constituted	  a	  pool	  
obtained	   by	  mixing	   equal	   amounts	   of	   RNA	   from	   4	   PMF	   patients.	   The	   Illumina	   2000	  
sequencing	  produced	  a	  total	  of	  787,	  913,	  722	  raw	  reads	  (131,	  318,	  954	  per	  sample	  on	  
average)	  that	  were	  deposited	  in	  Gene	  Expression	  Omnibus	  (GEO	  Series	  GSE69089).	  
It	  was	  detected	  a	  total	  of	  917	  sRNAs,	  including	  784	  know	  miRNAs,	  expressed	  in	  at	  least	  
one	  of	  the	  6	  considered	  CD34+	  samples.	  Notably,	  8	  known	  miRNAs	  (miR-­‐10a-­‐5p,	  miR-­‐
181a-­‐5p,	  miR-­‐191-­‐5p,	  miR-­‐92a-­‐3p,	   let-­‐7a-­‐5p,	  miR-­‐146b-­‐5p,	  miR-­‐26a-­‐5p	  and	   let-­‐7f-­‐5p)	  
are	   highly	   expressed	   and	   contribute	   to	   the	   total	   miRNA	   expression	   throughout	   all	  
samples	  from	  2.5%	  to	  25%,	  representing	  all	  together	  the	  80%	  of	  the	  total	  expression.	  
Moreover,	   it	  was	  detected	  133	  new	  sRNAs,	   including	  34	  new	  miRNAs	  produced	  from	  
known	  hairpins,	  and	  99	  microRNA-­‐offset	  RNAs	  (moRNAs).	  Table	  25	  reports	  a	  summary	  




	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  	  	  	  	  Tab.	  25:	  Summary	  of	  small	  RNAs	  expressed	  in	  CD34+	  cells.	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Statistical	   analyses	   was	   showed	   that	   patients	   and	   controls	   sRNAs	   profiles	   are	  
significantly	   different	   from	   each	   other	   and	   highlight	   a	   characteristic	   miRNA	   and	  
moRNA	  expression	  profile	  in	  PMF.	  
5.2.2	  NEW	  MIRNAS	  IN	  CD34+	  CELLS	  OF	  PMF.	  
	  
In	  addition	  to	  784	  miRNAs	  annotated	  in	  miRBase,	  our	  in-­‐house	  pipeline	  miR&moRe	  let	  







Position Sequence CTR PMF 
hsa-miR-107* 0 19 - chr10:89592794-89592815 AGCTTCTTTACAGTGTTGCCTT 
hsa-miR-1255a* 7 0 - chr4:101330326-101330346 CTATCTTCTTTGCTCATCCTT 
hsa-miR-1256* 13 29 - chr1:20988343-20988363 CTAAAGAGAAGTCAATGCATG 
hsa-miR-1276* 18 0 - chr15:85770510-85770530 TGTCTCCACTGAGCACTTGGG 
hsa-miR-1284* 6 4 - chr3:71542003-71542021 GAAAGCCCATGTTTGTATT 
hsa-miR-1289-1* 12 7 - chr20:35454037-35454057 TGCAGACTCTTGGTTTCCACC 
hsa-miR-1291* 0 10 - chr12:48654462-48654490 
ACTGTGGCTGTTGGTTTCAAGCAGAG
GCC 
hsa-miR-1294* 0 2 + chr5:154347193-154347213 ACAGTGCCAACCTCACAGGAC 
hsa-miR-1302-




11* 0 1 + chr19:72019-72038 TAGCATAAATATGTCCCAAG 
hsa-miR-1302-2* 0 1 + chr1:30412-30431 TAGCATAAATATGTCCCAAG 
hsa-miR-1302-9* 0 1 + chr9:30190-30209 TAGCATAAATATGTCCCAAG 
hsa-miR-1303* 0 3 + chr5:154685789-154685810 AGCGAGACCTCAACTCTACAAT 
hsa-miR-153-1-
5p 10 19 - 
chr2:219294165-
219294185 GTCATTTTTGTGATCTGCAGC 
hsa-miR-2110* 103 153 - chr10:114174110-114174132 TCACCGCGGTCTTTTCCTCCCAC 
hsa-miR-3155a* 16 7 + chr10:6152207-6152228 CCTCCCACTGCAGAGCCTGGGG 
hsa-miR-3648-1* 0 3 + chr21:8208593-8208617 GTCGGCCGCGCTCGAGGGGTCCCCG 
hsa-miR-3648-2* 0 3 + chr21:8987119-8987143 GTCGGCCGCGCTCGAGGGGTCCCCG 
hsa-miR-421* 0 42 - chrX:74218427-74218448 CTCATTAAATGTTTGTTGAATG 
hsa-miR-4424* 8 21 + chr1:178677801-178677821 GTCCATTTCAAGTTAACTCTG 
hsa-miR-4473* 0 21 - chr9:20411202-20411225 CACTTGTAATGGAGAACACTAAGC 
hsa-miR-451a* 0 4 - chr17:28861384-28861404 TTTAGTAATGGTAATGGTTCT 
hsa-miR-466* 22 0 - chr3:31161754-31161774 TGTGTTGCATGTGTGTATATG 
hsa-miR-548ag-
2* 28 66 + 
chr20:60564601-
60564621 CAAGAACCTCAATTACCTTTG 
hsa-miR-5696* 6 12 + chr2:101309514-101309534 TCAGACTACCTAAATGAGCAC 
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hsa-miR-599* 0 6 - chr8:99536688-99536707 TTTGATAAGCTGACATGGGA 
hsa-miR-600* 5 2 - chr9:123111598-123111618 CATAGGAAGGCTCTTGTCTGT 
hsa-miR-641* 4 6 - chr19:40282557-40282576 TGACTGTCCTATGTCTTTCC 
hsa-miR-7854-5p 6 3 + chr16:81533905-81533926 CTTCCATCTCCATCACCTTGAG 
hsa-miR-941-1* 3 2 + chr20:63919454-63919478 ACATGTGCCCAGGGCCCGGGACAGC 
hsa-miR-941-2* 3 2 + chr20:63919510-63919534 ACATGTGCCCAGGGCCCGGGACAGC 
hsa-miR-941-3* 3 2 + chr20:63919566-63919590 ACATGTGCCCAGGGCCCGGGACAGC 
hsa-miR-941-4* 3 2 + chr20:63919761-63919785 ACATGTGCCCAGGGCCCGGGACAGC 
hsa-miR-941-5* 3 2 + chr20:63919873-63919897 ACATGTGCCCAGGGCCCGGGACAGC 
 
Tab.	  26:	  New	  miRNAs	  discovered	  that	  are	  expressed	  in	  CD34+.	  The	  Table	  reports	  expression	  (per	  sample	  
group	  normalized	  read	  count),	  position	  and	  sequence	  of	  new	  miRNAs.	  
	  
To	   find	   new	   miRNAs,	   it	   was	   considered	   all	   the	   hairpins	   precursors	   annotated	   in	  
miRBase,	   to	   be	   used	   as	   reference	   for	   read	   mapping	   and	   small	   RNA	   detection	   and	  
quantification.	  Some	  of	  the	  listed	  hairpin	  precursors	  were	  known	  to	  only	  generate	  one	  
mature	   miRNA	   with	   only	   a	   handful	   of	   reads	   reported	   in	   miRBase	   across	   all	   NGS	  
experiments	  surveyed.	  After	  identifying	  the	  hairpin	  region	  that	  would	  most	  likely	  pair	  
with	  annotated	  mature	   it	  was	  classified	  as	  new	  miRNAs	  all	   the	  clusters	  of	   reads	   that	  
map	  there.	  A	  consistent	  number	  of	  reads	  were	  attributed	  to	  new	  miRNAs.	  Since	  these	  
reads	  passed	  stringent	  quality	  filtering	  and	  mapping	  criteria,	  it	  is	  improbable	  that	  they	  
originate	  from	  sequencing	  errors.	  Furthermore,	  two	  of	  these	  new	  miRNAs,	  miR-­‐2110*	  
and	  miR-­‐548ag-­‐2*,	  resulted	  highly	  expressed	  and	  showed	  a	  mean	  expression	  over	  the	  
median	  of	  expression	  values	  calculated	  on	  all	  small	  RNAs.	  
5.2.3	  MORNAS	  DISCOVERY.	  
As	  anticipated,	  it	  was	  	  also	  detected	  in	  samples	  sequences	  aligning	  to	  hairpins	  outside	  
known	  and	  novel	  miRNAs,	  that	  correspond	  to	  expressed	  microRNA-­‐offset	  RNAs,	  called	  
moRNAs.	  MoRNAs	  sequences	  partially	  overlap	  miRNA	  regions	  but	  generally	   span	   the	  
Drosha	  cutting	  sites,	   letting	  us	  hypothesize	  a	  non	  canonical	  processing	  of	   the	  hairpin	  
precursor	   in	   moRNA	   biogenesis	   (Bortoluzzi	   et	   al.,	   2012).	   A	   complete	   list	   of	   all	   the	  
detected	  moRNAs	  is	  in	  Table	  27.	  	  
	  
moRNA Read count Strand Position Sequence CTR PMF 
hsa-moR-
101-1-5p 
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hsa-moR-
106b-5p 


















































































































































246 98 - chr19:13836566-13836592 CCGACCCTGAGCTCT
GCCACCGAGGAT 
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hsa-moR-
24-1-5p 
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hsa-moR-
551b-3p 






































































































































9 27 + chr22:46113671-46113689 CAAGGCCGGGCCTGG
CGGG 
	   80	  
hsa-moR-
let-7d-5p 








31 37 + chr12:62603669-62603689 TCCCCGACACCATGG
CCCTGG 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Tab.	  27:	  List	  of	  moRNAs	  expressed	  in	  considered	  CD34+	  samples.	  The	  first	  seven	  moRNAs	  are	  
expressed	  over	  the	  third	  quartile	  of	  all	  sRNAs	  expression.	  
	  
Noteworthy,	   28	  moRNAs	  were	  highly	  expressed,	  26	  of	   them	  over	   the	  median	  of	   the	  
short	  RNAs	  expression	  values	  distribution	  and	  12	  of	  them	  even	  over	  the	  third	  quartile	  
(Table	  28	  ).	  
	  
	  
Tab.	  28.	  List	  of	  most	  abundant	  moRNAs	  in	  considered	  CD34+	  samples,	  which	  are	  expressed	  	  
over	  the	  third	  quartile	  of	  all	  sRNAs	  expression.	  
	  
It	   was	   classified	   moRNAs	   on	   the	   basis	   of	   the	   hairpin	   precursor	   arm	   they	   where	  
processed	  from:	  5’-­‐moRNAs	  mapping	  to	  the	  5’	  hairpin	  arm,	  and	  3’-­‐moRNAs	  spanning	  
over	   the	   3’	   hairpin	   arm.	   5’	   -­‐moRs	   were	   significantly	   more	   abundant	   respect	   to	   3’	   -­‐
moRs.	  Out	  of	  99	  
moRNAs	  expressed	  in	  considered	  samples,	  only	  16	  (16.2%)	  were	  processed	  from	  the	  3’	  	  
hairpin	   arm,	  while	   83	   (83.8%)	  were	   5’	   -­‐moRs.	   According	   to	   our	   data,	   seven	   hairpins	  
were	   processed	   producing	   two	  moRNAs	   each.	   5’-­‐moRs	   estimated	   expression	   values	  
were	  10	  times	  higher	  than	  3’-­‐moRs,	  ranging	  from	  summed	  up	  normalized	  values	  over	  
all	  samples	  of	  5	  to	  40,739,	  compared	  to	  a	  3’-­‐moRs	  range	  of	  6	  to	  7,478.	  Both	  3’-­‐moRs	  
and	  5’-­‐moRs	  are	  more	  expressed	  in	  controls	  than	  in	  PMF	  patient	  samples.	  Considering	  
the	  9	  most	  expressed	  moRNAs,	  Fig	  23	  A	  shows	  expression	  estimations	  in	  PMF	  and	  CTR	  
samples	   of	   all	   the	   expressed	   small	   RNAs	   that	   are	   produced	   from	   the	   same	   hairpins	  
precursor.	  Specific	  hairpins,	  as	  hsa-­‐mir-­‐421	  and	  hsa-­‐mir-­‐941-­‐1,	   reported	   in	  Fig	  23	  A	   ,	  
express	  two	  moRNAs	  each.	  
	  




Fig.23	   :	  A)	  Expression,	   in	  CD34+	  cells	  of	  PMF	  patients	  and	  controls,	  of	  miRNAs	  and	  moRNAs	  produced	  
from	   the	   same	   hairpin,	   considering	   the	   hairpins	   expressing	  most	   abundant	  moRNAs;	   the	   box	   plot	   in	  
panel	   (B)	  shows	  the	  distribution	  of	  Pearson	  correlation	  values	  calculated	  pairwise	  between	  expression	  
profiles	  of	  moRNAs	  and	  miRNAs	  produced	  from	  the	  same	  hairpin	  arm,	  considering	  all	  moRNAs	  detected	  
in	  CD34+	  cells.	  
	  
Considering	  the	  miRNA	  and	  the	  moRNA	  produced	  from	  the	  same	  hairpin	  arm,	   it	  was	  
noted	  that	  in	  4	  out	  the	  9	  reported	  in	  Fig	  23	  A	  the	  moRNA	  is	  more	  expressed	  than	  the	  
miRNA	  and	   in	   one	   the	  miRNA	   close	   to	   the	  moRNA	   is	   not	   detected	   at	   all.	  Moreover,	  
some	  hairpins	  show	  a	  similar	  trend	  toward	  up-­‐	  or	  down-­‐regulation	  for	  both	  the	  miRNA	  
and	  the	  moRNA,	  whereas	  in	  others	  the	  two	  sRNAs	  show	  opposite	  behavior.	  It	  was	  then	  
compared	   the	  expression	  behavior	  of	   all	   expressed	  moRNAs	  with	   that	  of	   the	  miRNA	  
coming	  from	  the	  same	  hairpin	  arm.	  The	  boxplot	  in	  Fig	  23	  B	  shows	  the	  distribution	  of	  93	  
Pearson	  correlation	  values	  calculated	  pairwise	  between	  expression	  profiles	  of	  detected	  
moRNAs	  and	  miRNAs	  from	  the	  same	  hairpin	  arm:	  the	  values	  range	  from	  -­‐0.93	  to	  +1,	  
with	   median	   and	   mean	   values	   of	   0.17	   and	   0.21,	   indicating	   a	   very	   slight	   tendency	  
toward	  positive	  correlation,	  the	  presence	  of	  abundant	  anticorrelated	  pairs	  (36,38.7%).	  
Considering	   the	   statistical	   significance	   of	   correlation,	   only	   7	   pairs	   (7.5%)	   resulted	  
significantly	   correlated	   (with	   a	   q-­‐value	   at	   most	   0.1);	   since	   they	   include	   an	  
anticorrelated	  pair	   (5’	  moR-­‐93	  and	  miR-­‐93-­‐5p)	  and	  do	  not	  overlap	  with	   the	  group	  of	  
highly	  expressed	  moRNAs,	  it	   is	  possible	  to	  conclude	  that	  moRNA	  expression	  is	   largely	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independent	  from	  that	  of	  the	  close	  miRNA.	  Even	  if	  moRNAs	  mechanism	  of	  action	  is	  still	  
unknown,	   their	   considerable	   high	   expression	   level	   in	   this	   dataset	   together	   with	  
previously	   reported	   observations	   (Bortoluzzi	   et	   al.,	   2012;	   Gaffo	   et	   al.,	   2014;	  
Langenberger	   et	   al.,	   2009)	   offers	   an	   indirect	   but	   intriguing	   indication	   of	   a	   biological	  
role.	  
5.2.4	  IDENTIFICATION	  OF	  sRNA	  DIFFERENTIALLY	  EXPRESSED	  IN	  PMF	  vs	  
CTR.	  
It	  was	   recognized	   37	   sRNAs	   significantly	   differentially	   expressed	   (DE)	   in	   PMF	  patient	  
samples	  respect	  to	  control	  CD34+	  (Table	  29).	  	  
	  









hsa-miR-1185-5p 0 136 15.00 1.24E-05 6.98E-04 
hsa-miR-127-5p 0 317 15.00 4.66E-07 7.01E-05 
hsa-miR-1277-5p 0 98 15.00 1.53E-04 6.28E-03 
hsa-miR-299-3p 0 210 15.00 1.78E-04 6.69E-03 
hsa-miR-323a-3p 0 121 15.00 5.34E-03 7.29E-02 
hsa-miR-377-3p 0 206 15.00 9.34E-04 1.92E-02 
hsa-miR-377-5p 0 155 15.00 8.32E-06 6.25E-04 
hsa-miR-379-3p 0 89 15.00 2.76E-04 9.56E-03 
hsa-miR-382-5p 0 205 15.00 2.97E-04 9.56E-03 
hsa-miR-431-3p 0 80 15.00 1.72E-03 3.11E-02 
hsa-miR-490-3p 0 719 15.00 2.48E-03 3.99E-02 
hsa-miR-539-3p 0 204 15.00 1.37E-03 2.58E-02 
hsa-miR-543 0 262 15.00 4.64E-04 1.40E-02 
hsa-miR-654-5p 0 99 15.00 6.37E-04 1.60E-02 
hsa-miR-656 0 78 15.00 8.90E-04 1.91E-02 
hsa-miR-665 0 317 15.00 2.67E-03 4.15E-02 
hsa-miR-758-3p 0 171 15.00 3.04E-03 4.56E-02 
hsa-miR-873-5p 0 211 15.00 6.57E-04 1.60E-02 
hsa-miR-25-3p 37 226192 12.59 2.85E-27 1.29E-24 
hsa-miR-29a-3p 206 44817 7.77 6.73E-04 1.60E-02 
hsa-miR-136-5p 34 1516 5.47 1.24E-04 5.57E-03 
hsa-miR-495-3p 8 281 5.09 6.43E-04 1.60E-02 
hsa-miR-873-3p 7 239 5.04 5.15E-03 7.27E-02 
hsa-miR-485-5p 12 353 4.84 1.17E-03 2.30E-02 
hsa-miR-19b-3p 3795 99173 4.71 7.13E-07 8.03E-05 
hsa-miR-432-5p 14 343 4.62 2.09E-03 3.62E-02 
hsa-5'-moR-542 9 232 4.62 6.72E-03 8.66E-02 
hsa-miR-379-5p 31 561 4.16 7.86E-03 9.58E-02 
hsa-miR-19a-5p 15 265 4.16 5.16E-03 7.27E-02 
hsa-miR-33b-5p 26 394 3.90 6.09E-03 8.08E-02 
hsa-miR-1307-5p 779 10914 3.81 8.23E-04 1.86E-02 
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hsa-miR-142-3p 5954 33867 2.51 7.73E-03 9.58E-02 
hsa-miR-3150b-3p 196 7 -4.90 2.23E-03 3.73E-02 
hsa-miR-10b-5p 11950
4 
2855 -5.39 2.15E-08 4.84E-06 
hsa-3'-moR-128-2 2489 0 -15.00 1.15E-05 6.98E-04 
hsa-miR-128-2* 102 0 -15.00 1.87E-05 9.36E-04 
hsa-miR-5008-3p 149 0 -15.00 4.17E-06 3.76E-04 
 
Tab.	  29:	  miRNAs	  and	  moRNAs	  significantly	  differentially	  expressed	  (DE)	  in	  PMF	  patient	  respect	  	  
to	  control	  CD34+,	  according	  to	  RNA-­‐seq	  data.	  
	  
	  
Fig	  24	  A	  shows	  the	  logarithm	  of	  the	  mean	  expression	  ratio	  in	  PMF	  and	  control	  cells	  for	  
DE	  miRNAs	  and	  moRNAs.	  While	  only	  five	  small	  RNAs	  are	  downregulated,	  the	  majority	  
of	   DE	   sRNAs	   resulted	   upregulated	   in	   PMF	   patients.	   Noteworthy,	   among	   the	  
differentially	   expressed	   sRNAs,	   2	   moRNAs	   (5’	   -­‐moR-­‐542	   and	   3’	   -­‐	   moR-­‐128-­‐2)	   are	  
included.	   Incidentally,	   the	   two	   miRNAs	   (miR-­‐542-­‐5p	   and	   miR-­‐128-­‐3p)	   that	   are	  
produced	   by	   the	   same	   hairpin	   arm	   of	   differentially	   expressed	   moRNAs	   are	   not	  
differentially	  expressed	  in	  the	  same	  sample	  comparison.	  5’	  -­‐moR-­‐542	  is	  up-­‐regulated	  in	  
PMF	  with	  a	  log2	  FC	  of	  3.5.	  3’-­‐moR-­‐128-­‐2	  is	  highly	  expressed	  in	  normal	  CD34+	  cells,	  at	  
levels	   over	   the	   third	   quartile	   of	   the	   overall	   small	   RNA	   expression	   distribution,	   and	  
dramatically	   downregulated	   in	   PMF	   patients:	   the	   moRNA	   was	   not	   detected	   in	  
considered	  PMF	  samples.	  It	  was	  mapped	  3’	  -­‐moR-­‐128-­‐2	  sequence	  to	  the	  whole	  human	  
genome	   to	   exclude	   multiple	   matching	   loci	   and	   to	   rule	   out	   mapping	   or	   annotations	  
artifacts.	   Thus,	   It	   was	   possible	   to	   exclude	   that	  moRNA-­‐associated	   reads	   could	   come	  
from	   different	   or	   contaminating	   RNAs.	   An	   additional	   UCSC	   Blat	   (Kent	   et	   al.,	   2002)	  
analysis	   confirmed	   that	   the	  moRNA	  sequence	  only	  aligned	   to	  a	   single	  genomic	   locus	  
(chr3:35786042–	  35786062).	  It	  is	  therefore	  confident	  that	  the	  detected	  small	  RNA	  is	  a	  





	   84	  
	  
	  
Fig	   24:	   Differential	   expression	   of	   small	   RNAs	   in	   PMF	   vs	   CTR	   CD34+.	   A)	   Log2	   FC	   of	   37	   small	   RNA	   differentially	  
expressed	   considering	   PMF	   vs	   CTR	   CD34+,	   according	   to	   RNA-­‐seq	   data	   (FDR<0.05).	   When	   a	   small	   RNA	   was	   not	  
expressed	  in	  one	  sample	  category,	  the	  ratio	  was	  infinite	  and	  we	  represent	  it	  as	  the	  arbitrary	  maximum	  value	  of	  15.	  
B)	  RT-­‐PCR	  expression	  calculation	  of	  five	  selected	  miRNAs	  in	  granulocytes	  collected	  from	  an	  independent	  cohort	  of	  
normal	  controls	   (n	  =	  10)	  and	  of	  PMF	  (50)	  samples;	  ***,	  **	  and	  *	   indicate	  respectively	  a	  P	  value	  <0.001,	  <0.01	  or	  
<0.05.	  
	  
5.2.5	  VALIDATIONS	  OF	  SELECTED	  DIFFERENTIALLY	  EXPRESSED	  MIRNAS	  IN	  	  	  	  	  
PMF	  GRANULOCYTES.	  	  
It	   was	   selected	   the	  most	   significantly	   deregulated	   and	   highly	   expressed	  miRNAs	   for	  
further	   analysis.	   Specifically,	   it	   was	   considered	   6	   miRNAs	   among	   the	   differentially	  
expressed	   for	   a	  quantification	  with	  Real-­‐time	  PCR	   (RT-­‐PCR)	   in	   granulocytes	   collected	  
from	  an	   independent	  and	   sizeable	   cohort	  of	  normal	   controls	   (N	  =	  10)	   and	  PMF	   (N	  =	  
50),	   PV	   (N	   =	   30)	   or	   ET	   (N	   =	   30)	   patients.	   miR-­‐10b-­‐5p	   and	   moR-­‐128-­‐2	   resulted	  
significantly	   downregulated	   in	   PMF	   granulocytes	   samples,	   as	   according	   to	   RNA-­‐seq	  
data	  in	  CD34+	  cells	  (Figs	  24B	  	  and	  25B	  ).	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Fig.	  25:	  Differential	  expression	  of	  3’-­‐moR-­‐128-­‐2	  in	  PMF	  (n	  =	  3)	  vs	  CTR	  (3)	  cells.	  A)	  moR	  expression	  in	  PMF	  
and	  CTR	  CD34+	  according	  to	  RNA-­‐seq	  data.	  B)	  RT-­‐PCR	  expression	  (RQ)	  in	  CD34+	  cells	  from	  independent	  
cohort	  of	  normal	  controls	  (n	  =	  8)	  and	  of	  PMF	  (n=20)	  samples.	  C)	  RT-­‐PCR	  expression	  (RQ)	  in	  granulocytes	  
from	  independent	  cohort	  of	  normal	  controls	  (n	  =	  10)	  and	  of	  PMF	  (50)	  samples;	  ***,	  **	  and	  *	   indicate	  
respectively	  a	  P	  value	  <0.001,	  <0.01	  or	  <0.05.	  
	  
Two	   additional	  miRNAs	   (miR-­‐379-­‐5p	   and	  miR-­‐543)	   showed	   in	   PMF	   granulocytes	   the	  
same	  trend	  toward	  upregulation	  in	  PMF	  granulocytes	  (	  Fig.	  24B	  )	  as	   in	  CD34+	  cells	  by	  
RNA-­‐seq	  data.	  Both	  miR-­‐29a-­‐3p	  and	  miR-­‐19b-­‐3p	  resulted	  significantly	  downregulated	  
in	  PMF	  granulocytes	  (Fig	  24B	  ).	  Furthermore,	  among	  the	  six	  small	  RNAs	  considered	  for	  
validation	  in	  PMF	  granulocytes,	  5	  showed	  the	  same	  trend	  of	  changes	  also	  in	  ET	  or	  PV	  
granulocytes,	   whereas	   miR-­‐543	   resulted	   upregulated	   in	   PMF	   and	   ET,	   and	  
downregulated	  in	  PV,	  with	  small	  variations.	  miR-­‐379-­‐5p	  was	  upregulated	  in	  ET	  and	  in	  
PV,	  as	  in	  PMF;	  miR-­‐543	  was	  slightly	  increased	  in	  ET,	  as	  in	  PMF,	  but	  not	  in	  PV;	  miR-­‐19b-­‐
3p	  and	  moR-­‐128-­‐2	  showed	  a	  similar	  trend,	  being	  decreased	  both	  in	  ET	  and	  in	  PV,	  but	  at	  
a	  lower	  extent	  than	  in	  PMF;	  miR-­‐10b-­‐5p	  was	  decreased	  in	  ET	  and	  in	  PV,	  also	  more	  than	  
in	  PMF.	  Notably,	  considering	  the	  statistical	  significance	  of	  the	  observed	  variation,	  miR-­‐
10b-­‐5p	   is	   significantly	  downregulated	  both	   in	  PV	  and	  ET	  samples,	   indicating	   that	   it	   is	  
associated	  with	  MPN	  in	  general	  more	  than	  being	  specific	  for	  PMF.	  
5.2.6	  VALIDATION	  OF	  POTENTIAL	  mRNA	  TARGETS.	  
Bioinformatics	   predictions	   yielded	   several	   hundreds	   putative	   target	   genes	   for	   each	  
selected	  small	  RNA	  (moR-­‐128-­‐2,	  miR-­‐379-­‐5p,	  miR10b-­‐5p,	  miR-­‐19b-­‐3p,	  miR-­‐29a-­‐3p	  and	  
miR-­‐543).	  
Because	  only	  a	  few	  predicted	  targets	  have	  been	  experimentally	  validated	  in	  vitro	  or	  in	  
vivo,	  and	  in	  order	  to	  narrow	  the	  analysis	  to	  a	  manageable	  number	  of	  variables,	  it	  was	  
choose	   to	   focus	   on	   possible	   targets	   eventually	   selected	   based	   on	   their	   potential	  
pathogenetic	   role	   in	   PMF.	   TaqMan®	   assays	   were	   carried	   out	   for	   18	   putative	   target	  
genes	   in	  an	   independent	  cohort	  of	  CD34+	  cells	   from	  20	  PMF	  patients	  and	  10	  healthy	  
subjects	  (Table	  30).	  Using	  real-­‐time	  RT-­‐PCR,	  it	  was	  founded	  that	  TNSF10,	  MME,	  TCF4,	  
TRPS1	   and	   SYS1	  were	   all	   significantly	   reduced	   in	   PMF	  CD34+	   compared	  with	   healthy	  
controls,	  whereas	  BRCA1	  and	   FKBP10	  were	   increased.	  Other	   genes,	   probably	   due	   to	  
the	   limited	  number	  of	   samples,	  did	  not	   reach	  a	   statistically	   significant	  difference	  yet	  
they	  showed	  the	  expected	  trend	  of	  expression	  changes.	   In	  particular,	   it	  was	  founded	  
that	  MECOM,	  MEIS1,	  AGO1,	  AGO3,	  RAN,	  CAV1,	  AKR1C1,	  TIMP3,	  FSTL1	  were	  increased	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in	  CD34+	  of	  PMF	  patients	  compared	  with	  normal	  subjects,	  while	  JAKMIP2	  and	  PTPN4	  
were	  reduced.	  
According	  to	  miRNAs	  expression	  levels,	  and	  considering	  only	  significantly	  differentially	  
expressed	  genes,	  an	  opposite	  behavior	  of	  expression	  variation	  was	  found	  for	  miR-­‐379-­‐
5p	   and	  MME,	   TCF4	   and	   SYS1;	  miR-­‐19b-­‐3p	   and	  miR-­‐543	  with	   TRPS1.	  Moreover,	  miR-­‐
10b-­‐5p	  and	  FSTL1	  showed	  opposite	  behavior	  and	  5	  tested	  genes	  (AGO1,	  RAN,	  MECOM,	  
MEIS1,	  and	  CAV1)	  putative	   targets	  of	  moR-­‐128-­‐2	   showed	  a	   trend	   toward	   increase	   in	  
PMF,	   opposite	   to	   the	   moRNA.	   Table	   30	   reports	   results	   of	   mRNA	   expression	   tests,	  
indicating,	  for	  each	  miRNA-­‐mRNA	  pair,	  if	  the	  observed	  variations	  are	  in	  the	  same	  or	  in	  
the	  opposite	   sense.	  However,	   before	  one	   can	   reliably	   conclude	   that	   these	  predicted	  
interactions	   do	   play	   a	   role	   in	   PMF	   cell	   abnormalities	   and	   disease	   pathogenesis,	  
functional	  studies	  of	  miRNA	  modulation	  will	  be	  required.	  
	  
	  
Tab.	  30.	  Expression	  pattern	  of	  18	  mRNAs	  potentially	  targeted	  by	  miRNAs,	  according	  to	  qRT-­‐PCR	  data.	  For	  each	  mRNA,	  miRNA	  and	  
moRNA,	  it	  was	  report	  if	  it	  is	  increased	  (I)	  or	  decreased	  (D)	  in	  the	  PMF	  vs	  CTR	  sample	  comparison;	  the	  mRNAs	  p-­‐values	  associated	  
to	  a	   significant	  difference	  are	   listed;	   the	   last	   column	   indicates	   if	   the	  expression	  of	  observed	   target	  mRNA	  variation	   is	   inversely	  
related	  to	  the	  corresponding	  miRNA	  or	  moRNA.	  
	  
All	  the	  results	  obtained	  in	  this	  second	  part	  of	  study,	  and	  reported	  in	  this	  thesis,	  were	  
published	  in	  Plos	  One:	  Guglielmelli	  P,	  Bisognin	  A,	  Saccoman	  C,	  Mannarelli	  C,	  Coppe	  A,	  
Vannucchi	  AM,	  et	  al.	  (2015).	  Small	  RNA	  Sequencing	  Uncovers	  New	  miRNAs	  and	  
moRNAs	  Differentially	  Expressed	  in	  Normal	  and	  Primary	  Myelofibrosis	  CD34+	  Cells.	  PLoS	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5.3	  EVALUATION	  OF	  PLASMA	  MIRNAS	  EXPRESSION	  PROFILE	  IN	  
PMF	  PATIENTS.	  
	  	  	  	  	  	  	  	  	  	  	  
5.3.1	  MIRNAS	  EXPRESSION	  PROFILE	  IN	  PLASMA	  SAMPLES.	  
	  
It	  was	  analyzed	  the	  expression	  of	  175	  miRNAs	  in	  RNA	  plasma	  samples	  collected	  from	  
25	   patients	   with	   PMF	   and	   6	   healthy	   donors	   (Table	   31).	   The	   miRNA	   detection	  
experiments	   were	   performed	   by	   qRT-­‐PCR	   on	   Serum/Plasma	   Focus	   microRNA	   PCR	  
Panel.	  	  
	  
Variable	   Value	  
	  Number	  PMF	   Total	   25	  
Sex	   Male	   18	  
Female	   7	  
Age	  (yrs)	  at	  diagnosis:	  median	  (range)	   65	  (38-­‐86)	  
Leukocyte	  count	  	  x	  109/L	  :	  median	  (range)	   8,08	  (2,05-­‐37)	  
Hemoglobin	  	  g/L:	  median	  (range)	   10,40	  (16-­‐48,4)	  
Platelets	  x	  109/L:	  median	  (range)	   296,5	  (65-­‐1199)	  
Blasts	  (%):	  median	  (range)	   1	  (0-­‐8)	  
Splenomegaly	  
(n=23)	  
Non	  palpable	   5	  
palpable	  <	  20	  cm	   12	  
palpable	  >	  20	  cm	   6	  
	  	  	  	  	  	  	  	  	  	  	  	  	  
Bone	  marrow	  
fibrosis	  grade	  at	  
diagnosis	  (N=24)	  
	  
1	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  9	  
2	   9	  
3	   6	  
	  	  	  	  	  	  	  	  	  	  	  	  	  IPSS	  
	  	  	  	  	  	  	  	  	  	  	  (n=25)	  
Total	   25	  
low	  risk	   3	  
intermediate	  risk	  1	   8	  
intermediate	  risk	  2	   5	  
intermediate	  risk	  3	   9	  
Abnormal	  Karyotype	   12	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Median	  JAK2V617F	  Allele	  burden	  %	  (range)	   50(	  0-­‐100)	  
JAK2	  mutants	   12	  
MPL	  mutants	   1	  
IDH1/2	  mutants	   2	  
DNMT3A	  mutants	   1	  
ASXL1	  mutants	   7	  
EZH2	  mutants	   2	  
SRSF2	  mutants	   3	  
CALR	  mutants	   6	  
Constitutional	  sintoms	   15	  
LAM	   2	  
Deads	   14	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Tab.31:	  Laboratory	  and	  clinical	  parameters	  of	  25	  patients.	  
	  
	   	  
	  Fig.	  26:	  	  miRnas	  resulted	  differentially	  expressed	  in	  PMF	  patients	  plasma	  compared	  to	  the	  controls.	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It	  was	  	  identified	  differentially	  expressed	  miRNAs	  but	  only	  6	  of	  them	  were	  statistically	  
different	   (P	   value<0.05):	   miR-­‐let7b*,	   miR-­‐10b-­‐5p,	   miR-­‐424	   and	   miR-­‐99a	   were	   up-­‐
regulated	   while	   miR-­‐144*	   and	   miR-­‐375	   were	   down-­‐regulated	   in	   PMF	   patients	  
compared	  to	  the	  controls	  (Fig.	  26).	  	  Of	  interest,	  miR-­‐99a	  and	  miR-­‐144*	  were	  reported	  	  
to	  be	  deregulated	  in	  granulocytes	  of	  PMF	  patients	  (Guglielmelli	  et	  al.,2007).	  
	  
	  
5.3.2 CORRELATION	  BETWEEN	  MUTATIONAL	  STATUS,	  PHENOTYPIC	  
CHARACTERISTICS	  	  AND	  MIRNA	  EXPRESSION.	  
 
From	   analysis	   of	   mutational	   status	   in	   this	   group	   of	   patients	   it	   was	   found	   12	   (48%)	  
mutated	   In	   JAK2	   gene,	   1	   (4%)	   in	  MPL,	   2	   (8%)	   in	   EZH2,	   7	   (28%)	   in	   ASXL1,	   2	   (8%)	   in	  
IDH1/2,	   3	   (12%)	   in	   SRSF2	   and	   6	   (24%)	   in	   CALR	   (Table	   31).	   Comparing	   miRnas	   and	  
mutational	   status	   of	   this	   genes	   we	   observed	   that	   there	   is	   a	   significative	   correlation	  
only	  between	  the	  variation	  of	  miR-­‐let-­‐7b*	  expression	  and	  ASXL1	  mutational	  status,	  in	  
fact	  patients	  with	  ASXL1	  mutation	  seem	  to	  have	  also	  greater	  expression	  of	  miR-­‐let-­‐7b*	  
than	  ASXL1	  non-­‐mutated	  (Fig.	  27).	  	  
	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Fig.	  27:	  ASXL1	  mutational	  status	  in	  relation	  to	  miR-­‐let7b*	  expression.	  
	  
Also,	   comparing	   miRNAs	   and	   clinical	   data	   it	   was	   found	   that	   BM	   fibrosis	   grade	  
correlated	   with	   miR-­‐let7b*,	   miR-­‐10b-­‐5p	   and	   miR-­‐144*(P=	   0.04,	   0.02	   and	   0.02	  
respectively)	  (Fig.28):	  in	  particular,	  increased	  expression	  	  of	  miR-­‐let7b*	  ad	  miR-­‐10b-­‐5p	  
appears	  to	  be	  associated	  with	  a	  lower	  grade	  of	  fibrosis,	  on	  the	  contrary,	  the	  decreased	  
expression	  of	  mir-­‐144*	  appears	  to	  be	  associated	  with	  a	  BM	  fibrosis	  grade	  3.	  
	  
	  






Fig.28:	   Correlation	   between	   BM	   Fibrosis	   grade	   with	   miR-­‐let7b*(A),	   miR-­‐10b	   (B)	   and	   miR-­‐144*(C)	  
expression.	  
	  
Also,	   an	   abnormal	   karyotype	   was	   associated	   with	   miR-­‐let7b*(p=0.04),	   miR-­‐424	  
(p=0.001)	  and	  miR-­‐99a	  (p=0.003):	  in	  particular,	  high	  levels	  of	  expression	  of	  these	  three	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Fig.29:	   Correlation	   between	   abnormal	   Kariotipe	   and	   miR-­‐let7b*	   (A),	   miR-­‐424	   (B)	   and	   miR-­‐99a	   (C)	  
expression.	  
	  
Finally,	  the	  platelet	  count	  correlated	  directly	  only	  with	  miR-­‐144*	  and	  miR-­‐375	  (p=0.03	  
and	  0.02	   respectively):	   a	   lower	  expression	  of	   these	  miRnas	  appears	   to	  be	  associated	  




Fig.	  30:	  Correlation	  between	  plateled	  count	  and	  expression	  of	  miR-­‐144*(A)	  and	  miR-­‐375	  (B).	  
	  
	  
Progression	  to	  acute	  leukemia	  was	  observed	  in	  2	  (8%)	  patients	  and	  14	  (56%)	  patients	  
was	   died	   but	   no	   impact	   of	   miRnas	   differentially	   expression	   on	   OS	   and	   leukemia	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5.4	  MIRNAS	  EXPRESSION	  PROFILE	  IN	  JAK2V617F	  KI	  MOUSE	  
MODEL.	  
5.4.1	  STUDY	  OF	  MIRNAS	  PROFILE	  IN	  GR1+	  E	  TER119+	  CELLS.	  
	  
In	   order	   to	   clarify	   the	   contribution	   of	   miRNAs	   to	   the	   pathogenesis	   of	   JAK2V617F-­‐
positive	  MPNs,	   it	  was	  analysed	  the	  miRNAs	  expression	  pattern	  in	  erythroid	  (TER119+)	  
and	  mieloid	  (GR1+)	  cells	  purified	  from	  BM	  of	  JAK2V617F	  knock-­‐in	  (L2)	  mouse	  model	  (2	  
KI	   and	   2	   WT)	   mice	   by	   using	   a	   combination	   of	   immunomagnetic	   and	   cell	   sorting	  
approaches	  (Figure	  31	  A	  and	  B).	  
	  
	   	  
Fig.	  31:	  Flow	  cytometry	  data	  plots	  of	  A)	  TER119+and	  B)	  GR1+.	  
	  
Only	   samples	   with	   a	   purity	   greater	   than	   90%	   were	   analyzed.	   In	   order	   to	   obtain	  
sufficient	  quantity	  of	  miRNA	  for	  subsequent	  analysis	   it	  was	  necessary	  to	  extract	  total	  
RNA	   from	   both	   L2	   (TER119+and	   GR1+)	   cells	   and	   L-­‐	   (TER119+and	   GR1+).Total	   RNA	  
fraction	   was	   used	   to	   determine	   the	   RNA	   Integrity	   Number	   (RIN),	   which	   was	   in	   the	  
range	   of	   7.4	   to	   9.6,	   and	   to	   assess	   RNA	   concentration	   and	   rRNA	   ratio	   [28	   s/18	   s]	   by	  
means	  of	  a	  bioanalyzer	  (Agilent®).	  
Once	  samples	  passed	  this	  quality	  control,	  the	  analysis	  of	  micro-­‐RNA	  expression	  profile	  
was	   performed	   by	   miRCURY	   LNA™	   Universal	   RT	   microRNA	   PCR	   KIT	   (Exiqon®)	   that	  
includes	  384	  miRNAs	  covering	  most	  well-­‐characterized	  miRNAs	  in	  the	  miRNA	  Registry	  
v14	  (http://microrna.sanger.ac.uk).	  It	  was	  performed	  an	  initial	  data	  analysis	  using	  the	  
software	  supplied	  with	  the	  real-­‐time	  PCR	  instrument	  to	  obtain	  raw	  Ct	  values.	  Then	  the	  
statistical	  analysis	  of	  results	  was	  carried	  out	  with	  the	  collaboration	  of	  the	  bioinformatic	  
group	  of	  Biology	  Department	  of	  University	  of	  Padova,	  under	   the	  supervision	  of	  Dr	  S.	  
Bortoluzzi	   (AGIMM).	   It	   was	   identified	   a	   list	   of	   differentially	   expressed	   miRNAs:	   64	  
differentially	  modulated	  in	  TER119+	  (6	  up-­‐and	  58	  down-­‐regulated)	  and	  66	  in	  GR1+	  (44	  
up-­‐and	  and	  22	  down-­‐regulated)	  (Fig.32).	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Fig.32:	  miRnas	  resulted	  differenzially	  expressed	  in	  First	  analysis	  In	  TER119+	  (A)	  and	  In	  GR1+	  (B)	  cells.	  
	  
	  
	  5.4.2	  VALIDATION	  OF	  THE	  SELECTED	  MIRNAS. 
 
Among	   them,	   the	  most	   differentially	   expressed	  were	   selected	   for	   validation:	   5	  were	  
up-­‐regulated	   (miR-­‐147-­‐3p,	   miR-­‐15-­‐5p,	   193a-­‐3p,	   miR-­‐7a-­‐5p,	   291b-­‐5p)	   and	   7	   down-­‐
regulated	   (miR-­‐29b-­‐3p,	  miR-­‐467b-­‐5p,	  miR-­‐150-­‐5p,	  miR-­‐28a-­‐5p,	  miR-­‐592-­‐5p,	  miR-­‐484,	  
miR-­‐10a)	  (Table	  32).	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Tab.	  32:	  mRnas	  selected	  for	  the	  validation	  phase,	  relative	  chomosome	  location	  and	  expression.	  
Pink	  boxes:	  up-­‐regulated	  miRnas;	  Blu	  boxes:	  down-­‐regulated.	  
	  
	  
Therefore,	   the	   expression	   level	   of	   selected	  miRNAs	  was	   evaluated	   in	   the	   same	   cells	  
type	  of	  5	  JAK2V617F	  KI	  and	  5	  JAK2	  WT	  mice	  by	  TaqMan®	  miRna	  assays.	  
It	  was	  confirmed	  up-­‐regulation	  of	  miR-­‐7a-­‐5p	  and	  miR-­‐291b-­‐5p	  and	  down-­‐regulation	  of	  
miR-­‐150-­‐5p	   in	  GR1+;	   in	   TER119+,	   up-­‐regulation	   of	  miR-­‐7a-­‐5p	   and	   down-­‐regulation	   of	  
miR-­‐150-­‐5p	  and	  miR-­‐592-­‐5p	  (Table	  33).	  
	  
	  
	  Tab	  33:	  MiRnas	  confirmed	  up	  and/or	  down	  regulated	  in	  the	  validation	  phase.	  nd:	  no	  different	  expression.	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Moreover,	  in	  not-­‐validated	  miRNAs	  it	  was	  found	  significant	  up-­‐regulation	  of	  miR-­‐147-­‐
3p,	  miR-­‐467-­‐5p	  in	  TER119+	  and	  of	  miR-­‐193-­‐3p,	  miR-­‐28a-­‐5p,	  miR-­‐484	  and	  miR-­‐10a-­‐5p	  in	  
GR1+.	   Only	   2	   differentially	   expressed	   miRNAs	   were	   shared	   by	   both	   erythroid	   and	  
myeloid	   cells	   (miR-­‐7a-­‐5p	   and	   miR-­‐150-­‐5p,	   up	   and	   down-­‐regulated	   respectively),	  
suggesting	  a	  direct	  relationships	  between	  these	  miRNAs	  and	  JAK2V617F.	  
	  
5.4.3	  MIRNAS	  TARGET	  PREDICTION	  ANALYSIS.	  
Potential	   mRNA	   targets	   were	   predicted	   in	   silico	   according	   to	   Targetscan	   6.1.	   The	  
TargetScan	   Human	   resource	   provides	   miRNA	   target	   predictions	   based	   on	   sequence	  
complementary	   to	   target	   sites	   with	   emphasis	   on	   perfect	   base-­‐pairing	   in	   the	   seed	  
region	  and	  sequence	  conservation.	  These	  web-­‐based	  computational	  tools	  are	  based	  on	  
different	  algorithms	  which	  are	  based	  on	  several	  parameters	  calculated	  individually	  for	  
each	   miRNA.	   These	   target	   prediction	   analysis	   included	   genes	   involved	   in	   pathways	  
having	   functional	   relevance	   for	   MPN	   such	   as	   mTOR	   signaling	   pathway	   (PIK3R1	   and	  
EIF4B),	  CXCR4	  pathway	  (CXCR4	  and	  PTK2),	  cell	  cycle	  (e.g.	  TP53,	  MDM2,	  RB1,	  E2F1	  and	  
CDK2),	   apoptosis	   (i.e.	   CASP9,	  BCL2	  and	  BCL2L1),	   epigenetic	   regulation	   (i.e.	   EZH1	  and	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6	  DISCUSSION	  
The	   molecular	   basis	   of	   MPN	   has	   been	   appreciated	   recently	   with	   the	   description	   of	  
mutations	   in	   JAK2,	   MPL,	   CALR	   and	   other	   genes	   but	   several	   aspects	   of	   their	  
pathogenesis	   remain	   elusive.	   In	   particular,	   the	   mechanisms	   and/or	   the	   molecules	  
involved	   in	   the	   phenotypic	   mimicry	   of	   these	   disorders,	   on	   the	   basis	   of	   an	   unique	  
mutational	   event,	   are	   largely	   unknown.	   In	   addition	   to	   this,	   because	   miRNAs	   were	  
recently	  demonstrated	  to	  be	  deregulated	  in	  MPN	  cells	  (Guglielmelli	  et	  al.,	  2007;	  Lin	  et	  
al.,	  2013),	  interest	  regarding	  their	  putative	  involvement	  in	  pathogenetic	  mechanisms	  is	  
progressively	   growing.	   However,	   most	   of	   the	   miRNA	   and	   mRNA	   expression	   studies	  
performed	  to	  date	  have	  been	  conducted	  using	  terminally	  differentiated	  hematopoietic	  
cells,	  namely	  granulocytes	  or	  MKs	  (Guglielmelli	  et	  al.,	  2007;	  Slezak	  et	  al.,	  2009;	  Hussein	  
et	   al.,	   2009).	   Because	   MPNs	   are	   considered	   to	   arise	   from	   the	   HSC	   compartment,	  
understanding	  of	  the	  pathogenetic	  molecular	  mechanisms	  might	  be	  best	  assessed	  by	  
studying	  CD34+	  cells.	  
So	  far,	  only	  2	  studies	  have	  reported	  data	  on	  miRNA	  expression	  profiling	  in	  a	  very	  small	  
number	  of	  MPN	  CD34+	  samples	  (Lin	  et	  al.,	  2013;	  Zhan	  et	  al.,	  2013)	  and	  no	  integrated	  
miRNA-­‐mRNA	  expression	  analysis	  was	  available	  until	  now.	  For	  these	  reasons,	  in	  the	  fist	  
part	  of	  this	  work,	  I	  performed	  an	  extensive	  study	  that	  concurrently	  profiled	  both	  gene	  
and	   miRNA	   expression	   in	   the	   same	   CD34+	   cells	   sample	   from	   PMF	   patients	   by	  
MicroArray	  technique.	  GEP	  and	  miEP	  analysis	  showed	  that	  PMF	  CD34+	  cells	  present	  a	  
different	   expression	   pattern	   compared	   with	   BM	   and	   unmobilized	   PB	   CD34+	   cells.	  
Differential	   expression	   analysis	   enabled	   the	   identification	   of	   several	   deregulated	  
miRNAs	   and	   mRNAs	   suitable	   as	   biomarkers	   or	   as	   putative	   molecular	   targets	   for	  
diagnostic	   or	   prognostic	   purposes.	   Thereafter,	   the	   most	   upregulated	   genes	   and	  
miRNAs	   were	   monitored	   in	   PMF	   granulocytes	   because	   these	   cell	   could	   represent	   a	  
more	  suitable	  source	  for	  clinical	  practice,	  whereas	  secreted	  proteins	  were	  assessed	  in	  
the	   patients’	   sera.	   In	   this	  work,	   It	  was	   identified	   a	   set	   of	   5	   genes	   (ie,	   LCN2,	  OLFM4,	  
ANXA3,	  FGR,	  and	  LEPR)	  and	  6	  miRNAs	  (ie,	  miR-­‐19a-­‐3p,	  miR-­‐335-­‐5p,	  miR-­‐376c-­‐3p,	  miR-­‐
379-­‐5p,	  miR-­‐487b-­‐3p,	   andmiR-­‐494-­‐3p)	   whose	   expression	   levels	   are	   aberrant	   in	   PMF	  
granulocytes	  as	  well	  as	  in	  CD34+	  cells.	  Evidence	  in	  PMF	  of	  a	  higher	  mRNA	  expression	  of	  
the	  leptin	  receptor	  (LEPR),	  previously	  reported	  in	  AML	  (Konopleva	  et	  al.,	  1999),	  as	  well	  
as	  of	  Src	  kinase	  FGR	   (Dos	  Santos	  et	  al.,	  2013)	   could	  also	  be	  useful	  hints	   to	  drive	   the	  
future	   design	   of	   targeted	   drugs.	   Of	   note,	   LEPR	   and	   Src	   kinase	   inhibitors	   are	   already	  
being	  used	  in	  preclinical	  or	  clinical	  trials	  (Shiplman	  et	  al.,	  2011;	  Tokuhisa	  et	  al.,	  2014).	  
In	  addition	  it	  was	  demonstrated	  that	  OLFM4	  and	  LCN2	  secreted	  protein	  levels	  could	  be	  
considered	  as	  PMF	  biomarkers	  because	  they	  were	  significantly	  higher	  in	  patients’	  sera	  
compared	   with	   those	   of	   healthy	   controls.	   Strikingly,	   >80%	   of	   the	   PMF	   patients	  
presented	  with	  higher	  OLFM4	  protein	  levels	  compared	  with	  all	  the	  evaluated	  controls.	  
The	   first	   part	   of	   this	   work	   has	   mainly	   provided	   information	   about	   the	   molecular	  
mechanisms	  underlying	  PMF	  pathogenesis.	   Indeed,	  data	  analysis	  clearly	   showed	  that	  
several	  genes	  involved	  in	  adhesion	  or	  migration	  processes	  (TM4SF1,	  RHOB,	  ARHGAP18,	  
and	  MMP8)	  as	  well	  as	  fibrogenic	  potential	  (LEPR,	  MMP9,	  and	  TIMP3)	  are	  deregulated	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in	  PMF	  CD34+	  cells.	  Interestingly,	  regulators	  of	  megakaryocytic	  commitment	  were	  also	  
upregulated	   (ie,	   NFE-­‐2,	  MEF2C,	   miR-­‐146b-­‐5p,	   and	  miR-­‐34a-­‐5p).	   Furthermore,	   it	   was	  	  
found	  an	   increased	  expression	  of	  genes	  or	  miRNAs	  with	  oncogenic	  potential,	  such	  as	  
CEACAM8,	   ANGPT1,	   miR-­‐29a-­‐3p,	   and	   miRNAs	   belonging	   to	   the	   miR-­‐17-­‐92	   cluster	  
(Schotte	   et	   al.,	   2012;	   Lemoli	   et	   al.,	   2009).	   Because	   one	   of	   the	   main	   mechanisms	  
through	   which	   miRNAs	   act	   is	   degradation	   of	   specific	   targets	   (Ameres	   et	   al.,	   2013)	  
miRNAs	  and	  their	  targets	  are	  expected	  to	  display	  anticorrelated	  expression.	  Hence,	  an	  
Integrative	  Analysis	  (IA)	  approach	  was	  	  used	  to	  select	  the	  most	  reliable	  interactions.	  	  
As	  chromatin	  remodeling	  is	  one	  of	  the	  main	  processes	  involved	  in	  PMF	  pathogenesis,	  it	  
was	   determined	   whether	   a	   DEM	   could	   affect	   this	   pathway.	   It	   was	   found	   that	  
chromatin	   remodeler	  genes	   such	  as	  PHC3	  and	  HMGB3	  could	  be	  downregulated	  by	  a	  
network	   of	   upregulated	   targeting	  miRNAs	   (ie,	   miR-­‐18a-­‐5p,	   miR-­‐433-­‐3p,	   miR-­‐195-­‐5p,	  
miR-­‐200c-­‐3p,	  and	  miR-­‐152-­‐3p).	   It	  was	  also	  observed	   that	   low	  expression	  of	  different	  
hematopoietic	  transcription	  factors	  as	  well	  as	  leukemia	  suppressors	  (ie,	  CEBP,	  FOXO1,	  
and	  MLL5)	   is,	   at	   least	   in	   part,	   caused	   by	   several	   highly	   expressed	   oncomiRs	   such	   as	  
miR-­‐21-­‐5p	  and	  miR-­‐29a-­‐3p.	  Finally,	  it	  was	  found	  a	  single	  regulatory	  network	  collecting	  
the	  highest	  number	  of	  oncomiRs	  and	  target	  genes	   involved	   in	  malignant.	  Of	  note,	  by	  
means	  of	   3’UTR	   luciferase	   reporter	   assays,	   11/17	   (64.7%)	  putative	   interactions	  were	  
confirmed	   for	   the	   previously	   mentioned	   network,	   highlighting	   the	   good	   predictive	  
power	  of	  IA	  in	  identifying	  true	  miRNA-­‐target	  interactions.	  Specifically,	  the	  upregulation	  
of	  several	  targeting	  miRNAs	  explains	  the	  negative	  regulation	  of	  genes	  like	  CDC42	  and	  
NR4A3,	  whose	  downregulation	  leads	  to	  myeloproliferative	  disorders	  in	  murine	  models	  
(Ramirez-­‐Herrick	  et	  al.,	  2011;	  Yang	  et	  al.,	  2007)	  as	  well	  as	  HMGB3,	  which	  codes	  for	  a	  
regulator	  of	   the	  self-­‐	   renewal/differentiation	  balance	   in	  murine	  HSCs	   (Nemeth	  et	  al.,	  
2006).	  Moreover,	  up-­‐regulated	  miR-­‐155-­‐5p,	  miR-­‐195-­‐5p,	   and	  miR-­‐152-­‐3p	   share	   the	  
experimentally	  observed	   target	   JARID2,	  a	  chromatin	  remodeler	   that	   is	  a	  member	  of	  
the	   Jumonji	   family	   of	   transcription	   factors	   belonging	   to	   the	   polycomb	   repressive	  
complex	  2	  (Peng	  et	  al.,	  2009).	  	  Of	  note,	  Puda	  and	  colleagues	  demonstrated	  that	  JARID2	  
is	   frequently	   deleted	   in	   leukemic	   transformation	   of	   chronic	   myeloid	   malignancies	  
(Puda	   et	   al.,	   2012).	   However,	   although	   the	   function	   of	   JARID2	   in	   hematopoiesis	   has	  
been	  already	  partially	  unraveled	  in	  mouse	  embryo	  development	  studies,	  there	  are	  no	  
data	  about	  its	  role	  in	  human	  primary	  hematopoietic	  CD34+cells	  (Kitajima	  et	  al.,	  1999).	  
Thus,	   it	   was	   decided	   to	   investigate	   the	   effect	   of	   JARID2	   downregulation	   in	  
hematopoiesis	  by	  means	  of	  RNAi-­‐mediated	  silencing	  in	  human	  normal	  CD34+	  cells.	  The	  
findings	   of	   this	   work	   support	   the	   contributing	   role	   of	   JARID2	   deficiency	   in	   the	  
expansion	  of	  the	  MK	  lineage	  both	  in	  liquid	  and	  in	  semisolid	  culture.	  Because	  the	  most	  
effective	  miRNA	   in	   downregulating	   JARID2	   3’UTR-­‐luciferase	   activity	  was	  miR-­‐155-­‐5p,	  
whose	  enforced	  expression	  causes	  a	  myeloproliferative	  disorder	  in	  mice	  (O’Connell	  et	  
al.,	   2008)	   this	   miRNA	   was	   accordingly	   overexpressed	   in	   hematopoietic	   CD34+cells.	  
These	  experiments	  lead	  to	  show	  that	  miR-­‐155-­‐5p	  overexpression	  is	  implicated	  in	  the	  
downregulation	   of	   JARID2	   mRNA,	   thereby	   promoting	   the	   expansion	   of	   the	   MK	  
compartment.	   In	   parallel,	  miRNA	   inhibition	   in	   PMF	   CD34+	  cells	   clearly	   confirm	   a	   link	  
between	  miR-­‐155-­‐5p	  and	  the	  increased	  megakaryopoiesis	  observed	  in	  PMF	  patients.	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Finally,	  the	  restoration	  of	  JARID2	  expression	  level	  in	  miR-­‐155-­‐5p–overexpressing	  CD34+	  
cells	   impaired	   the	   expansion	   of	   MK	   lineage	   induced	   by	   miR-­‐155-­‐5p;	   this	   unbalance	  
could	   be	   prevented	   by	   simultaneusly	   silencing	   JARID2	   and	  miR-­‐155-­‐5p	   as	   well,	   thus	  
definitively	   demonstrating	   that	   miR155-­‐5p	   affects	   megakaryopoiesis	   via	   JARID2	  
modulation.	  Overall,	  this	  interaction	  could	  explain	  the	  MK	  hyperplasia	  observed	  in	  BM	  
biopsies	  of	  PMF	  patients	  and	  the	  high	  proliferative	  potential	  of	  MKs	  derived	  from	  PMF	  
CD34+	  cells	  reported	  in	  studies	  in	  vitro	  (Balduini	  et	  al.,	  2011).	  Moreover,	  the	  analysis	  of	  
miR-­‐155-­‐5p	  and	  JARID2	  mRNA	  levels	  in	  ET	  CD34+	  cells	  revealed	  that	  this	  regulatory	  axis	  
specifically	   works	   in	   PMF	   CD34+	   cells.	   Taken	   together,	   integration	   of	   GEP	   and	  miEP	  
uncovered	   regulatory	   networks	   in	   which	   aberrantly	   expressed	   miRNAs	   and	   genes	  
interact,	  thereby	  elucidating	  some	  of	  the	  pathogenetic	  characteristics	  of	  PMF.	  Finally,	  
IA	  has	  proved	  to	  be	  a	  good	  approach	  for	  identifying	  reliable	  mRNA/miRNA	  interactions	  
that	  could	  contribute	  to	  PMF	  pathogenesis,	  such	  as	  the	  JARID2-­‐miR-­‐155-­‐5p	  axis,	  which	  
is	  involved	  in	  hyperplastic	  megakaryopoiesis.	  
In	   order	   to	   corroborate	   data	   obtained	   in	   the	   first	   part	   of	   this	   work	   regarding	  
deregulation	  of	  miRNAS	  as	  well	  as	  with	  the	  aim	  to	  discover	  new	  miRnas,	  isomiRna	  and	  
moRnas	   in	  PMF	  cell,	  a	   	  RNA-­‐seq	  technique	  was	  employed	  to	  comprehensively	  profile	  
small	  RNA	  expressed	  in	  PMF	  CD34+	  cells	  compared	  with	  control	  CD34+	  cells	  .	  
Such	  an	  approach	  enable	  the	  	  detection	  of	  784	  know	  miRNAs	  expressed	  in	  CD34+	  cells	  
and	  the	  discovery	  of	  34	  new	  miRNAs	  produced	   from	  known	  hairpins.	   It	  was	  showed	  
that	   expressed	   miRNAs	   with	   unique	   sequence	   are	   rare	   and	   that	   most	   miRNAs	   are	  
isomiR	  mixtures,	  whose	  expression	  needs	  to	  be	  considered	  when	  dealing	  with	  overall	  
miRNA	   expression	   estimation	   and	   for	   differential	   expression	   detection.	  Moreover,	   a	  
set	   of	   99	   microRNAoffset	   RNAs	   (moRNAs)	   probably	   produced	   from	   alternative	  
microRNA	   precursors	   was	   discovered.	   Cluster	   analyses	   and	   heatmaps	   of	   samples	  
demonstrated	  that	  patients’and	  controls’	  small	  RNAs	  profiles	  are	  significantly	  different	  
and	  highlighted	  a	  characteristic	  miRNA	  and	  moRNA	  expression	  profile	  in	  PMF.	  In	  fact,	  
according	   to	   RNA-­‐seq	   data,	   it	   was	   identified	   that	   several	   sRNAs	   are	   expressed	   at	  
significantly	   different	   level	   in	   patients’	   compared	   to	   controls’	   CD34+.	   Subsequent	  
analysis	  in	  granulocytes	  from	  independent	  patients	  and	  controls	  samples	  strengthened	  
the	  evidence	  of	  6	  differentially	  expressed	  sRNAs,	  including	  3’-­‐moR-­‐128-­‐2.	  	  
In	  the	  group	  of	  the	  miRnas	  with	  statistically	  significant	  different	  expression,	  of	  interest,	  
is	   miR-­‐10b-­‐5p	   that	   resulted	   downregulated	   both	   in	   PMF	   CD34+	   and	   granulocytes.	  
Accordingly,	  miR-­‐10b-­‐5p	   has	   been	   previously	   reported	   to	   be	   deregulated	   in	   breast	  
cancer	   (Gee	  et	   al.,	   2008;	  Chan	  et	   al.,	   2013)	   and	   involved	   in	   chemoresistance	   related	  
pathway	  (Ouyang	  et	  al.,	  2014).	  It	  has	  been	  validated	  as	  downregulated	  in	  endometrial	  
carcinoma	   (Tsukamoto	  et	  al,	  2014)	  bladder	  cancer	   (Zaravinos	  et	  al.,	  2012),	  advanced	  
stage	  of	  small	  cell	  carcinoma	  of	  the	  cervix	  (SCCC)	  (Huang	  et	  al.,	  2012)	  and	   i	  clear	  cell	  
renal	  cell	  carcinoma	  (ccRCC)	  and	  its	  expression	  level	  has	  been	  also	  included	  in	  a	  linear	  
model	  that	  captures	  the	  metastatic	  tumor	  signature	  and	  patient	  prognosis	  (Wu	  et	  al.,	  
2012).	  
miR-­‐29a-­‐3p	  was	  found	  upregulated	  in	  CD34+	  from	  PMF	  patients,	  and	  further	  validated	  
by	  RT-­‐PCR	   in	  an	   independent	   set	  of	  CD34+	  cells	   from	  10	  PMF	  patients	  and	  8	  healthy	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subjects,	   by	   Rna-­‐seq	   analysis	   confirmibg	   also	   data	  with	   RNA	   array.	  Of	   interest,	  miR-­‐
29a-­‐3p	   resulted	   upregulated	   in	   patients	   CD34+	   in	   respect	   to	   controls,	   but	  
downregulated	  in	  the	  same	  comparison	  when	  considering	  mature	  granulocytes.	  This	  
observation	  is	  also	  in	  accordance	  with	  results	  previously	  obtained	  by	  Han	  et	  al.	  (Han	  et	  
al.,	  2010)	  who	  showed	  that	  miR-­‐29a-­‐3p	  is	  expressed	  at	   lower	   levels	   in	  hematopoietic	  
progenitors	   compared	   to	   lineage-­‐committed	   progenitors,	   including	   granulocytes,	  
overall	   indicating	   that	   its	   expression	   level	   increases	   along	   with	   commitment.	  
Therefore,	   the	   seobservations	   point	   to	  miR-­‐29a	   as	   a	   deregulated	   small	   RNA	   in	   PMF,	  
whose	  expression	   is	  uniquely	  modulated	  along	  myeloid	  differentiation	  of	  PMF	  CD34+	  
cells.	   Consistently	   with	   our	   finding,	   Han	   et	   al.	   also	   showed	   also	   that	   sustained	  
expression	   of	  miR-­‐29a-­‐3p	   in	  mouse	   HSC/progenitors	   pushed	  myeloid	   progenitors	   to	  
self-­‐renewal	  capacity,	  to	  biased	  myelopoiesis	  and	  to	  the	  onset	  of	  a	  myeloproliferative	  
disorder	   that	  progressed	  to	  acute	  myeloid	   leukemia.	  Althougt	   in	   the	   first	  part	  of	   this	  
work	  also	   the	  upregulation	  of	  miR-­‐379-­‐5p,	  miR-­‐543	  and	  miR-­‐19b-­‐3p	  was	  validated	   in	  
an	  independent	  set	  ofPMF	  CD34+,	  the	  RNA-­‐seq	  data	  were	  conversely	  unable	  to	  confirm	  
a	   statistically	   significant	  upregulation	  of	   these	  miRNAs	   in	  PMF,	  although	   there	  was	  a	  
trend	   for	   miR	   379-­‐5p	   and	   miR-­‐543.	   Interestingly,	   previously,	   validated	   microarray-­‐
based	  observations	  using	  two	  sets	  of	  qRT-­‐PCR	  experiments,	  conducted	  on	  CD34+	  cells	  
and	   on	   granulocytes,	   showing	   that	   PMF-­‐specific	   variations	   of	   a	   few	  miRNAs	  may	   be	  
observed	   in	   CD34+	   cells	   unlike	   in	   granulocytes.	   Indeed,	  miR-­‐486-­‐3p	  was	   significantly	  
downregulated	   in	   PMF	   granulocytes	   and	   upregulated	   in	   PMF	   in	   CD34+	   cells.	   In	  
summary,	   available	   evidence	   indicate	   that	   miR-­‐10b-­‐5p	   and	   moR-­‐128-­‐2	   are	  
downregulated	   in	   PMF	   CD34+	  cells,	   whereas	  miR-­‐19b-­‐3p,	   miR-­‐379-­‐5p	   and	  miR-­‐543	  
are	  upregulated.	  For	  these	  miRNAs	  the	  evidence	  of	  differential	  expression	  in	  PMF	  was	  
robust,	  since	   it	  was	  detected	  by	  NGS	  and	  also	  validated	  technically	   (by	  qRT-­‐PCR)	  and	  
biologically	  (in	  independent	  samples).	  
Regarding	   the	   newly	   discovered	   3'-­‐moR-­‐128-­‐2,	   it	   was	   investigated	   in	   detail	   the	  
sequence,	   structure,	   expression	   and	  possible	   functions,	   also	  by	   comparison	  with	   the	  
cognate	  miR-­‐128-­‐3p;	   results	   showed	   that	   the	  miRNA	  and	  moRNA	  expression	  profiles	  
are	   poorly	   correlated.	   At	   the	   functional	   level,	   assuming	   that	   moRNAs	   may	   act	   as	  
miRNAs,	  it	  was	  noticed	  that	  3'-­‐moR-­‐128-­‐2	  and	  miR-­‐128-­‐3p	  potential	  target	  genes	  and	  
pathways	  are	  markedly	  different.	  	  
Interestingly,	   3'-­‐moR-­‐128-­‐2,	   that	   was	   expressed	   in	   normal	   CD34+	   cells	   and	   resulted	  
absent	   in	   PMF	   cells,	  may	   target	   pathways	   related	   to	   the	   control	   of	   cell	   growth	   and	  
proliferation	  and,	  strikingly,	  target	  several	  genes	  involved	  in	  microRNA	  biogenesis	  or	  in	  
miRNA-­‐mediated	   silencing.	   Its	   expression	   level	   was	  measured	  with	   qRT-­‐PCR	   both	   in	  
CD34+	   cells	   and	   in	   granulocytes.	   RT-­‐PCR	   validation	   in	   CD34+	   cells	   were	   conducted	  
considering	   8	   normal	   controls	   and	   20	   PMF	   patients,	   whereas	   the	   validation	   in	  
granulocytes	  was	  done	  with	  the	  same	  design	  and	  samples	  used	  for	  miRNA	  validation.	  A	  
consistent	  downregulation	  of	  3’-­‐moR-­‐128-­‐2	  was	  found	  in	  PMF	  patients	  according	  to	  
RNA-­‐seq	  and	  RT-­‐PCR	  data	  in	  CD34+	  and	  to	  RT-­‐PCR	  data	  in	  granulocytes.	  Moreover,	  3’-­‐
moR-­‐128-­‐2	   was	   decreased,	   but	   at	   a	   lower	   extent,	   without	   reaching	   statistical	  
significance,	   also	   in	   PV	   and	   ET	   granulocytes.	   Intrigued	   by	   the	   striking	   expression	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pattern	   of	   the	   newly	   discovered	   3'-­‐moR-­‐128-­‐2	   in	   collaboration	   with	   University	   of	  
Padua	   group	   it	   was	   looked	   in	   details	   into	   sequence,	   structure,	   expression	   and	  
functional	  differences	  of	  3'-­‐moR-­‐	  128-­‐2	  and	  miR-­‐128-­‐3p.	  
	  
	  
Fig	  33:	  The	  3’-­‐moR-­‐128-­‐2	  is	  produced	  by	  the	  precursor	  sequence	  of	  miR-­‐128-­‐3p.	  A)	  The	  moRNA	  is	  derived	  from	  a	  
region	  of	   the	  primary	  miRNA	  sequence	  exceeding	   the	   canonical	  hairpin	  precursor	   sequence,	   and	   it	   is	  not	  exaclty	  
adjactent	  to	  the	  annotated	  miRNA.	  B)	  Minimum	  free	  energy	  (MFE)	  folding	  structure,	  predicted	  by	  RNA	  fold,	  for	  the	  
canonical	   hairpin	   sequence	   and	   for	   the	   longer	   one,	   from	   which	   the	   moRNA	   is	   probably	   derived.C)	   Both	   the	  
considered	  small	  RNAs	  are	  conserved	  in	  evolution	  through	  vertebrates.	  
	  
In	  Fig	  33	  we	  show	  additional	  sequence	  information	  regarding	  miR-­‐128-­‐3p	  and	  3’-­‐moR-­‐
128-­‐2.	  Since	  the	  moRNA	  sequence	  is	  not	  contained	  in	  the	  canonical	  hairpin	  (Fig	  33A),	  
the	  moRNA	  probably	  derives	  from	  the	  processing	  of	  an	  alternative	  hairpin	  precursor.	  
In	  Fig	  33B	   it	  was	  showed	  the	  RNA	  fold	  predicted	  minimum	  free	  energy	  (MFE)	  folding	  
structure	  of	  the	  canonical	  hairpin	  and	  of	  a	  longer	  sequence	  from	  which	  the	  moRNA	  can	  
be	  derived.	  Fig	  33C	  shows	  that	  mir-­‐128	  locus	  is	   inside	  an	  intron	  of	  ARPP21	  gene,	  and	  
displays	   the	   genomic	   region	   Mammals	   UCSC	   base-­‐wise	   PhyloP	   conservation	   score.	  
moRNA	   biological	   roles	   and	  mechanisms	   of	   function	   still	   deserve	   investigation.	   Very	  
likely,	  moRNAs	  can	  function	  as	  miRNAs	   in	  post-­‐transcriptional	  gene	  silencing,	  guiding	  
RISC	   to	   complementary	   target	  mRNAs.	   This	   was	   first	   demonstrated	   by	   Umbach	   and	  
colleagues,	   that	   used	   a	   luciferase-­‐based	   indicator	   assay	   to	   demonstrate	   that	   a	   viral	  
moRNA	   (moR-­‐rR1-­‐3-­‐5p)	   has	   inhibitory	   activity	   against	   an	   artificial	   mRNA	   bearing	   a	  
perfect	   target	  site	   (Umbachet	  al.,	  2010;	  Bortoluzzi	  et	  al.,	  2011).	  Beyond	  this	  proof	  of	  
principle	   experiment,	   a	   recent	   study	   reported	  moRNA	   specific	   expression	   in	   human	  
embryonic	  stem	  cells	  (Asikainen	  et	  al.,	  2015)	  (hESCs).	   In	  the	  same	  study,	  moRNA	  and	  
miRNA	   transfection	   experiments	   and	   microarray	   quantification	   of	   gene	   expression	  
were	   conducted	   and	   identified	   gene	   silenced	   by	   moR-­‐103a-­‐2-­‐3p,	   one	   of	   the	   most	  
abundantly	  expressed	  moRNAs	  in	  hESCs,	  and	  by	  miR-­‐103a.	  In	  line	  with	  these	  previous	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studies,	   it	  was	  assumed	   that	  3’	   -­‐moR-­‐128-­‐2	   can	  act	  as	  a	  miRNA,	  and	   investigated	   its	  
possible	   impact	   on	   target	   gene	   silencing	   and	   on	   specific	   pathways	   or	   biological	  
processes.	  To	  this	  end,	  it	  was	  considered	  how	  sequence	  variants	  (isomiRs)	  of	  these	  two	  
small	  RNAs	  relate	  to	  each	  other.	  For	  miR-­‐128-­‐3p,	  it	  was	  identified	  7	  variants	  expressed	  
in	   the	   analyzed	   CD34+	   samples:	   one	   exact	   isomiR,	   corresponding	   to	   the	   miRBase	  
annotated	  mature	  form,	  and	  6	  “	  shorter	  or	  longer”	  	  variants	  (miR-­‐128-­‐3p-­‐SL-­‐1	  to	  miR-­‐
128-­‐3p-­‐SL-­‐6),	  whereas	   only	   2	   3'-­‐moR-­‐128-­‐2	   isomoR	  were	   found	   out	   (3'-­‐moR-­‐128-­‐2-­‐1	  
and	  3'-­‐moR-­‐128-­‐2-­‐2).	  According	  to	  the	  conservative	  hypothesis	  that	  interprets	  moRNA	  
as	   byproducts	   of	   Drosha	   cleavage	   (Ma	   et	   al.,	   2013)	   one	   should	   expect	   comparable	  
mean	   levels	   of	   miRNA	   and	   moRNA	   cognate	   variants	   (i.e.	   obtained	   from	   a	   single	  
endonucleolytic	  cleavage	  cut)	   in	  PMF	  and	  CTR	  samples.	  The	  observation	  that	  3'-­‐moR-­‐
128-­‐2-­‐1,	   the	  most	   abundant	   isomoR,	   is	   expressed	   only	   in	   CTR	   samples	   and	   its	   only	  
viable	  cognate	  partner	  is	  the	  miR-­‐128-­‐3p-­‐exact	  variant	  that	  is	  highly	  and	  nearly	  equally	  
expressed	   in	   CTR	   and	   PMF	   samples	   does	   not	   apparently	   support	   such	   statements.	  
Neither	   do	   the	   poor	   correlation	   of	   expression	   levels,	   in	   CTR	   and	   PMF	   samples,	   of	  
cognate	  isomiRs	  and	  isomoRs,	  the	  fact	  that	  some	  abundant	  isomiRs	  are	  not	  associated	  
to	  detected	  isomoR	  sequences,	  the	  good	  conservation	  of	  moRNA	  sequence	  (Fig	  33C),	  
and	   the	  previously	   reported	  observation	   that	  both	   isomoRs	  are	  not	  contained	   in	   the	  
canonical	  hairpin	  (Figs	  33A	  and	  33B).	  Finally,	  target	  predictions	  of	  miRnas	  and	  moRnas	  
resulted	   differentially	   expressed	   	   (miR-­‐10b-­‐5p,	  miR-­‐19b-­‐3p,	  miR-­‐29a-­‐3p,	  miR-­‐379-­‐5p,	  
miR-­‐543	  and	  moR-­‐128-­‐2)	  were	  performed	  by	  using	   two	  different	  programs,	  miRanda	  
(Enright	  et	  al.,	  2004)	  and	  PITA	  (Kertesz	  et	  al.,	  2007)	  which	  implement	  orthogonal	  target	  
prediction	  strategies,	  and	   for	  which	   the	  code	  availability	  allowed	  us	   to	  make	  custom	  
predictions	  of	  possible	  miRNA	  and	  moRNA	  target	  genes,	  by	  using	  as	  query	  sequences	  
the	   identified	   isomiR	   and	   isomoR	   sequences.	   Among	   different	   isomiRs	   detected	   for	  
each	  considered	  miRNA,	  it	  was	  considered	  the	  most	  expressed,	  even	  if	  it	  was	  different	  
from	   the	   annotated	   sequence.	   It	   was	   also	   considered	   those	   isomiRs	   that	   were	  
significantly	   contributing	   to	   miRNA	   total	   expression,	   and	   which	   were	   differently	  
expressed	   in	   patients	   respect	   to	   controls	   (t-­‐test	   p-­‐value	   <	   0.05	   and	   |log2	   FC|>	   1),	  
according	  to	  RNA-­‐seq	  data.	  Accordingly,	  both	  isomoRs	  were	  considered	  for	  moR-­‐128-­‐2.	  
After	   the	   analysis	   it	   was	   found	   that	   different	  miRNAs	   target	   genes	   converge	   to	   the	  
same	   enriched	   pathways,	   as	   “	   Signaling	   in	   FGFR	   in	   disease”,	   “DAP12	   signaling”	   ,	  	  
“Oncogene	  induced	  senescence”	  	  and	  “	  Post-­‐transcriptional	  silencing	  by	  small	  RNAs”	  .	  
Human	   fibroblast	   grow	   factor	   receptors	   (FGFRs)	  are	  a	   family	  of	   four	   tyrosine	  kinase	  
receptors	   (FGFR1–	  4),	  which	  are	   involved,	   in	  a	  variety	  of	  cellular	  processes.	  They	  are	  
indeed	  key	  regulators	  of	   fibrogenesis,	  embryogenesis,	  angiogenesis,	  metabolism,	  and	  
many	  other	  processes	  of	  proliferation	  and	  differentiation	  (Broocks	  et	  al.,	  2012;	  Tiong	  
et	  al.,	  2013).	  Deregulation	  of	  FGFR	  signaling	  has	  been	  observed	   in	  numerous	   tumors	  
(Katoh	  et	  al.,	  2014;	  Tan	  et	  al.,	  2014).	  	  
DAP12	   is	   an	   immunoreceptor	   tyrosine-­‐based	   activation	   motif	   (ITAM)-­‐bearing	  
transmembrane	   adapter	   molecule	   and	   it	   is	   reported	   to	   be	   signaling	   partner	   of	  
activating	  natural	  killer	  receptors.	  DAP12	  complex	  to	  TREM-­‐1	  and	  MDL-­‐1	  receptors	  to	  
form	   receptor	   complexes	   involved	   in	   macrophage	   differentiation	   (Aoki	   et	   al.,	   2000)	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and	  apoptosis	  in	  M1	  leukemia	  cells	  (Aoki	  et	  al.,	  2002),	  significant	  monocytic	  activation	  
of	  myeloid	  cell,	  calcium	  mobilization	  and	  inflammatory	  response	  (Gingras	  et	  al.,	  2002;	  
Bakker	   et	   al.,	   1999).	   Its	   elevated	   expression	   levels	   are	   associates	   with	   enhanced	  
cytotoxic	  characteristics	  in	  large	  granular	  lymphocyte	  leukemia	  (Chen	  et	  al.,	  2009).	  
Oncogene	  senescence	  (OIS)	  occurs	  when	  the	  activation	  of	  an	  oncogene	  is	  triggered;	  in	  
this	   case	   it	   is	   termed	   oncogene-­‐induced	   senescence.	   OIS	   acts	   as	   a	   barrier	   against	  
tumour	  progression	  by	  driving	  stable	  growth	  arrest	  of	  cancer	  progenitor	  cells	  (Hills	  et	  
al.,	  2014).	  
As	   anticipated,	   the	   putative	   targets	   of	   	   3'-­‐moR-­‐128-­‐2	   and	   miR-­‐128-­‐3p	   were	  
comoaratively	  analzyed.	  It	  was	  predicted	  the	  targets	  of	  the	  four	  most	  expressed	  miR-­‐
128-­‐3p	   isomiRs	   (miR-­‐128-­‐3p-­‐exact,	   miR-­‐128-­‐3p-­‐SL-­‐2,	   miR-­‐128-­‐3p-­‐SL-­‐3,	   and	   miR-­‐128-­‐
3p-­‐SL-­‐4)	   and	   targets	   of	   the	   two	   3'-­‐moR-­‐128-­‐2	   isomoRs	   (3'-­‐moR-­‐128-­‐2-­‐1	   and	   3'-­‐moR-­‐
128-­‐2-­‐2),	   assuming	   that	   they	   would	   act	   as	   miRNA,	   as	   indicated	   by	   the	   available	  
experimental	   data	   (Bortoluzzi	   et	   al.,	   2011).	   It	   was	   compared	   the	   union	   of	   predicted	  
targets	   of	   miR-­‐128-­‐3p	   variants	   and	   the	   union	   of	   predicted	   targets	   of	   3-­‐moR-­‐128-­‐2	  
variants,	  to	  understand	  if	  and	  how	  much	  the	  moRNA	  function	  can	  be	  related	  to	  that	  of	  
the	   cognate	   miRNA,	   as	   previously	   supposed	   (Asikainen	   et	   al.,	   2015).	   Only	   a	   small	  
fraction	  of	  3-­‐moR-­‐128-­‐2	  target	  genes,	  less	  than	  17%,	  is	  putatively	  targeted	  also	  by	  at	  
least	   one	   of	   the	  miR-­‐128-­‐3p	   isomiRs.	   Different	   pathways	   are	   enriched	   in	   predicted	  
targets	  of	  3’	  -­‐moR-­‐128-­‐2	  and	  of	  miR-­‐128-­‐3p.	  miR-­‐128-­‐3p	  targets	  are	  enriched	  in	  genes	  
that	   are	   part	   of	   cellular	   pathways	   for	   the	   most	   part	   related	   to	   NGF,	   FGFR,	   ERBB4,	  
ERBB2	   signaling	   and	   transduction	   and	   to	   calcium	   ion	   homeostasis	   and	   signal	  
transduction.	   Targets	   of	   3’	   -­‐moR-­‐128-­‐2	   are	   enriched	   too	   in	   genes	   part	   of	   several,	  
distinct,	  pathways	  related	  to	  cellular	  signaling	  in	  growth	  and	  proliferation	  as	  “	  Signaling	  
by	   Notch“,	   “Signaling	   by	   ERBB4”,	   “	   Signaling	   by	   FGFR	   in	   disease”	   	   but	   also,	   quite	  
interestingly,	  in	  genes	  part	  of	  the	  “	  Post	  transcriptional	  silencing	  by	  small	  RNAs”	  	  and	  of	  
the	   more	   general	   “Regulatory	   RNA	   pathways”.	   Remembering	   that	   3’-­‐moR-­‐128-­‐2	   is	  
highly	  expressed	  in	  normal	  and	  not	  detected	  in	  PMF.	  CD34+,	  it	   is	  worth	  notice	  that	  4	  
out	   of	   7	   genes	  of	   the	   “	   Post-­‐transcriptional	   silencing	  by	   small	   RNAs”	  path,	   namely	  
AGO1,	  AGO3,	   TNRC6A,	   and	   TNRC6B,	   can	   be	   targeted	   by	   at	   least	   one	   isomoR	  of	   3-­‐
moR-­‐128-­‐2.	  Moreover,	  both	  considered	  3-­‐moR-­‐128-­‐2	   isomoRs	  could	  also	  target	  RAN,	  
the	   RAS-­‐related	   nuclear	   protein,	   member	   of	   the	   RAS	   Oncogene	   Family,	   which	   is	  
required	   for	   RNA	   export	   from	   the	   nucleus.	   In	   principle	   3’-­‐moR-­‐128-­‐2,	   where	   it	   is	  
expressed,	  as	  in	  CD34+	  hematopoietic	  stem	  cells,	  could	  affect	  the	  expression	  of	  genes	  
important	  for	  the	  entire	  process	  of	  miRNA-­‐based	  silencing.	  It	  can	  indeed	  target	  genes	  
essential	   for	  post-­‐transcriptional	  silencing	  both	  by	  translation	  repression,	  as	  AGO1/3,	  
and	   by	   mRNA	   degradation,	   as	   TNRC6A/B.	   AGO1	   and	   AGO3	   are	   required	   for	   post-­‐
transcriptional	  translation	  repression	  activity;	  AGO1	   is	  also	   involved	  in	  transcriptional	  
silencing	   of	   promoters	   (Romero-­‐Cordoba	   et	   al.,2014),	   and	   AGO3	   is	   also	   putatively	  
involved	   into	   the	   modulation	   of	   mature	   miRNA	   incorporation	   to	   the	   RISC	   complex,	  
thus	  controlling	  the	  ratio	  between	  micro-­‐	  RNA	  guide	  and	  passenger	  strand	  (Winter	  et	  
al.,	   2013).	   TNRC6A,	   and	   TNRC6B	   play	   a	   role	   in	   miRNA-­‐dependent	   translation	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repression	   and	   endonucleolytic	   cleavage,	   by	   recruiting	   specific	   deadenylase	  
complexes.	  
The	  multifunctional	  protein	  RAN	  is	  involved	  in	  many	  processes	  and	  diseases:	  it	  controls	  
cell	  cycle	  progression	  and	  it	   is	  a	  potential	  therapeutic	  target	  for	  treatment	  of	  cancers	  
with	   activation	   of	   the	   PI3K/Akt/mTORC1	   and	   Ras/MEK/ERK	   pathways	   (Yuen	   et	   al.,	  
2012).	  Specifically	   in	  relation	  to	  the	  above	  mentioned	  findings,	  as	  known,	  RAN	  play	  a	  
key	   role	   in	  RNA	  export	   from	  the	  nucleus	  and	   for	   the	  biogenesis	  of	  all	  miRNAs.	  Thus,	  
RAN	  silencing	  by	  3’-­‐moR-­‐128-­‐2	  can	  impair	  premiRNA	  transportation	  to	  the	  cytoplasm	  
and	  output	  a	  reduction	  of	  miRNA	  biogenesis.	  A	  similar	  situation	  was	  documented	  by	  a	  
recent	  study	  that	  identified,	   in	  Bombyx	  mori,	  a	  virus-­‐encoded	  miRNA	  that	  suppresses	  
the	   host	   miRNA	   biogenesis,	   exactly	   by	   targeting	   the	   host	   exportin-­‐5	   RAN	   cofactor	  
(Singh	  et	  al.,	  2012).	  
The	  interest	  related	  to	  the	  study	  of	  the	  possible	  alteration	  in	  expression	  levels	  of	  genes	  
and	  miRNA	   in	   PMF	   led	   to	  extensively	   investigate	   also	   the	   expression	   of	   circulating	  
miRNAs	  in	  plasma	  of	  PMF	  patiens	  and	  healty	  donors	  in	  order	  to	  identify	  new	  potential	  
biomarkers	   for	   this	  disease.	  This	  study	  was	  encouraged	  by	  the	   fact	   that	  many	  recent	  
works	  demonstrated	  that	  the	  deregulated	  expression	  level	  of	  circulating	  miRnas	  can	  be	  
biomarker	  of	  various	  form	  of	  cancer	  (see	  Par	  2.4.7).	  
In	   this	   part	   of	   study,	   6	   differentially	   expressed	   miRNA	   resulted	   deregulated	   in	  
significant	   statistically	   way	   (P	   value<0.05):	   miR-­‐let7b*,	   miR-­‐10b-­‐5p,	   miR-­‐424	   and	  
miR-­‐99a	   were	   resulted	   up-­‐regulated	   instead	   miR-­‐144*	   and	   miR-­‐375	   were	   down-­‐
regulated	   in	   PMF	   patients	   compared	   to	   the	   controls.	   Between	   these	  miR-­‐99a	   and	  
miR-­‐144*	  were	  resulted	  already	  equally	  de-­‐regulated	  in	  granulocytes	  of	  PMF	  patients	  
in	  a	  previous	  work	  (Guglielmelli	  et	  al.,	  2007).	  	  
Also	  this	  time,	  the	  miR-­‐10b-­‐5p	  is	  deregulated	  but	  in	  contrast	  with	  the	  data	  obtained	  
in	  CD34+	  and	   granulocyte	  of	   PMF	   in	  which	   it	  was	  down-­‐regulated.	   In	  addition,	  very	  
interesting	  was	  the	  down-­‐regulation	  of	  miR-­‐375.	  	  
MiR-­‐375	  expression	  was	  decreased	  in	  most	  human	  cancer	  and	  overexpression	  of	  miR-­‐
375	  suppressed	  cancer	  cell	  proliferation	  and	  invasion,	  indicating	  that	  miR-­‐375	  might	  be	  
a	  tumor	  suppressor	  (Fig.	  34).	  
	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Fig.34:	  Role	  of	  tumor	  suppressor	  and	  main	  targets	  of	  miR-­‐375.	  
	  
The	   dysregulation	   of	  miR-­‐375	   expression	   in	   different	   human	   cancer	   is	   caused	   by	   a	  
variety	   of	   mechanisms,	   such	   as	   the	   dysregulation	   of	   transcription	   factors,	   aberrant	  
promoter	   methylation,	   and	   aberrant	   histone	   deacetylation.	   Promoter	   DNA	  
hypermethylation	   leading	  to	  the	  downregulation	  of	  miR-­‐375	  was	  frequently	  occurred	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in	   hepatocellular	   carcinoma	   (Furuta	   et	   al.,	   2010),	   oesophageal	   squamous	   cell	  
carcinoma	  (ESCC)	  (Kong	  et	  al.,	  2012),	  and	  other	  cancers	  (Chu	  et	  al.,	  2014).	  	  
Recently,	  Xu	  et	  al.	  indicated	  that	  the	  down-­‐regulation	  of	  miR-­‐375	  in	  plasma	  is	  matched	  
in	   colorectal	   cancer	   (Xu	   et	   al.,	   2014)	   and	   Yin	   et	   al.	   already	   demonstrated	   the	  
importance	   of	  miR-­‐375	   as	   a	   tumor	   suppressor	   in	  MPN	  by	   targeting	   JAK.	   They	   found	  
miR-­‐375	   expression	   is	   increased	   in	   JAK2V617F-­‐positive	   patients	   compared	   with	  
JAK2V617F-­‐negative	  patients.	  This	  negative	   correlation	   indicates	  MPN	  patients	  with	  
low	  expression	  of	  miR-­‐375	  may	  have	  high	  expression	  of	  JAK2,	  which	  might	  contribute	  
to	  the	  further	  activation	  of	  JAK2/STAT	  signaling.	  Conseguently,	  Yin	  et	  al.	  proposed	  the	  
combination	  of	  the	  JAK2	  kinase	  inhibition	  and	  restoration	  of	  miR-­‐375	  expression	  as	  a	  
possible	  strategy	   for	  clinical	   therapies	  of	  MPN	  (Yin	  et	  al.,	  2015).	   	  On	  the	  basis	  of	  our	  
and	  litterature	  data,	  	  it	  is	  possible	  to	  conclude	  that	  miR-­‐375	  can	  be	  a	  good	  candidate	  
as	  a	  biomarker	  of	  disease	  in	  PMF	  patients	  plasma.	  
Finally,	   in	   order	   to	   clarify	   	   also	   the	   contribution	   of	   miRNAs	   to	   the	   pathogenesis	   of	  
JAK2V617F-­‐positive	  MPNs,	  it	  was	  analysed	  the	  miRNAs	  expression	  pattern	  in	  erythroid	  
(TER119+)	  and	  mieloid	  (GR1+)	  cells	  purified	  from	  BM	  of	  JAK2V617F	  knock-­‐in	  (KI)	  mouse	  
model.	  At	  the	  end	  of	  this	  work,	  it	  was	  confirmed	  up-­‐regulation	  of	  miR-­‐7a-­‐5p	  and	  miR-­‐
291b-­‐5p	  ad	  down-­‐regulation	  of	  miR-­‐150-­‐5p	  in	  GR1+;	  in	  TER119+,	  up-­‐regulation	  of	  miR-­‐
7a-­‐5p	   and	   down-­‐regulation	   of	   miR-­‐150-­‐5p	   and	   miR-­‐592-­‐5p.	   Only	   2	   differentially	  
expressed	  miRNAs	  were	   shared	   by	   both	   erythroid	   and	  myeloid	   cells	   (miR-­‐7a-­‐5p	   and	  
miR-­‐150-­‐5p,	   up-­‐	   and	   down-­‐regulated	   respectively),	   suggesting	   a	   direct	   relationships	  
between	  these	  miRNAs	  and	  JAK2V617F.	  Infact,	  to	  confirm	  this	  relationship,	  Gebauer	  et	  
al.	   already	   demostrated	   that	   the	   expression	   of	   miR-­‐150	   could	   further	   be	   shown	   to	  
correlate	  with	  JAK2	  allele	  burden	  in	  MPNs	  (Gebauer	  et	  al.,	  2013).	  Indeed,	  Bruchova	  et	  
al.	   showed	   that	   the	   expression	   of	   miR-­‐150	   progressively	   declines	   with	   eritroid	  
differentiation	   and	   the	   down	   regulation,	   in	   particular	   in	   PV,	   suggested	   possible	  
involvement	  of	  miR-­‐150	   in	  pathogenesis	  of	   this	  disease	   (Bruchova	  et	  al.,	  2007).	  miR-­‐
150	   is	  predicted	   to	   target	  cMYB	  proto-­‐oncogene,	   therefore,	  a	   significant	  decrease	  of	  
miR-­‐150	   and	   a	   simultaneous	   increase	   of	   the	   expression	   level	   of	   this	   gene	   may	   be	  
responsible	   for	   maintaining	   proliferation	   at	   early	   stages	   and	   for	   the	   inhibition	   of	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7	  FINAL	  STATEMENTS	  
At	  the	  conclusion	  of	  this	  work,	   I	  can	  summarize	  the	  main	  points	  as	  follows:	  1-­‐	   	  novel	  
data	  regarding	  the	  expression	  profile	  of	  small	  RNA	  in	  CD34+,	  granulocytes	  and	  plasma	  
of	   PMF	   patients	   as	  well	   as	   of	   healthy	   controls	   and	   their	   possible	   impact	   on	   specific	  
genes	   and	   pathways	   have	   been	   provided;	   2-­‐	   new,	   previously	   undescribed	   moRNAs	  
have	  been	  reported	  which	  might	  contribute	  to	  disease	  pathogenesis;	  3-­‐	  a	  number	  of	  
differentially	   expressed	  miRNAs	   in	   JAK2V617F	   KI	  mouse	   have	   been	   identified	  whose	  
deregulation	   very	   likely	   contributes	   to	   the	   development/phenotype	   of	   MPN	   in	   this	  
unique	  model.	  Overall,	   these	   information	  may	  represent	  the	  basis	   for	   further	  studies	  
aimed	  at	  a	  deeper	  knowledge	  of	  the	  prognostic	  and	  therapeutical	  role	  of	  miRNAs	  and	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